(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) **EP 1 565 749 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Description Paragraph(s) 10

(48) Corrigendum issued on:
25.04.2012 Bulletin 2012/17

(45) Date of publication and mention of the grant of the patent:
21.09.2011 Bulletin 2011/38

(21) Application number: **03774152.7**

(22) Date of filing: **21.11.2003**

(51) Int Cl.:
G01N 33/569 *(2006.01)*

(86) International application number:
PCT/JP2003/014920

(87) International publication number:
WO 2004/048567 (10.06.2004 Gazette 2004/24)

(54) METHODS OF SCREENING FOR COMPOUNDS THAT INHIBIT THE BIOSYNTHESIS OF GPI IN MALARIA PARASITES

VERFAHREN ZUM SCREENEN VON VERBINDUNGEN, WELCHE DIE GPI BIOSYNTHESE VON MALARIAPARASITEN HEMMEN

PROCEDES DE CRIBLAGE POUR DES COMPOSES INHIBANT LA BIOSYNTHESE DE GPI CHEZ LES PARASITES DE LA MALARIA

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
AL LT LV MK

(30) Priority: **22.11.2002 US 428589 P**

(43) Date of publication of application:
24.08.2005 Bulletin 2005/34

(73) Proprietor: **Eisai R&D Management Co., Ltd.**
Tokyo 112-8088 (JP)

(72) Inventors:
- **HATA, Katsura**
  Tsukuba-shi, Ibaraki 305-0035 (JP)
- **OGAWA, Kaoru**
  Tsukuba-shi, Ibaraki 305-0821 (JP)
- **TSUKADA, Itaru**
  Ushiku-shi, Ibaraki 300-1233 (JP)
- **NAKAMOTO, Kazutaka**
  Tsukuba-shi, Ibaraki 305-0031 (JP)
- **SAGANE, Koji**
  Tsukuba-shi, Ibaraki 300-0005 (JP)
- **TANAKA, Keigo**
  Tsukuba-shi, Ibaraki 305-0035 (JP)
- **TSUKAHARA, Kappei**
  Tsukuba-shi, Ibaraki 305-0051 (JP)
- **HORII, Toshihiro**
  Toyonaka-shi, Osaka 560-0002 (JP)

(74) Representative: **Vossius & Partner**
Siebertstrasse 4
81675 München (DE)

(56) References cited:
WO-A-01/13923 WO-A-02/04626
WO-A-98/14583 WO-A-02/052014

- **SHAMS-ELDIN HOSAM ET AL: "The GPI1 homologue from Plasmodium falciparum complements a Saccharomyces cerevisiae GPI1 anchoring mutant." MOLECULAR AND BIOCHEMICAL PARASITOLOGY. MAR 2002, vol. 120, no. 1, March 2002 (2002-03), pages 73-81, XP002382219 ISSN: 0166-6851 & DATABASE EMBL [Online] 11 February 2002 (2002-02-11), SHAMS-ELDIN ET AL.: retrieved from EBI Database accession no. AJ249657**

Printed by Jouve, 75001 PARIS (FR)

(Cont. next page)

- DATABASE EMBL [Online] 1 July 2000 (2000-07-01), SHAMS-ELDIN: "Plasmodium falciparum mRNA for GPI8p transamidase (gpi8 gene)" XP002382224 retrieved from EBI Database accession no. AJ401202
- LEIDICH S D ET AL: "TEMPERATURE-SENSITIVE YEAST GPI ANCHORING MUTANTS GPI2 AND GPI3 AREDEFECTIVE IN THE SYNTHESIS OF N-ACETYLGLUCOSAMINYL PHOSPHATIDYLINOSITOL" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 270, no. 22, 2 June 1995 (1995-06-02), pages 13029-13035, XP002014328 ISSN: 0021-9258 & DATABASE EMBL [Online] 19 October 1995 (1995-10-19), LEIDICH ET AL.: retrieved from EBI Database accession no. U23788
- DELORENZI MAURO ET AL: "Genes for glycosylphosphatidylinositol toxin biosynthesis in Plasmodium falciparum." INFECTION AND IMMUNITY. AUG 2002, vol. 70, no. 8, August 2002 (2002-08), pages 4510-4522, XP002382220 ISSN: 0019-9567
- WOODEN J M ET AL: "Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum." MOLECULAR AND BIOCHEMICAL PARASITOLOGY. MAR 1997, vol. 85, no. 1, March 1997 (1997-03), pages 25-40, XP002382221 ISSN: 0166-6851
- BROPHY V H: "Identification of Cryptosporidium parvum Dihydrofolate Reductase Inhibitors by Complementation in Saccharomyces cerevisiae" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 44, no. 4, 2000, pages 1019-1028, XP002358215 ISSN: 0066-4804
- PAN W ET AL: "Vaccine candidate MSP-1 from Plasmodium falciparum: A redesigned 4917 bp polynucleotide enables synthesis and isolation of full-length protein from Escherichia coli and mammalian cells" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 27, no. 4, 15 February 1999 (1999-02-15), pages 1094-1103, XP002348256 ISSN: 0305-1048
- WITHERS-MARTINEZ C ET AL: "PCR-based gene synthesis as an efficient approach for expression of the A+T-rich malaria genome" PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 12, no. 12, December 1999 (1999-12), pages 1113-1120, XP002230671 ISSN: 0269-2139
- ZHANG HANBANG ET AL: "Analysis of the antimalarial drug resistance protein Pfcrt expressed in yeast." THE JOURNAL OF BIOLOGICAL CHEMISTRY. 20 DEC 2002, vol. 277, no. 51, 25 September 2002 (2002-09-25), pages 49767-49775, XP002382222 ISSN: 0021-9258
- HALL N ET AL: "Sequence of Plasmodium falciparum chromosomes 1, 3-9 and 13" NATURE (LONDON), vol. 419, no. 6906, 3 October 2002 (2002-10-03), pages 527-531, XP002277348 ISSN: 0028-0836 cited in the application
- GEROLD P ET AL: "BIOSYNTHESIS OF GLYCOSYLPHOSPHATIDYLINOSITOLS OF PLASMODIUM FALCIPARUM IN A CELL-FREE INCUBATION SYSTEM: INOSITOL ACYLATION IS NEEDED FOR MANNOSYLATION OF GLYCOSYLPHOSPHATIDYLINOSITOLS" BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 344, 1999, pages 731-738, XP002935594 ISSN: 0264-6021 cited in the application
- NAIK RAMACHANDRA S ET AL: "Developmental stage-specific biosynthesis of glycosylphosphatidylinositol anchors in intraerythrocytic Plasmodium falciparum and its inhibition in a novel manner by mannosamine" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 32, 11 August 2000 (2000-08-11), pages 24506-24511, XP002935593 ISSN: 0021-9258
- UMEMURA M ET AL: "GWT1 GENE IS REQUIRED FOR INOSITOL ACYLATION OF GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORS IN YEAST" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 278, no. 26, 27 June 2003 (2003-06-27), pages 23639-23647, XP001179768 ISSN: 0021-9258 cited in the application
- GARDNER M J ET AL: "GENOME SEQUENCE OF THE HUMAN MALARIA PARASITE PLASMODIUM FALCIPARUM" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 419, 2002, pages 498-511, XP001156336 ISSN: 0028-0836 cited in the application
- CARLTON J M ET AL: "GENOME SEQUENCE AND COMPARATIVE ANALYSIS OF THE MODEL RODENT MALARIA PARASITE PLASMODIUM YOELII YOELII" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 419, no. 6906, 2002, pages 512-519, XP001156232 ISSN: 0028-0836 cited in the application

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Description

Technical Field

[0001] The present invention relates to methods of screening for compounds that inhibit the biosynthesis of GPI in malaria parasites.

Background Art

[0002] Malaria is the most common infectious human disease caused by parasitic protozoans. The disease is caused by infection with malaria parasites and is mediated by the mosquito, *Anopheles gambiae.* Every year there are estimated 500 million cases of malaria infection, including more than two million fatal cases (Gardner, et al., Nature 419:498-511, 2003). At present 40% of the world's population lives in malaria-epidemic areas, where it is said that one in every three infants dies from malaria.

[0003] Glycosylphosphatidylinositol (GPI) is known to play a key role in the growth and infectivity of parasites, including malaria parasites. There are many GPI-anchored proteins on the cell surface of these parasites. GPI-anchored proteins include proteins such as MSP-1 that function when the parasites invade red blood cells. GPI-anchored proteins act as parasitic antigens and initiate an immune response in the host. Thus, they have long been the subject of research aimed at vaccine development.

[0004] GPI not only functions as an anchor to tether proteins to the cell membrane, but is also an abundant glycolipid component of malaria parasite cell membranes. Recent studies have revealed that GPI is toxic and causes lethal symptoms. GPI induces the expression of inflammatory cytokines such as TNF-α, and of adhesion molecules. As a result, infected red blood cells adhere to capillaries, obstructing vessels (sequestration), brain blood vessels in particular. This induces further inflammatory reactions that are believed to lead to encephalopathy. Very recently, Schofield *et al.* reported that an anti-GPI antibody reduces lethality in an *in vivo* infection model system using the murine malaria parasite *Plasmodium berghei*, and that *in vitro*, the antibody inhibits late inflammatory reactions caused by *Plasmodium falciparum* (Schofield L, et al., Nature 418:785-789, 2002). These findings suggest that GPI is a major factor in the lethality of malarial infections.

[0005] It has also been reported that the acylation of inositol is essential for binding mannose to GPI (Gerold, P. et al., Biochem. J. 344:731-738, 1999), and that the inhibition of inositol acylation, caused by excess glucosamine, inhibits the maturation of the malaria parasite *P. falciparum* (Naik, R. S. et al., J. Biol. Chem. 278:2036-2042, 2003). Thus, compounds that can selectively inhibit GPI biosynthesis, particularly the acylation of inositol, may be highly useful antimalarial drugs.

[0006] In Brophy et al., Antimicrobial Agents and Chemotherapy 44:1019-1028, 2000, a method was shown to screen potential inhibitors of Cryptosporidium parvum DHFR by complementation using the eukaryote Saccharomyces cerevisiae.

Disclosure of the Invention

[0007] An objective of the present invention is to provide antimalarial drugs that inhibit the biosynthesis of GPI. More specifically, the present invention provides the malaria parasite DNA that encodes the GWT1 protein, which is a protein involved in the biosynthesis of GPI (GPI synthase). The present invention also provides a method of using this DNA in methods of screening for antimalarial drugs. The present invention also provides degenerate mutant DNAs of the DNA that encodes the malaria parasite GPI biosynthesis protein. These degenerate mutant DNAs have a lower AT content than the original DNA. The present invention also provides a method of using the degenerate mutant DNAs in methods of screening for antimalarial drugs.

[0008] The GWT1 gene was originally found to encode a fungal GPI-anchored protein synthase (WO 02/04626), and is conserved in organisms ranging from yeasts to humans. The present inventors confirmed that GWT1 homologues (PfGWT1 for *P. falciparum* GWT1; PyGWT1 for P. yoelii yoelii GWT1) are included in the entire genomic sequences of Plasmodium *falciparum (P. falciparum)* and Plasmodium yoelii yoelii (P. yoelii yoelii) (Gardner, et al., Nature 419:498-511, 2003; Carlton et al., Nature 419:512-519, 2003). The present inventors also found that the GWT1 gene product acts as a GlcN-PI acyltransferase in the GPI biosynthesis pathway. The PfGWT1 gene product is expected to have similar activity, and thus compounds that inhibit this activity can be promising antimalarial drugs.

[0009] In WO 02/04626, the present inventors disclosed a group of compounds that inhibit the activity of the fungal GWT1 gene product. Compounds inhibiting the activity of the PfGWT1 gene product were expected to be antimalarial drugs.

[0010] In the present invention, the present inventors succeeded in isolating a region thought to be almost the full length of the PfGWT1. Using the GWT1 gene products of malaria parasites such as *P. falciparum,* antimalarial drugs

can be screened through binding assays, glucosaminyl(acyl)phosphatidylinositol (PI-GlcN) acyltransferase assays, or using GPI-anchored protein detection systems. Compounds obtained from such screenings can be promising antimalarial drugs. From Pan et al., Nucleic acid res 27: 1094-1103, 1999, it was known that a plasmodium falciparum gene, msp-1, has a high AT content of 74%, which prevented stable full-size cloning of the gene in E. coli.

Furthermore, the present inventors revealed that degenerate mutant DNAs (degenerate mutants of the DNA that encodes the malaria parasite GPI biosynthesis protein) having a lower AT content than the original DNA, complement the phenotype of the GWT1 gene-deficient fungus. Thus, it is possible to screen for compounds that inhibit the activity of proteins involved in GPI biosynthesis in malarial parasites by using, as an index, the phenotype of a GPI synthase gene-deficient fungus, into which a degenerate mutant DNA with a lower AT content (than the DNA encoding the GPI biosynthesis protein in malaria parasites) has been introduced.

[0011] Specifically, the present invention provides the following [1] to [10]:

[1]. A DNA encoding a protein that has the activity of complementing the phenotype of a GPI synthase gene-deficient yeast, which is a degenerate mutant of a DNA according to any one of (a) to (c), and which has an AT content of 70% or less of the original DNA according to any one of (a) to (c):

(a) a DNA encoding a protein that comprises the amino acid sequence of SEQ ID NO: 2;
(b) a DNA hybridizing under stringent conditions to the DNA that comprises the nucleotide sequence of SEQ ID NO: 1, wherein the DNA encodes a protein involved in GPI biosynthesis in malaria parasites and has at least 80% identity to the amino acid sequence of SEQ ID NO: 2;
(c) a DNA encoding a protein which comprises the amino acid sequence of SEQ ID NO: 2, in which one or more amino acids have been added, deleted, substituted and/or inserted, wherein the DNA encodes a protein involved in GPI biosynthesis in malaria parasites and has at least 80% identity to the amino acid sequence of SEQ ID NO: 2.

[2]. The DNA of item [1], comprising the nucleotide sequence of SEQ ID NO: 5.
[3]. A vector into which the DNA according to item [1] or [2] is inserted.
[4]. A transformant which retains, in an expressible state, the DNA according to item [1] or [2], or the vector according to item [3].
[5]. The transformant according to item [4], which is

(a) a GPI synthase gene-deficient fungus; or
(b) a GPI synthase gene-deficient yeast.

[6]. A method for producing a protein encoded by the DNA according to item [1] or [2], which comprises the steps of culturing the transformant according to item [4] or [5], and recovering the expressed protein from the transformant or the culture supernatant.
[7]. A method of screening for a compound having antimalarial activity, which comprises the steps of:

(a) contracting a test sample with a GPI synthase gene-deficient fungus that expresses the DNA according to item [1] or [2];
(b) assaying the growth of that fungus; and
(c) selecting a test compound that inhibits the growth of that fungus.

[8]. A method of screening for a compound having antimalarial activity, which comprises the steps of:

(a) contacting a test sample with a GPI synthase gene-deficient fungus expressing the DNA according to item [1] or [2];
(b) determining the amount of a GPI-anchored protein transported to the fungal cell wall; and
(c) selecting a test sample that decreases the amount of the GPI-anchored protein transported to the cell wall, as determined in step (b).

[9]. A method of screening for a compound having antimalarial activity, which comprises the steps of

(a) introducing the DNA according to item [1] or [2] into a GPI synthase gene-deficient fungus and expressing the protein encoded by the DNA;
(b) preparing the protein expressed in step (a);
(c) contacting the prepared protein with a test sample and a labeled compound that has the activity of binding to the protein;

(d) detecting the labeled compound that binds to the protein; and
(e) selecting a test sample that decreases the amount of labeled compound that binds to the protein.

[10]. A method of screening for a compound having antimalarial activity, which comprises the steps of:

(a) introducing the DNA according to item [1] or [2] into a GWT1-deficient fungus, and expressing the protein encoded by the degenerate mutant DNA;
(b) preparing the protein expressed in step (a);
(c) contacting the prepared protein with a test sample;
(d) detecting GlcN-(acyl)PI; and
(e) selecting a test compound that decreases the level of GlcN-(acyl)PI.

[0012] The DNA encoding the GWT1 protein of *Plasmodium falciparum* (PfGWT1) was isolated for the first time in the present invention. The nucleotide sequence of the DNA encoding the PfGWT1 protein is shown in SEQ ID NO: 1, and the amino acid sequence of the PfGWT1 protein is set forth in SEQ ID NO: 2. In addition, the nucleotide sequence of the DNA encoding the GWT1 protein of Plasmodium vivax (PvGWT1) is shown in SEQ ID NO: 3, and the amino acid sequence of the PvGWT1 protein is set forth in SEQ ID NO: 4.

[0013] The GWT1 protein is involved in the biosynthesis of glycosylphosphatidylinositol (GPI), which is essential for the growth and infectivity of malaria parasites. Thus, compounds that inhibit the activity of the malaria parasite GWT1 protein can be used as antimalarial drugs. Such antimalarial drugs can be screened using this malaria parasite GWT1 protein.

[0014] The present invention provides DNAs encoding the malaria parasite GWT1 protein. Such DNAs may include DNA encoding a protein comprising the amino acid sequence of SEQ ID NO: 2 or 4, and DNA comprising the nucleotide sequence of SEQ ID NO: 1 or 3.

[0015] Also described herein are DNAs encoding proteins that are functionally equivalent to the protein comprising the amino acid sequence of SEQ ID NO: 2 or 4. Herein, the expression "functionally equivalent" refers to having biological properties equivalent to those of the protein of interest, comprising the amino acid sequence of SEQ ID NO: 2 or 4 (the PfGWT1 or PvGWT1 proteins). The biological properties of the PfGWT1 and PvGWT1 proteins include GlcN-PI acyltransferase activity. The GlcN-PI acyltransferase activity can be measured by the method reported by Costello and Orlean (J. Biol. Chem. (1992) 267:8599-8603), or Franzot and Doering (Biochem. J. (1999) 340:25-32).

[0016] DNAs encoding proteins functionally equivalent to the protein comprising the amino acid sequence of SEQ ID NO : 2 cr 4 include: DNAs that hybridize under stringent conditions to the DNA comprising the nucleotide sequence of SEQ ID NO: 1 or 3, and DNA encoding a protein which comprises the amino acid sequence of SEQ ID NO: 2 or 4, in which one or more amino acids have been added, deleted, substituted, and/or inserted.

[0017] The DNAs of the present invention can be isolated by methods well known to those skilled in the art. Examples of such methods include the use of hybridization (Southern E.M., J. Mol. Biol. 98: 503-517, 1975) and the polymerase chain reaction (PCR) (Saiki R.K. et al., Science 230: 1350-1354, 1985; Saiki R.K. et al., Science 239: 487-491, 1988). More specifically, it would be routine experimentation for those skilled in the art to isolate, from malaria parasites, a DNA highly homologous to DNA comprising the nucleotide sequence of SEQ ID NO: 1 or 3, using the DNA of SEQ ID NO: 1 or 3 or portions thereof as a probe, or by using as a primer a DNA which specifically hybridizes to the DNA comprising the nucleotide sequence of SEQ ID NO: 1 or 3. Furthermore, DNAs that can be isolated by hybridization or PCR techniques, and that hybridize with the DNA comprising the nucleotide sequence of SEQ ID NO: 1 or 3, are also comprised in the DNAs described herein. Such DNAs may include DNA encoding a malaria parasite homologue of the protein comprising the amino acid sequence of SEQ ID NO: 2 or 4. The malaria parasite homologue includes those of *Plasmodium falciparum, Plasmodium vivax*, *Plasmodium malariae*, and *Plasmodium ovale,* which comprise the amino acid sequence of SEQ ID NO: 2 or 4.

[0018] Preferably, a DNA described above is isolated using hybridization reactions under stringent hybridization conditions. As used herein, the expression "stringent hybridization conditions" refers to, for example, hybridization in 4x SSC at 65°C followed by washing in 0.1x SSC at 65°C for one hour. Alternative stringent conditions are hybridization in 4x SSC containing 50% formamide at 42°C. Further alternative stringent conditions are hybridization in PerfectHyb™ (TOYOBO) solution at 65°C for 2.5 hours, followed by washing: (1) in 2x SSC containing 0.05% SDS at 25°C for five minutes; (2) in 2x SSC containing 0.05% SDS at 25°C for 15 minutes; and (3) in 0.1x SSC containing 0.1% SDS at 50°C for 20 minutes. The DNA thus isolated is expected to encode a polypeptide with a high homology at the amino acid level to the amino acid sequence of SEQ ID NO: 2 or 4. Herein, "high homology" means a sequence identity of at least 70% or more, preferably 80% or more, more preferably 90% or more, and most preferably 95% or more, in the whole amino acid sequence.

[0019] The degree of identity at the amino acid sequence level or nucleotide sequence level can be determined using the BLAST algorithm of Karlin and Altschul (Karlin S. and Altschul S. F, Proc. Natl. Acad. Sci. USA. 87: 2264-2268,

1990; Karlin S. and Altschul S.F, Proc. Natl. Acad. Sci. USA. 90: 5873-5877, 1993). BLAST algorithm-based programs, called BLASTN and BLASTX, have been developed (Altschul S.F. et al., J. Mol. Biol. 215: 403, 1990). When a nucleotide sequence is analyzed using BLASTN, the parameters are set, for example, at score= 100 and word length= 12. On the other hand, when an amino acid sequence is analyzed using BLASTX, the parameters are set, for example, at score= 50 and word length= 3. When the BLAST and Gapped BLAST programs are used, the default parameters for each grogram are used. Specific procedures for such analysis are known (please see the web site of the National Institute of Biotechnology Information http://www.ncbi.nim.nih.gov).

[0020] DNAs of the present invention comprise genomic DNAs, cDNAs, and chemically synthesized DNAs. A Genomic DNA or DNA can be prepared according to conventional methods known to those skilled in the art. For example, a genomic DNA can be prepared as follows: (i) extracting a genomic DNA from malaria parasites; (ii) constructing a genomic library (using, for example, a plasmid, phage, cosmid, BAC, or PAC, as a vector); (iii) spreading the library; and then (iv) conducting colony hybridization or plaque hybridization using probes prepared based on a DNA which encodes the malaria parasite GWT1 protein of the present invention (e.g., SEQ ID NO: 1 or 3). Alternatively, genomic DNA can be prepared by PCR, using primers specific to a DNA which encodes the malaria parasite GWT1 protein described herein (e.g., SEQ ID NO: 1 or 3). On the other hand, cDNA can be prepared, for example, as follows: (i) synthesizing cDNA based on mRNA extracted from malaria parasites; (ii) constructing a cDNA library by inserting the synthesized cDNA into vectors such as λZAP; (iii) spreading the cDNA library; and (iv) conducting colony hybridization or plaque hybridization as described above. Alternatively, the cDNA can also be prepared using PCR.

[0021] Also described herein are DNAs encoding proteins structurally similar to the protein comprising the amino acid sequence of SEQ ID NO: 2 or 4. Such DNAs include those which comprise nucleotide sequences encoding proteins comprising amino acid sequences in which one or more amino acid residues are substituted, deleted, inserted, and/or added. There is no limitation on the number and site of the amino acid mutation in proteins mentioned above, so long as the mutated protein retains functions of the original protein such as those described in Mark, D. F. et al., Proc. Natl. Acad. Sci. USA (1984) 81, 5562-5666; Zoll er, M. J. & Smith, M., Nucleic Acids Research (1982) 10, 6487-6500; Wang, A. et al., Science 224, 1431-1433; Dalbadie-McFarland, G. et al., Proc. Natl. Acad. Sci. USA (1982) 79, 6409-6413. The percentage of mutated amino acids is typically 10% or less, preferably 5% or less, and more (preferably 1% or less of the total amino acid residues. In addition, the number of mutated amino acids is usually 30 amino acids or less, preferably 15 amino acids or less, more preferably five amino acids or less, still more preferably three amino acids or less, even more preferably two amino acids or less.

[0022] It is preferable that the mutant amino acid residue be one that retains the properties of the side-chain after its mutation (a process known as conservative amino acid substitution). Examples of amino acid side chain properties are hydrophobicity (A, I, L, M, F, P, W, Y, V) and hydrophilicity (R, D, N, C, E, Q, G, H, K, S, T). Side chains include: aliphatic side-chains (G, A, V, L, I, P); side chains containing an hydroxyl group (S, T, Y) ; side chains containing a sulfur atom (C, M); side chains containing a carboxylic acid and an amide (D, N, E, Q); basic side-chains (R, K, H); and aromatic side-chains (H, F, Y, W).

[0023] A fusion protein comprising the malaria parasite GWT1 protein is an example of a protein to which one or more amino acids residues have been added. Fusion proteins can be made by techniques well known to a person skilled in the art. For example, and without limitation to this particular technique, the DNA encoding the malaria parasite GWT1 protein of the present invention can be combined with DNA encoding another peptide or protein such that their reading frames match. A protein of the present invention can form a fusion protein with a number of known peptides. Such peptides include FLAG (Hopp, T. P. et al., Biotechnology (1988) 6, 1204-1210), 6x His, 10x His, Influenza agglutinin (HA), human c-myc fragment, VSP-GP fragment, p18HIV fragment, T7-tag, HSV-tag, E-tag, SV40T antigen fragment, lck tag, α-tubulin fragment, B-tag, and Protein C fragment. Examples of proteins that may be fused to a protein of the present invention include glutathione-S-transferase (GST), HA, immunoglobulin constant region, β-galactosidase, and maltose-binding protein (MBP).

[0024] In addition to using the above-mentioned hybridization and PCR techniques, those skilled in the art could prepare the above-described DNA by methods including, for example, site-directed mutagenesis to introduce mutations in that DNA (Kramer W. and Fritz H-J., Methods Enzymol. 154: 350, 1987). A protein's amino acid sequence may also be mutated in nature due to mutation of the nucleotide sequence which encodes the protein. In addition, degenerate mutant DNAs, in which nucleotide mutations do not result in amino acid mutations in the proteins (degeneracy mutants), are also comprised in the present invention. Furthermore, the present invention also comprises proteins encoded by the above-described DNAs of this invention.

[0025] The present invention provides vectors containing the DNAs of the present invention, transformants retaining the DNAs or vectors of the present invention, and methods for producing proteins of the present invention which utilize these transformants.

[0026] A vector of the present invention is not limited so long as the DNA inserted into the vector is stably retained. For example, pBluescript® vector (Stratagene) is preferable as a cloning vector when using *E. coli* as a host. An expression vector is particularly useful when using a vector to produce a protein of the present invention. The expression vector is

not specifically limited, so long as it expresses proteins *in vitro,* in *E. coli,* in cultured cells, and *in vivo.* Preferable examples of expression vectors include the pBEST vector (Promega Corporation) for *in vitro* expression, the pET vector (Novagen) for expression in *E. coli,* the pME18S-FL3 vector (GenBank Accession No. AB009864) for expression in cultured cells, and the pME18S vector (Mol. Cell Biol. 8: 466-472, 1988) for *in vivo* expression. The insertion of a DNA of the present invention into a vector can be carried out by conventional methods, for example, by a ligase reaction using restriction enzyme sites (Current Protocols in Molecular Biology, ed. by Ausubel et al., John Wiley & Sons, Inc. 1987, Section 11.4-11.11).

[0027] The host cell into which the vector of the present invention is introduced is not specifically limited, and various host cells can be used according to the objectives of this invention. For example, cells that can be used to express the proteins include, but are not limited to, bacterial cells (*e.g.*, *Streptococcus*, *Staphylococcus*, *E. coli, Streptomyces, Bacillus subtilis*), fungal cells (*e.g.,* yeast, *Aspergillus*), insect cells (*e.g.*, Drosophila S2, Spodoptera SF9), animal cells (*e.g.*, CHO, COS, HeLa, C127, 3T3, BHK, HEK293, Bowes melanoma cell), and plant cells. The transfection of a vector to a host cell can be carried out by conventional methods such as calcium phosphate precipitation, electroporation (Current protocols in Molecular Biology, ed. by Ausubel et al., John Wiley & Sons, Inc. 1987, Section 9.1-9.9), the Lipofectamine method (GIBCO-BRL), and microinjection.

[0028] By incorporating an appropriate secretion signal into the protein of interest, the protein expressed in host cells can be secreted into the lumen of the endoplasmic reticulum, into cavities around the cells, or into the extracellular environment. These signals may be endogenous or exogenous to the protein of interest.

[0029] When a protein of the present invention is secreted into the culture medium, it is collected from that medium. If a protein of the present invention is produced intracellularly, the cells are lysed and then the protein is collected.

[0030] A protein of the present invention can be collected and purified from a recombinant cell culture using methods known in the art, including, but not limited to, ammonium sulfate or ethanol precipitation, acid extraction, anionic or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography.

[0031] Compounds including DNAs of the present invention are isolated compounds. Herein, the term "isolated" refers to being separated from the original environment (for example, the natural environment if it is naturally-occurring). A compound in a sample where the compound of interest is substantially abundant, and/or in a sample where the compound of interest has been partially or substantially purified, is an "isolated" compound. The term "substantially purified", as used herein, refers to a state where the compound has been separated from the original environment, and from which at least 60%, preferably 75%, and most preferably 90% of other coexisting natural components have been removed.

[0032] Also described herein is an antimalarial drug that inhibits the activity of the GWT1 gene product of malaria parasites. A preferred compound inhibiting the activity of the GWT1 gene product of malaria parasites is the compound described in WO 02/04626, and includes the compounds (1) to (5):



compound (1): 1-(4-butyl benzyl) isoquinoline



compound (2) : 4-[4-(1-isoquinolylmethyl)phenyl]-3-butyne-1-ol



(3)

compound (3): 5-butyl-2-(1-isoquinolyl methyl) phenol



(4)

compound (4): 2-(4-bromo-2-fluorobenzyl)-3-methoxypyridine



(5)

compound (5): N-[2-(4-butyl benzyl) -3-pyridyl]-N- methylamine

[0033] A Compound that inhibits the activity of the malaria parasite GWT1 gene product, or a salt thereof, or a hydrate thereof, can be administered as it is to mammals (preferably humans). It can also be formulated by a conventional method into a tablet, powder, fine granule, granule, coated tablet, capsule, syrup, troche, inhalant, suppository, injection, ointment, eye ointment, eye drop, nasal drop, ear drop, cataplasm, lotion, and such, and then administered.

[0034] For formulation of a pharmaceutical, auxiliary agents ordinarily used in pharmaceutical formulations (for example, fillers, binders, lubricants, coloring agents, flavoring agents, and as necessary, stabilizers, emulsifiers, absorbefacient, surfactants, pH regulators, antiseptics, and antioxidants) can be used. A pharmaceutical formulation can be prepared using an ordinary method combining components that are generally used as ingredients for pharmaceutical preparations.

[0035] For example, oral formulations can be produced by combining a compound of the present invention or a pharmaceutically acceptable salt thereof with a filler, and as necessary, a binder, disintegrator, lubricant, coloring agent, flavoring agent, and such, and then formulating the mixture into a powder, fine granule, granule, tablet, coated tablet, capsule, and such by usual methods.

[0036] Examples of these components include: animal fat and vegetable oils such as soybean oil, beef tallow, and synthetic glyceride; hydrocarbons such as liquid paraffin, squalene, and solid paraffin; ester oils such as octyldodecyl myristate and isopropyl myristate; higher alcohols such as cetostearyl alcohol and behenyl alcohol; silicone resin; silicone oil; surfactants such as polyoxyethylene fatty acid ester, sorbitan fatty acid ester, glycerol fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hardened castor oil, and polyoxyethylene polyoxypropylene block copolymer; water-soluble macromolecules such as hydroxyethyl cellulose, polyacrylic acid, carboxyvinyl polymer, polyethylene glycol, polyvinyl pyrrolidone, and methyl cellulose; lower alcohols such as ethanol and isopropanol; polyhydric alcohols such as glycerol, propylene glycol, dipropylene glycol, and sorbitol; sugars such as glucose and sucrose; inorganic powder such as silicic acid anhydride, magnesium aluminum silicate, and aluminum silicate; and purified water. Examples of fillers include lactose, corn starch, refined white sugar, glucose, mannitol, sorbitol, crystalline cellulose, and silicon

dioxide. Binders are polyvinyl alcohol, polyvinyl ether, methyl cellulose, ethyl cellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, polypropyleneglycol polyoxyethylene block polymer, meglumine, and such. Examples of disintegrators include starch, agar, powdered gelatin, crystalline cellulose, calcium carbonate, sodium hydrogencarbonate, calcium citrate, dextrin, pectin, and calcium carboxymethylcellulose. Lubricants are magnesium stearate, talc, polyethyleneglycol, silica, hardened vegetable oil, and such. Examples of coloring agents are those accepted for addition to pharmaceuticals. Flavoring agents are cocoa powder, *l*-menthol, aromatic dispersant, mint oil, borneol, cinnamon powder, and such. The use of sugar coating and other appropriate coating as necessary is of course permissible for these tablets and granules.

[0037] Furthermore, liquid formulations such as syrups and injections can be prepared using conventional methods. In such methods, pH regulators, solubilizers, isotonizing agents, and such, and as necessary solubilizing adjuvants, stabilizers, and so on, are added to the compounds described herein or pharmaceutically acceptable salts thereof.

[0038] Methods for producing external formulations are not restricted and can be conventional methods. That is, base materials used for formulation can be selected from various materials ordinarily used for medicaments, quasi-drugs, cosmetics, and such. Specifically, the base materials to be used are, for example, animal fat and vegetable oils, mineral oils, ester oils, waxes, higher alcohols, fatty acids, silicone oils, surfactants, phospholipids, alcohols, polyhydric alcohols, water soluble macromolecules, clay minerals, and purified water. As necessary, pH regulators, antioxidants, chelating agents, antiseptic and antifungal agents, coloring matters, fragrances, and such may also be added. However the base materials of the external formulations of the present invention are not limited thereto. Furthermore, as necessary, components such as those that have a differentiation-inducing effect, blood flow accelerants, fungicides, antiphlogistic agents, cell activators, vitamins, amino acids, humectants, and keratolytic agents can be combined. The above-mentioned base materials are added in an amount that leads to the concentration usually used for external formulations.

[0039] The term "salt" as described herein, preferably includes, for example, a salt with an inorganic or organic acid, a salt with an inorganic or inorganic base, or a salt with an acidic or basic amino acid. In particular, a pharmaceutically acceptable salt is preferable. Acids and bases form salts at an appropriate ratio of 0.1 to 5 molecules of acid or base to one molecule of the compound.

[0040] Preferable examples of a salt with an inorganic acid are a salt with hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. Preferably, a salt with an organic acid includes a salt with acetic acid, succinic acid, fumaric acid, maleic acid, tartaric acid, citric acid, lactic acid, stearic acid, benzoic acid, methanesulfonic acid, and p-toluenesulfonic acid.

[0041] Preferable examples of a salt with an inorganic base are: an alkali metal salt such as a sodium salt and a potassium salt; an alkaline earth metal salt such as a calcium salt and a magnesium salt; an aluminum salt, and an ammonium salt. Preferably, a salt with an organic base includes a salt with diethylamine, diethanolamine, meglumine, and N,N'-dibenzylethylenediamine.

[0042] Preferable example of a salt with an acidic amino acid are a salt with aspartic acid and glutamic acid, and preferably, a salt with a basic amino acid includes a salt with arginine, lysine, and ornithine.

[0043] The compounds described herein or salts thereof, or hydrates thereof can be administered orally or parenterally by a conventional method without limitation as to their form. They can be formulated into dosage forms such as tablets, powders, fine granule, capsules, syrups, troches, inhalants, suppositories, injections, ointments, eye ointments, eye drops, nasal drops, ear drops, cataplasms, and lotions. The dose of the pharmaceutical compositions described herein can be selected appropriately depending on the degree of the symptoms, the patient' s age, sex and weight, the dosage form, the type of salt, the specific type of disease, and such.

[0044] Compounds described herein are administered to a patient in a therapeutically effective dose. Herein, "therapeutically effective dose" refers to the amount of pharmaceutical agent that yields the desired pharmacological result and is effective in the recovery or relief from the symptoms of the patient to be treated. The dose differs markedly depending on the type of disease, the degree of symptoms, the patient's weight, age, sex, sensitivity to the agent. However, the normal adult dosage for one day is about 0.03 mg to 1000 mg, preferably 0.1 mg to 500 mg, more preferably 0.1 mg to 100 mg, when administered from once to several times a day, or from once to several times over several days. The dose for injections is normally, about 1 to 3000 μg/kg, and is preferably about 3 to 1000 μg/kg.

[0045] In addition, the present invention relates to a method of screening for antimalarial drugs using the malaria parasite GWT1 gene product. Such a screening method may include, but is not limited to: [1] A binding assay which screens for compounds that compete with a labeled compound to bind with the malaria parasite GWT1 gene product; [2] A GlcN-PI acyltransferase assay system to screen for compounds that inhibit the GlcN-PI acyltransferase activity of the malaria parasite GWT1 gene product; and [3] A GPI-anchored protein detection system in which the malaria parasite GWT1 gene product is expressed in cells, preferably fungal cells, and then the GPI-anchored proteins on the cell surface are detected.

[0046] The methods [1] to [3] listed above are described below in detail.

[1] A binding assay to screen for compounds that compete with a labeled compound to bind with the malaria parasite GWT1 gene product

[0047] The two methods described herein are disclosed below, namely (1) a method for preparing the malaria parasite GWT1 gene product (hereinafter referred to as the malaria parasite GWT1 protein) and (2) a method for a binding experiment involving a labeled compound (hereinafter referred to as a binding assay).

(1) Method for preparing the malaria parasite GWT1 protein

[0048] The malaria parasite GWT1 protein may be prepared from a cell membrane fraction, preferably from fungal cells, more preferably from cells of *S. cerevisiae* into which the DNA encoding the malaria parasite GWT1 protein of SEQ ID NO: 2 has been introduced. It is preferable to introduce such a DNA into GWT1 gene-deficient cells. In the binding assay, the prepared membrane fraction may be used without any further treatment, or can be further purified before use. The procedure using *S. cerevisiae* is described below in detail.

(a) Introduction of the malaria parasite GWT1 gene

[0049] The malaria parasite GWT1 gene used herein can be a naturally-occurring gene, or preferably, it can be synthesized based on the amino acid sequence of SEQ ID NO: 2 or 4. The malaria parasite GWT1 gene is very rich in adenine and thymine. Thus, it was predictable that the gene will be difficult to manipulate with ordinary gene recombination techniques, and that gene expression in yeast, cells, and such will be inefficient. Therefore, it is preferable to design a nucleotide sequence in which codons corresponding to each of the corresponding amino acids have been replaced with those that are thought to express efficiently in yeast, cells, and such, and conduct DNA synthesis based on this designed sequence to create an artificial malaria parasite GWT1 gene, which is then used in the experiments described below.

[0050] An expression plasmid for the malaria parasite GWT1 is prepared by inserting the malaria parasite GWT1 gene into an *S. cerevisiae* expression vector, for example, an expression vector prepared by inserting a suitable promoter and terminator, such as the pKT10-derived GAPDH promotor and GAPDH terminator, into the expression vector YEp352's multi-cloning site (Tanaka et al., Mol. Cell Biol., 10:4303-4313, 1990). *S. cerevisiae* (e.g., G2-10 strain) is cultured in an appropriate medium (e.g., YPD medium (Yeast extract-Polypeptone-Dextrose medium)) while shaking at an appropriate temperature (e.g., 30°C), and the cells are harvested during the late logarithmic growth phase. After washing, the GWT1-expression plasmid is introduced into *S. cerevisiae* cells using, for example, the lithium-acetate method. This method is described in the User Manual of YEAST MAKER™ Yeast Transformation System (BD Biosciences Clontech). A malaria parasite GWT1-overexpressing strain and a strain carrying a negative control vector can be obtained by culturing the transformed cells on SD (ura-) medium at 30°C for two days.

[0051] Expression vectors and gene transfer methods for fungal species other than *S. cerevisiae* have been reported as follows: expression vectors such as pcL for *Schizosaccharomyces pombe (S. pombe)* and their transfer methods are described by Igarashi et al. (Nature 353:80-83, 1991); expression vectors such as pRM10 for *C. albicans* and their transfer methods are described by Pla J. et al. (Yeast, 12: 1677-1702, 1996); expression vectors such as pAN7-1 for A. fumigatus and their transfer methods are described by Punt P.J. et al. (GENE, 56: 117-124, 1987) ; and expression vectors such as pPM8 for *C. neoformans* and their transfer methods are described by Monden P. et al. (FEMS Microbiol. Lett., 187: 41-45, 2000).

(b) Method for preparing membrane fractions

[0052] *S. cerevisiae* cells in which the malaria parasite GWT1 gene has been introduced are cultured in an appropriate medium (e.g., SD (ura-) liquid medium) while being shaken at an appropriate temperature (e.g. , 30°C). The fungal cells are harvested during the mid-logarithmic growth phase, washed, and then suspended in an appropriate amount (e.g., three times the volume of fungal cells) of homogenization buffer (e.g., 50 mM Tris-HCl, pH 7.5, 10 mM EDTA, Complete™ (Roche)). An appropriate amount of glass beads (e.g., four times the volume of fungal cells) is added to the suspension. The mixture is vortexed and then allowed to stand on ice. This operation is repeated several times to crush fungal cells.

[0053] One milliliter of the homogenization buffer is added to the resulting lysate. The mixture is centrifuged, for example at 2,500 rpm for five minutes, to precipitate the glass beads and uncrushed fungal cells. The supernatant is transferred to another tube. The tube is centrifuged, for example at 13,500 rpm for ten minutes, to precipitate a membrane fraction (total membrane fraction) comprising organelles. The precipitate is suspended in 1 ml of binding buffer (e.g., 0.1 M Phosphate buffer, pH 7.0, 0.05% Tween 20, complete™ (Roche)), and then centrifuged, for example, at 2,500 rpm for one minute to remove unsuspended material. The supernatant is then centrifuged, for example at 15,000 rpm for five minutes. The precipitate is resuspended in 150 to 650 μl of binding buffer to prepare a membrane fraction.

[0054] Membrane fractions can be prepared from fungal species other than *S. cerevisiae* using the method of Yoko-

o et al. for S. pombe (Eur. J. Biochem. 257:630-637, 1998); the method of Sentandreu M et al. for C. albicans (J. Bacteriol., 180: 282-289, 1998); the method of Mouyna I et al. for A. fumigatus (J. Biol. Chem., 275 : 14882-14889, 2000); and the method of Thompson JR et al. for C. neoformans (J. Bacteriol., 181: 444-453, 1999).

[0055] Alternatively, the malaria parasite GWT1 protein can be prepared by expressing an *E. coli,* insect and mammalian cell or the like in non-fungal cells.

[0056] When mammalian cells are used, the malaria parasite GWT1 gene is ligated with an over-expression vector containing, for example, the CMV promotor, and then introduced into the mammalian cells. Membrane fractions can then be prepared according to the method of Petaja-Repo et al. (J. Biol. Chem., 276:4416-23, 2001).

[0057] Insect cells expressing the malaria parasite GWT1 gene (e.g., Sf9 cells) can be prepared using, for example, a baculovirus expression kit such as the BAC-TO-BAC® Baculovirus Expression system (Invitrogen). Membrane fractions can then be prepared according to the method of Okamoto et al. (J. Biol. Chem., 276:742-751, 2001).

[0058] The malaria parasite GWT1 protein can be prepared from *E. coli* by, for example, ligating the malaria parasite GWT1 gene into an E. coli expression vector such as the pGEX vector (Amersham Biosciences Corp.), and introducing the construct into E. coli such as BL21.

(2) Binding assay methods

(a) Synthesis of labeled compound

[0059] The labeled compound is prepared from a compound that has been confirmed to bind to GWT1 proteins. Any compound which can bind to GWT1 proteins can be used. The labeled compound is preferably prepared from the compound described in WO 02/04626, more preferably from compounds according to (1) to (5) described above.

[0060] Any labeling method can be used. Preferably, the compound is labeled with a radioisotope, more preferably with ^{3}H. The radiolabeled compound can be prepared by typical production methods using a radioactive compound as a starting material. Alternatively, ^{3}H labeling can be achieved using an ^{3}H exchange reaction.

(b) Confirmation of specific binding

[0061] The labeled compound is added to the prepared membrane fraction and the mixture is allowed to stand on ice for an appropriate time, for example, one to two hours, while the binding reaction between the labeled compound and the membrane fraction takes place. The membrane fraction is precipitated by centrifuging the mixture, for example at 15,000 rpm for three minutes. The precipitate is resuspended in binding buffer, and the suspension is centrifuged. This is repeated appropriately (twice) to remove any unbound labeled compound. The precipitate is again suspended in binding buffer. The resulting suspension is transferred into a scintillation vial, and a scintillator is added. Radioactivity is measured using a liquid scintillation counter.

[0062] The specific binding of the labeled compound to the GWT1 protein can be confirmed by assessing whether binding of the labeled compound is inhibited by adding a large excess of unlabeled compound (ten times or more), and whether the compound binds negligibly to membrane fractions prepared from fungal cells which do not express the GWT1 protein.

(c) Binding inhibition of a labeled compound by a test sample

[0063] A test sample and the labeled compound are added to the prepared membrane fraction, and the mixture is allowed to stand on ice for an appropriate period of time, for example, one to two hours, while the binding reaction to the membrane fraction takes place. Test compounds used in the herein described screening method include: a simple naturally-occurring compound, an organic compound, an inorganic compound, a protein, or a peptide, as well as a compound library, an expression product of a genetic library, a cell extract, a cell culture supernatant, a product from fermentative bacteria, an extract of a marine organism, a plant extract, and the like.

[0064] The mixture is centrifuged, for example at 15,000 rpm for three minutes to precipitate the membrane fraction. The precipitate is resuspended in binding buffer and the suspension is centrifuged. This is repeated appropriately (twice) to remove any unbound labeled compound. The precipitate is suspended in the binding buffer. The suspension is transferred into a scintillation vial, and scintillator is added thereto. The radioactivity is measured using a liquid scintillation counter.

[0065] When the binding of the labeled compound to the membrane fraction is inhibited in the presence of a test sample, the test sample is judged to have the activity of binding to the malaria parasite GWT1 protein.

[2] The GlcN-PI acyltransferase assay system for screening compounds that inhibit the GlcN-PI acyltransferase activity of the malaria parasite GWT1 protein

[0066] The transfer of an acyl group to GPI can be detected by the method reported by Costello L.C and Orlean P., J. Biol. Chem. (1992) 267:8599-8603; or Franzot S.P and Doering T.L., Biochem. J. (1999) 340:25-32. A specific example of the method is described below. The following experimental conditions are preferably optimized for each malaria parasite GWT1 protein to be used.

[0067] The malaria parasite GWT1 protein is prepared according to the procedure described in Section 1. A membrane fraction comprising the malaria parasite GWT1 protein is added to a buffer which comprises an appropriate metal ion (Mg^{2+}, Mn^{2+}), ATP, Coenzyme A, and preferably an inhibitor that prevents the consumption of UDP-GlcNAc in other reactions, for example, nikkomycin Z as an inhibitor of chitin synthesis, or tunicamycin as an inhibitor of asparagine-linked glycosylation. A test sample is then added to the mixture and the resulting mixture is incubated at an appropriate temperature for an appropriate period of time (for example, at 24°C for 15 min).

[0068] A GlcN-(acyl)PI precursor (for example UDP-GlcNAc, Acyl-Coenzyme A, and preferably UDP-[^{14}C] GlcNAc) which has been appropriately labeled, and preferably radiolabeled, is added to the mixture. The resulting mixture is incubated for an appropriate period of time (for example, at 24°C for one hour). A mixture of chloroform and methanol (1:2) is added, the resulting mixture is stirred to halt the reaction, and the lipids are extracted. The extracted reaction product is dissolved in an appropriate solvent, preferably butanol. Then, GlcN- (acyl) PI produced in the reaction is separated by a method such as HPLC or thin layer chromatography (TLC), preferably TLC. When TLC is used, the developer can be selected appropriately from, for example, -$CHCl_3/CH_3OH/H_2O$ (65:25:4), $CHCl_3/CH_3OH$/1M NH_4OH (10:10:3), and $CHCl_3$/pyridine/HCOOH (35:30:7). A preferred developer is $CHCl_3/CH_3OH/H_2O$ (65:25:4). The separated GlcN- (acyl) PI is quantified using a method appropriate for the label used. When labeled with an radioisotope, the separated GlcN- (acyl) PI can be quantified based on its radioactivity.

[0069] When the amount of GlcN-(acyl)PI produced is reduced in the presence of a test sample, the test sample is judged to have the activity of inhibiting acyl group transfer by the malarial parasite GWT1 protein.

[3] A GPI-anchored protein detection system which comprises expressing the malaria parasite GWT1 protein in cells and detecting the GPI-anchored protein on the cell surface

[0070] The ability of a test sample to inhibit the activity of the malaria parasite GWT1 protein can be determined using a GPI-anchored protein detection system that comprises expressing the GWT1 protein in cells, preferably fungal cells, and then detecting the GPI-anchored protein on the cell surface. The fungi described herein are those belonging to Zygomycota, Ascomycota, Basidiomycota, and Deuteromycete, and preferably pathogenic fungi, Mucor, Saccharomyces, Candida, Cryptococcus, Trichosporon, Malassezia, Aspergillus, Trichophyton, Microsporum, Sporothrix, Blastmyces, Coccidioides, Paracoccidioides, Penicillinium, and Fusarium, more preferably *C. albicans*, *C. glabrata, C. neoformans,* and *A. fumigatus*, and even more preferably, yeast. Such yeasts include *S. cerevisiae* and *S.* pombe. The method for introducing into the above-described fungal cells an expression vector containing inserted DNA encoding the malaria parasite GWT1 protein is known to those skilled in the art.

[0071] When the malaria parasite GWT1 protein is expressed in fungal cells, the amount of GPI-anchored protein transported to the fungal cell wall can be determined by the following methods: (1) by using a reporter enzyme; (2) by using an antibody that reacts with the surface glycoprotein of fungal cell walls; (3) by using the protein's ability to adhere to animal cells; or (4) by observing fungal cells under a light microscope or electron microscope.

[0072] The methods of (1) to (4) have been disclosed in WO 02/04626, which is described specifically in Examples of this invention. The methods (1) to (4), and preferably a combination of these methods (1) to (4), can determine whether a test sample inhibits the transport of the GPI-anchored protein onto the cell wall, or the expression of the GPI-anchored protein on the fungal cell surface.

[0073] Hereinafter, the methods of (1) to (4) will be described.

(1) A method using a reporter enzyme

[0074] The process that transports GPI-anchored proteins to the cell wall can be quantified using a tracer experiment such as one where a GPI-anchored protein is labeled with a radioactive isotope, the fungal cell wall fraction is obtained, and immunoprecipitated using an antibody against the GPI-anchored protein. Alternatively, quantification can be more readily performed as follows: the C-terminal sequence, which is considered to function as a transport signal and is commonly observed among GPI-anchored proteins, can be expressed as a fusion protein with an easily measurable enzyme (reporter enzyme), the fungal cell wall fraction can be obtained,; and a reporter system that measures the enzyme activity of each fraction can be used (Van Berkel MAA et al., FEBS Letters, 349: 135-138, 1994). Hereinafter, a method which uses a reporter enzyme will be described.

[0075] First, the reporter gene is constructed and introduced into fungi. The reporter gene is constructed by linking a promoter sequence that functions in fungi with DNAs that respectively encode a signal sequence, a reporter enzyme, and a GPI-anchored protein C-terminal sequence in such a way that the reading frames match. Examples of the promoter sequence are GAL10 and ENO1. Examples of the signal sequence include α-factor, invertase, and lysozyme. Examples of reporter enzymes are β-lactamase, lysozyme, alkaline phosphatase, and β-galactosidase. Green Fluorescence Protein (GFP), which has no enzyme activity but can be easily detected, can also be used. GPI-anchored protein C-terminal sequences include the α-agglutinin C-terminal sequence, the CWP2 C-terminal sequence, and so on. Furthermore, it is preferable to insert an appropriate selection marker, such as LEU2 and URA3, into the vector comprising the constructed reporter gene.

[0076] The constructed reporter gene is inserted into fungi using an appropriate method, such as the lithium acetate method (Gietz D et al., Nucl. Acids Res. 20: 1425, 1992). The fungi are then cultured, as necessary, using a method that suits the selection marker (e.g. using Leu^- medium for LEU2 and Ura^- medium for URA3), and then fungi into which the DNA has been introduced are selected.

[0077] The effect of a test sample on the transport of GPI-anchored proteins to the cell wall is examined by the following method:

[0078] The reporter gene-introduced fungi are cultured under appropriate conditions, for example at 30°C for 48 hours, in the presence of a test sample. After culturing, the culture supernatant is centrifuged, and the reporter enzyme activity of the culture supernatant fraction is measured. The resulting cell fraction is washed, the cell wall components are separated using an appropriate method, such as degrading the cell wall glucan with glucanase, and then the reporter enzyme activity of the cell wall fraction and cytoplasmic fraction is measured. The assay can be simply carried out by using centrifugation to determine the amount of reporter enzyme in the cell fraction, then without washing the cells, using proportional calculations to determine the amount of reporter enzyme derived from the culture supernatant fraction that remains in the cell fraction, and subtracting this from the amount of reporter enzyme of the cell fraction.

[0079] If the test sample exhibits the activity of increasing reporter enzyme activity within the culture supernatant fraction (activity per cell), or the activity of decreasing the reporter enzyme activity in the cell wall fraction (activity per cell), the test sample is judged to have influenced the transport process of GPI-anchored proteins to the cell wall.

(2) A method using an antibody that reacts with the surface glycoprotein of fungal cell walls

[0080] A test sample's ability to influence the expression of a GPI-anchored protein at the fungal surface layer can be determined by quantification using an antibody that reacts with that GPI-anchored protein in the fungal cell wall.

[0081] Antibodies can be obtained by predicting the antigenic determinant using the amino acid sequence of, for example, a GPI-anchored protein such as α-agglutinin, Cwp2p, or Als1p (Chen MH et al., J. Biol. Chem., 270: 26168-26177, 1995; Van Der Vaat JM et al., J. Bacteriol., 177:3104-3110,1995; Hoyer LL et al., Mol. Microbiol., 15: 39-54, 1995), and then synthesizing the peptide of that region, binding it to an antigenic substance such as a carrier protein, and then immunizing a rabbit or such to obtain polyclonal antibodies, or a mouse or such to obtain a monoclonal antibody. A rabbit polyclonal antibody against the Als1p peptide is preferable.

[0082] In an alternative method, a monoclonal antibody against a GPI-anchored protein may be obtained by immunizing mice and such with fungi, preferably fungi which overexpress a GPI-anchored protein such as α-agglutinin, Cwp2p, and Als1p, (in some cases by immunizing further with a partially purified GPI-anchored protein), and then using ELISA, Western blot analysis, and so on to select resultant clones based on the antibody that they produce.

[0083] The following method can be used to determine the influence of a test sample on the process that transports a GPI-anchored protein to the cell wall, and on the amount of protein derived from that GPI-anchored protein in the cell wall.

[0084] Fungi are cultured in the presence of a test sample under appropriate conditions such as 30°C for 48 hours. The cultured fungi are collected by centrifugation and the cells are disrupted, preferably using glass beads. The washed, disrupted cells are preferably subjected to centrifugal extraction with SDS, and then the precipitate is washed. After extraction, the disrupted cells are treated with an enzyme that degrades glucan, preferably glucanase, and the centrifuged supernatant thereof is the GPI-anchored protein sample.

[0085] The anti-Als1p peptide antibody is coated onto a 96-well plate by overnight incubation at 4°C. The plate is washed with a washing solution, preferably PBS comprising 0.05% Tween 20 (PBST), and blocking is carried out using a reagent that blocks the non-specific adsorption sites of the 96-well plate, preferably a protein such as BSA or gelatin, more preferably BlockAce (Dainippon Pharmaceutical Co.,Ltd.). The plate is again washed with a washing solution, preferably PBST, and an appropriately diluted GPI-anchored protein sample is added. The reaction is then carried out for an appropriate time such as two hours at room temperature. After washing with a washing solution, preferably with PBST, an antibody against the enzyme-labeled *C. albicans,* preferably HRP-labeled anti-Candida antibody, is reacted for an appropriate time such as two hours at room temperature. The labeling method may be enzyme labeling or radioactive isotope labeling. After washing with a washing solution, preferably PBST, the amount of Als1p in the GPI-anchored protein sample is calculated by a method appropriate to the type of label, i.e. for an enzyme label, by adding

a substrate solution and then, upon stopping the reaction, measuring absorbance at 490 nm.

(3) A method using the ability to adhere to animal cells

[0086] The test sample' s influence on the expression of a GPI-anchored protein on the fungal surface can be determined by measuring the activity of that GDI-anchored protein in the fungal cell wall, and preferably by measuring the ability of fungi to adhere to animal cells and the like. In addition to the activity of Als1p, Hwp1p and' such in adhesion to animal cells, GPI-anchored protein activity includes that of α-agglutinin in mating, of Flo1p in yeast aggregation, and so on. Hereinafter, a method using the ability of fungi to adhere to animal cells will be described in detail.

[0087] A fungus with the ability to adhere to cells is used, and this fungus is preferably *C. albicans*. For mammalian cells, cells that adhere to the fungus, preferably intestinal epithelial cells, are used. The mammalian cells are cultured and fixed using an appropriate method, such as ethanol fixation. The test sample and the fungi are incubated for an appropriate time such as 48 hours at 30°C, then inoculated and cultured for a set time, for example, one hour at 30°C. The culture supernatant is then removed, and the cells are washed witch a buffer and overlaid with agar media such as Sabouraud Dextrose Agar Medium (Becton Dickinson Company, Ltd.). After culturing at 30°C overnight, the number of colonies is counted, and the adhesion rate is calculated.

[0088] If, when compared to fungi not treated with the compound, a test sample is observed to have the activity of decreasing the number of colonies formed.by cell adhesion, that test sample is judged to have influenced the process that transports GPI-anchored proteins to the cell wall.

(4) A method for observing fungi using an electron microscope or an optical microscope

[0089] The influence of a test sample on the expression of the GPI-anchored protein in the fungal surface can be determined by observing the structure of the fungal cell wall using an electron microscope.

[0090] In the presence of a test sample, a fungus such as *C. albicans* is cultured for a certain period of time, for example, 48 hours at 30°C, and its ultrafine morphological structure is observed using a transmission electron microscope. Herein, observation using a transmission electron microscope can be carried out, for example by the method according to the Electron Microscope Chart Manual (Medical Publishing Center). The flocculent fibrous structure of the outermost layer of a fungal cell has a high electron density and is observable by transmission electron microscope. This structure is not influenced by other existing antifungal agents and is considered to be a surface glycoprotein layer, including GPI-anchored proteins as its constituents. When this structure disappears, leaving only a slight layer with a high electron density, the test sample is judged to have influenced the process that transports GPT-anchored proteins to the cell"wall, compared to untreated cells.

[0091] When observation under both a transmission electronmicroscope and an optical microscope reveals, greatly swollen fungal cells and inhibited budding (division), the test sample is judged to have an influence on the cell wall.

[0092] Also described herein is a method for treating malaria, which comprises the step of administering a compound that inhibits the activity of a GWT1 protein a malaria parasite. Such a compound includes the compounds described in WO 02/04626 (for example, the compounds described herein in (1)-(5)).

[0093] The nucleotide sequence for the natural PfGWT1 protein is characterized by an exceedingly high AT content (80. 41%), and thus codon usage is biased. In addition, the gene contains sequence stretches comprising six or more consecutive A residues at 23 separate positions, and these sequence stretches may serve as pseudo-poly(A) sites, thus producing truncated proteins. Because of the features described above, the gene was only expressed poorly in yeast, and very difficult to amplify using PCR or to replicate in *E. coli*. It was also difficult to determine the nucleotide sequence. However, the present inventors succeeded in expressing the PfGWT1 protein with a high efficiency by using a degenerate mutant of the DNA (SEQ ID NO: 5), with a lower AT content than the DNA encoding the PfGWT1 protein. The inventors also revealed that the introduction of the degenerate mutant DNA can rescue the phenotype of GWT1-deficient yeast. This finding suggests that the GPI synthase of a malaria parasite is interchangeable with that of a fungus such as yeast.

[0094] The AT content of the gene encoding the malaria parasite GPI synthase is, for example, 79.35% for GPI8 and 77.89% for the GPI13 of *P. falciparum.* These AT contents are as high as that of PfGWT1. It is predicted that most *P. falciparum* genes are hardly expressed in other species, because the average AT content over the translated regions of the *P. falciparum* genome is 76.3%. The present inventors succeeded in expressing a degenerate mutant of the DNA with a lower AT content than that of the DNA encoding the PFGWT1 protein, in yeast. Hence, the malaria parasite GPI synthase can be expressed in a host other than malaria parasites by using such a degenerate DNA mutant. Furthermore, GPI-deficient yeast and GWT1-deficient yeast are known to exhibit similar phenotypes, including the characteristic of lethality and such. Thus, the phenotype of the GPI synthase gene-deficient fungus can be rescued by using the degenerate mutant DNA described above.

[0095] The phenotype of the GPI synthase gene-deficient fungus into which the degenerate mutant DNA described

above has been introduced depends on the activity of the malaria parasite GPI synthase Accordingly, compounds that inhibit the activity of the malaria parasite GPI synthase can be selected by screening using the phenotype of the GPI synthase gene-deficient'fungus as an index. Thus, antimalarial drugs targeting the GPI biosynthesis pathway can be selected without actually using the malaria parasites themselves.

[0096] The present invention provides a degenerate mutant DNA encoding a protein that has the activity of rescuing the phenotype of a GPI synthase gene-deficient fungus, and which has an AT content lower than that of the original DNA encoding the protein involved in the biosynthesis of GPI. Such a DNA can be used in the screening method of the present invention.

[0097] As used herein, the term "AT content" refers to the content of adenine and thymine in the entire nucleotide sequence of the coding region of the GPI synthase gene. The AT content in the degenerate mutant DNA of the present invention preferably ranges from 50% to 70%, more preferably from 53% to 65%, and still more preferably from 55% to 62%.

[0098] The phenotype of the GPI synthase gene-deficient fungus includes temperature sensitivity (preferably, sensitivity to high temperatures) and lethality.

[0099] The proteins described herein involved in the biosynthesis of GPI in malaria parasites include GWT1, GPI1, GLI8, GPI3/PIG-A, GPI10/PIG-B, YJR013W/PIG-M, GPI13/PIG-O, GAA1/GAA-1, DPM1, GPI2, GPI15, YDR437W, GPI12, MCD4, GPI11, GPI7, GPI17, GPI16, CDC91, DPM2, DPM3, and SL15. Of the proteins indicated above, GPI1 and GPI8 have been found to be present in malaria parasites, and GPI3/PIG-A, GPI10/PIG-B, YJR013W/PIG-M, GPI13/PIG-O, GAA1/GAA-1, and DPM1 have been suggested to be present in malaria parasites (Delorenzi et al., Infect. Immun. 70: 4510-4522, 2002). The nucleotide sequences of GWT1, GPI1, GPI8, GPI3/PIG-A, GPI10/PIG-B, YJR013W/PIG-M, GPI13/PIG-O, GAA1/GAA-1, and DPM1 of *P. falciparum* are shown in SEQ ID NO: 1 and the even sequence identification numbers in SEQ ID NOs: 6-21, respectively. Each corresponding amino acid sequence is shown in SEQ ID NO: 2 and the odd sequence identification numbers in SEQ ID NOs: 6-21. In addition, the nucleotide sequence of P. vivax GWT1 is shown in SEQ ID NO: 3, and the corresponding amino acid sequence is shown in SEQ ID NO: 4. Using a method known to those skilled in the art, for example, a method using hybridization or PCR, GWT1, GPI1, GPI8, GPI3/PIG-A, GPI10/PIG-B, YJR013W/PIG-M, GPI13/PIG-O, GAA1/GAA-1, or DPM1 of other malaria parasites can be cloned using DNA comprising any one of the nucleotide sequences shown in SEQ ID NO: 1 and 3, and the even-numbered SEQ ID NOs: 6-21.

[0100] Furthermore, GPI synthase genes other than GWT1, GPI1, GPI8, GPI3/PIG-A, GPI10/PIG-B, YJR013W/PIG-M, GPI13/PIG-O, GAA1/GAA-1, and DPM1 of malaria parasites can be cloned by using yeast or human GPI synthase genes. The nucleotide sequences of GPI2, GPI15, YDR437W, GPI12, MCD4, GPI11, GPI7, GPI17, GPI16, and CDC91 of yeast (*S. cerevisiae*) are shown in the even sequence identification numbers in SEQ ID NOs: 22-41 respectively; and each corresponding amino acid sequence is shown in the odd sequence identification numbers in SEQ ID NOs: 22-41. In addition, the nucleotide sequences of human DPM2, DPM3, and SL15 are shown in the even sequence identification numbers in SEQ ID NOs : 42-47 respectively; and each corresponding amino acid sequence is shown in the odd sequence identification numbers in SEQ ID NOs: 42-47.

[0101] The production of a degenerate mutant DNA encoding a protein involved in the biosynthesis of the GPI of malaria parasites, and with a lower AT content than that of the original DNA, consists of two steps: design, and synthesis. In the design step, the amino acid sequence of a protein of interest is first reverse-translated and then possible codons for each amino acid residue are listed. Reverse translation can be achieved by using commercially available gene analysis software (for example, DNASIS-Pro; Hitachi Software Engineering Co., Ltd). Of the codons listed, those meeting the purpose (for example, codons whose AT content is lower and codons frequently used in the host to be used for gene expression) are selected for each amino acid. The degenerate mutant DNA can be designed by rearranging the amino acid sequence of the protein of interest using these selected codons.

[0102] The DNA thus designed can be synthesized by a method known to those skilled in the art. The degenerate mutant DNA described herein can be synthesized based on the designed nucleotide sequence by, for example, using a commercially available DNA synthesizer.

[0103] The present invention also provides vectors in which the above-described regenerate mutant DNA has been inserted, and transformants (preferably GPI synthase gene-deficient fungi) that retain the DNA or the vector in an expressible state. The vector and the host may be those described above.

[0104] As used herein, the expression "deficient in the GPI synthase gene" means that the functional product of the gene is not expressed, or that the expression level is decreased. The GPI synthase gene-deficient fungus described herein can be prepared by disrupting the GPI gene. The disruption can be achieved by inserting DNA unrelated to the gene, for example a selection marker, based on homologous recombination technology, and the like. More specifically, such a mutant fungus can be prepared by introducing into yeast a selection marker cassette which comprises the his5 gene or the kanamycin resistance gene of *S. pombe* (Longtine et al., Yeast, 14: 953-961, 1998) amplified with primers, each of which comprises a nucleotide sequence homologous to a portion of the gene (ranging from 50 to 70 nucleotides).

[0105] The GPI synthase gene-deficient fungus described herein includes; for example, the GWT1 temperature-

sensitive mutant strain gwt1-20, GPI7 disruptant strain, GPI8 mutant strain gpi8-1, and GPI1 0 temperature-sensitive mutant strain per13-1.

[0106] A GPI synthase gene-deficient fungus which has been transformed with the degenerate mutant DNA, of the present invention may be prepared by introducing into a fungus a vector into which the degenerate mutant DNA has been inserted. pRS316, YEp351, or such can be used as the vector for *S. cerevisiae*, and pcL, pALSk, or such can be used as the vector for *S. pombe.*

[0107] The present invention also provides a method of screening for antimalarial drugs, which may comprise using GPI synthase gene-deficient fungi described above.

[0108] In such a method, the first step comprises contacting a test sample with a GPI synthase gene-deficient fungus that has been transformed with degenerate mutant DNA with a lower AT content than the DNA encoding a protein involved in the biosynthesis of GPI of malaria parasites. The "contact" can be achieved by adding a test sample to the culture of the above-mentioned fungus. When the test sample is a protein, a vector comprising DNA encoding the protein can be introduced into the above-mentioned fungus.

[0109] In the method described herein the next step may comprise measuring the degree of growth of the above-mentioned fungus. More specifically, the fungus is inoculated under typical culture conditions, specifically, the fungus is inoculated onto a liquid culture medium such as Yeast extract-polypeptone-dextrose medium (YPD medium) or onto an agar plate, and then incubated at 25 to 37°C for 4 to 72 hours. Thus GPI synthase gene-deficient fungus transformed with the degenerate mutant DNA of the present invention can be assessed for growth. The degree of growth can also be determined using the turbidity of the culture liquid, the number of colonies, or the size or color of the spots formed on the agar plate as an index. In the method described herein, the next step may comprise selecting compounds that inhibit the growth of the above-mentioned fungus.

[0110] In an alternative method, the first step may comprise contacting a test sample with a GPI synthase gene-deficient fungus in which the above-described degenerate mutant DNA has been introduced. The next step may comprise determining the amount of GPI-anchored protein transported onto the yeast cell wall. The detection method may include. (1) methods using a reporter enzyme; (2) methods using an antibody that reacts with a surface glycoprotein on the fungal cell wall; (3) methods using the ability to adhere to animal cells; and (4) methods using a light microscope or an electron microscope to observe the fungi. In the method described herein the next step comprises selecting a sample that decreases the amount of GPI-anchored protein transported to the cell wall.

[0111] Also described herein is a method of screening for antimalarial drugs using a protein involved in the biosynthesis of GPI, which is prepared using a degenerate mutant DNA of the present invention. Such methods include, for example, a binding assay system where screening is carried out to select compounds that bind to a protein involved in GPI biosynthesis in competition with a labeled compound bound to the protein. Specifically, a degenerate mutant DNA of the present invention is introduced into the GPI synthase gene-deficient fungus, the protein encoded by the DNA is expressed in the fungus, and the expressed protein is prepared. The prepared protein is then contacted with a test sample and with a labeled compound that can bind to the protein. In the next step, the labeled compound bound to the protein is detected, and test samples that decrease the amount of labeled compound bound to the protein are selected.

[0112] Also described herein is an assay system for GlcN-PI acyltransferase. Such a system comprises using a GWT1 protein which is prepared using a DNA encoding a protein that has the activity of complementing the phenotype of GWT1-deficient yeast, which the DNA is a degenerate mutant of a DNA encoding a malaria parasite GWT1 protein that has a lower AT content than the original DNA. Specifically, the degenerate mutant DNA is introduced into GWT1-deficient fungus, the protein encoded by the degenerate mutant DNA is expressed in the fungus, and the expressed protein is prepared. This protein is then contacted with a test sample, GlcN- (acyl) PI is detected, and a test sample that decreases the amount of GlcN- (acyl) PI is selected.

Brief Description of the Drawings

[0113] Fig. 1 depicts photographs showing the results of tetrad analysis. The gwt1-disrupted strain became viable after the introduction of the opfGWT1-overexpressing plasmid. The four spores derived from a single diploid cell were spotted vertically.

[0114] If one copy of the GWT1 gene was disrupted, only half of the spores grew. Thus, the ratio of [colony-forming spots]: [spots exhibiting no growth] is 2:2 in such cases. In the columns marked with an arrow, the lethal phenotype of the gwt1 disruptant was complemented by the introduced opfGWT1, and hence all four spots grew, each forming a colony.

[0115] Fig. 2 depicts a diagram showing the inhibitory activity of a compound with respect to the growth of yeast expressing the opfGWT1 gene. Either the yeast GWT1 gene or opfGWT1 gene was expressed in GWT1 gene-disrupted yeast.

[0116] A compound having the activity of inhibiting the GWT1-dependent growth of yeast also showed inhibitory activity with respect to the opfGWT1-dependent growth of yeast in which opfGWT1 was expressed.

[0117] Fig 3 depicts a diagram showing antimalarial activity. Human red blood cells were infected with *P. falciparum*.

A GWT1-inhibiting compound was added to these red blood cells, and inhibition of malaria parasite infection was determined.

[0118] All five compounds exhibiting antifungal activity also inhibited the malaria parasite infection of red blood cells.

Best Mode for Carrying out the Invention

[0119] Herein below, the present invention will be specifically described using Examples, but it is not to be construed as being limited thereto.

[Example 1] *P. falciparum* GWT1 (PfGWT1)

[0120]

(1) The nucleotide sequence of *P. falciparum* GWT1 (PfGWT1) (SEQ ID NO: 1) has been disclosed in the database of the *P. falciparum* genome (PlasmoDB database, http://plasmodb.org/). The PfGWT1 gene was cloned by PCR using genomic DNA purified from *P. falciparum* (the 3D7 strain) as a template. The 5' half and 3' half of the PfGWT1 gene were prepared separately, and the two halves were assembled at an XbaI (TCTAGA) restriction enzyme site. Thus, the full-length PfGWT1 gene was prepared. In addition, restriction enzymes sites outside the coding region were included, thus allowing insertion into an expression vector.

(2) The 5' half of the PfGWT1 gene was amplified by PCR using *P. falciparum* genomic DNA as a template and the primers pf152F (SEQ ID NO: 48) and pf136R (SEQ ID NO: 49). The 3' half was amplified by the same procedure described above, using the primers pf137F (SEQ ID NO: 50) and pf151R (SEQ ID NO: 51). The DNA fragments amplified were subcloned into the pT7-Blue vector (Novagen), and the nucleotide sequences of the inserts were sequenced to confirm homology to SEQ ID NO: 1. Clones containing the 5' half of the PfGWT1 gene were named PF15-5 clones. Clones containing the 3' half were named PF20-9 clones.

(3) Using PCR, cleavage sites for restriction enzymes were added outside the coding region to enable the PfGWT1 gene to be inserted into an expression vector. An EcoR1 cleavage site was added to the 5' half by PCR using PF15-5 as a template and the primers pf154FE (SEQ ID NO: 52) and pf157R (SEQ ID NO: 53). The amplified DNA fragment was subcloned into the pT7-Blue vector (Novagen) to prepare the clone pT7-plasmN2. Likewise, the 3' half was amplified by PCR using PF20-9 as a template and the primers pf168BK (SEQ ID NO: 54) and pf155RK (SEQ ID NO: 55). The amplified DNA fragments were subcloned to prepare pT7-plasmBK5 clones.

(4) The full-length PfGWT1 gene was prepared by the procedure described below. The yeast expression vector YEp352GAPII was digested with the restriction enzymes EcoRI and KpnI. The EcoRI-XbaI fragment (about 1500 bp) derived from pT7-plasmN2, and the XbaI-KpnI fragment (about 1100 bp) derived from pT7-plasmBK5, were inserted into the vector at a cleaved site. The expression vector YEp352GAPII-PfGWT1 containing the full-length PfGWT1 was then constructed.

[pf152F] ATGACAATGTGGGGAAGTCAACGGg (SEQ ID NO: 48)
[pf136R] TGTGTGGTTACCGTTCTTTGAATACATAGA (SEQ ID NO: 49)
[pf137F] ATAGAAAATGATTTATGGTACAGCTCAAA (SEQ ID NO: 50)
[pf151R] AGACCAAATTAATTATGCCTTTACATGTAC (SEQ ID NO: 51)
[pf154FE] agaattcaccATGAGCAACATGAATATACTTGCGTATCTT (SEQ ID NO: 52)
[pf157R] GAAATTCCAATGTATTCCATATTCACTTAT (SEQ ID NO: 53)
[pf168BK] AAGATCTAATACATTAAAACATTTTAGATTAATGAATATGTG (SEQ ID NO: 54)
[pf155RK] aggtaccGTACACTCCACTCTATGATGATCATTC (SEQ ID NO: 55)

[Example 2] A fully synthetic PfGWT1 gene

[0121] The adenine and thymine (AT) proportion is exceedingly high (80% or higher) in *P. falciparum* DNA, and thus routine biological techniques (PCR, *E. coli*-based gene engineering, expression systems for recombinant proteins, and so on) are often unavailable (Sato and Horii; Protein, Nucleic acid, and Enzyme Vol. 48, 149-155, 2003). Likewise, the AT content of PfGWT1 DNA was 80.41% including many consecutive A or T stretches. Thus, the gene was predicted to be difficult to replicate and express as a protein in yeast. Indeed, when native PfGWT1 ligated with a yeast overexpression vector was introduced into GWT1 disrupted yeast, the PfGWT1 did not rescue the lethal phenotype of the GWT1 disruptant at all. To reduce AT content, codons were replaced with synonymous codons without changing the original amino acid sequence.

[0122] The codon substitution was carried out based on the nucleotide sequence of *P. falciparum* GWT1 (SEQ ID NO: 1) disclosed in the *P. falciparum* genome database (PlasmoDB database, http://plasmodb.org/). The resulting

nucleotide sequence was named "optimized PfGWT1 (opfGWT1)" (SEQ ID NO: 5) .

[0123] The sequence described above was designed to include additional sequences outside the coding region; namely an EcoRI cleavage site sequence (GAATTC, at the 5' end), Kozak's sequence (ACC, at the 5' end), and a KpnI cleavage site sequence (GGTACC, at the 3' end). The synthesis of the resulting sequence was consigned to Blue Heron Inc. in the U.S.A. These additional restriction enzyme sites were used to ligate the fully synthetic opfGWT1 into the YEp352GAPII vector to construct an overexpression plasmid for opfGWT1. The construct was introduced into diploid cells (WDG2) in which only a single copy of the GWT1 gene had been disrupted. The resulting transformants were cultured on plates containing a sporulation medium to form spores for tetrad analysis.

[0124] The AT content of the newly designed codon-modified opfGWT1 was reduced to 61.55%. The results of tetrad analysis are shown in Fig. 1. The gwt1-disrupted strain became viable after introduction of the opfGWT1 overexpression plasmid. The findings described above indicate that the PfGWT1 gene can be expressed in yeast cells when its AT content is reduced by codon modification.

[Example 3] An assay for antimalarial activity using opfGWT1-expressing yeast

[0125] A screening system for compounds having antimalarial activity was constructed using opfGWT1-expressing yeast.

[0126] An expression cassette was constructed by inserting the *S. cerevisiae* GWT1 terminator, and the *S. cerevisiae* GAPDH promoter and multi-cloning site into the SacI-KpnI site of the single-copy vector pRS316. *S. cerevisiae* GWT1 and opfGWT1 were inserted into the multi-cloning site to prepare pGAP-ScGWT1 and pGAP-opfGWT1 plasmids, respectively. These plasmids were introduced into the GWT1 disruptant. Serial two-fold dilutions of compound (1) were prepared using YPAD to make the highest final concentration 50 μg/ml. A 50 μl aliquot of the diluted compound was added to each well of a 96-well plate. Overnight cultures of yeast cells comprising each plasmid were diluted 1000-fold and then a 50 μl aliquot of the dilution was added to each well. The plates were incubated at 30°C for two days, and then culture turbidity was determined at 660 nm (Fig. 2 and Table 1) .

[Table 1]

	0	6.25	12.5	25	50
pGAP-ScGWT1	0.7560	0.7370	0.6670	0.1140	0.0420
pGAP-opfGWT1	0.7150	0.6990	0.6910	0.3630	0.0530

[0127] Although the GWT1 disruptant was nonviable, the strain became viable after introduction of each plasmid (as shown at 0 μg/ml of compound concentration). The growth of ScGWT1 -expressing yeast was inhibited by compound (1), a GWT1-specific inhibitor. The use of the compound at 25 μg/ml resulted in about 85% inhibition of growth. When the compound was used at 50 μg/ml, the yeast was completely nonviable. The growth of opfGWT1-expressing yeast was also inhibited by compound (1). The use of the compound at 25 μg/ml resulted in about 50% inhibition of growth. When the compound was used at 50 μg/ml, the yeast was completely nonviable. Since growth of opfGWT1-expressing yeast depends on the activity of the introduced opfGWT1, growth inhibition can be attributed to the inhibition of the opfGWT1 function by compound (1). These findings suggest that compounds with *P. falciparum* GWT1-specific inhibitory activity GWT1 can be identified by screening compounds using this assay system.

[Example 4] Antimalarial activity

[0128] Representative compounds (1) to (5), that inhibit yeast GWT1, were assayed for antimalarial activity using a red blood cell culture system.



(1)

compound (1): 1-(4-butyl benzyl) isoquinoline



compound (2) : 4-[4-(1-isoquinolyl methyl)phenyl]-3-butyne-1-ol



compound (3): 5-butyl-2-(1-isoquinolyl methyl) phenol



compound (4): 2-(4-bromo-2-fluorobenzyl)-3-methoxypyridine



compound (5): N-[2-(4-butyl benzyl)-3-pyridyl]-N-methylamine

[0129] Specifically, a test compound was dissolved in 100% DMSO, diluted with a medium, and an 80 μl aliquot of the dilution was added to each well of a 96-well culture plate. *P. falciparum* FCR3 strain was pre-cultured in RPMI1640 medium containing 10% human serum at 37°C, and then 20 μl of the cultured cells (containing 10% red blood cells) was added to each well. At this time, 0.47% of red blood cells were infected. After culturing under 5% O_2, 5% CO_2, and 90% N_2 at 37°C for 48 hours, the malaria parasites were stained using Giemsa staining. The number of protozoan-infected red blood cells was determined in order to estimate infection rate (Fig 3). As a result, compound (3) was revealed to have strong antimalarial activity. The other four compounds also showed antimalarial activity. Compound (4) exhibited the lowest activity. Therefore, compounds inhibiting yeast GWT1 include compounds which have the activity of inhibiting

P. falciparum GWT1, suggesting that antimalarial drugs can be synthesized based on such compounds.

Industrial Applicability

[0130] The present invention succeeded in producing fungi that express malaria parasite GWT1. Using such fungi, antimalarial drugs targeting the pathway of GPI biosynthesis can be screened without using malaria parasites.

[0131] To date, no attempt has been made to express a malaria parasite gene in fungal cells and screen substances which inhibit the function of that gene. The methods of the present invention remove the need to actually using malaria parasites themselves, and thus this method proves the possibility of entirely new screening methods for drug discovery using comparative genomics in the post-genome era.

SEQUENCE LISTING

[0132]

<110> Eisai Co., Ltd.
<120> Methods of screening for compounds that inhibit the biosynthesis of GPI in malaria parasites
<130> E1-A0210P
<150> US 60/428,589 <151> 2002-11-22
<160> 55
<170> PatentIn version 3.1
<210> 1
<211> 2625
<212> DNA
<213> Plasmodium falciparum
<220>
<221> CDS
<222> (1).. (2625)
<223>
<400> 1

```
atg agc aac atg aat ata ctt gcg tat ctt ttg ata tgt ccc ttt aac      48
Met Ser Asn Met Asn Ile Leu Ala Tyr Leu Leu Ile Cys Pro Phe Asn
1               5                  10                  15

tta ata tat ata ttt gac ctt cct tca tat ata cct gag tta aat aaa      96
Leu Ile Tyr Ile Phe Asp Leu Pro Ser Tyr Ile Pro Glu Leu Asn Lys
            20                  25                  30

aag ctg gag aat gac gag gtg ttt ata tat gga aaa gaa ata aga aag     144
Lys Leu Glu Asn Asp Glu Val Phe Ile Tyr Gly Lys Glu Ile Arg Lys
        35                  40                  45

aat gaa tct gca tat tct tta cat tat gaa aaa tat tta tat gaa tta     192
Asn Glu Ser Ala Tyr Ser Leu His Tyr Glu Lys Tyr Leu Tyr Glu Leu
    50                  55                  60

tca aga aga tat tat gag ata ata tta aaa tat aat aag gag ctc ggg     240
Ser Arg Arg Tyr Tyr Glu Ile Ile Leu Lys Tyr Asn Lys Glu Leu Gly
65                  70                  75                  80

gtt aat caa gaa aaa gaa tat aat tta ata ata agt aga gag ata gat     288
Val Asn Gln Glu Lys Glu Tyr Asn Leu Ile Ile Ser Arg Glu Ile Asp
                85                  90                  95

aaa aaa aaa aaa aaa caa aaa aat agt aca caa gga gaa tat aat aat     336
```

Lys Lys Lys Lys Lys Gln Lys Asn Ser Thr Gln Gly Glu Tyr Asn Asn
100 105 110

gat gat gat aat aat tgg aaa tta ttc caa ata tat gag aag gaa gaa 384
Asp Asp Asp Asn Asn Trp Lys Leu Phe Gln Ile Tyr Glu Lys Glu Glu
115 120 125

ccc aga tca tac gaa tta ata cgt gtt gag att tac aaa aaa gat att 432
Pro Arg Ser Tyr Glu Leu Ile Arg Val Glu Ile Tyr Lys Lys Asp Ile
130 135 140

ctt tta att tat aaa aat gaa aaa acc aaa tca tca ata aaa ttt ata 480
Leu Leu Ile Tyr Lys Asn Glu Lys Thr Lys Ser Ser Ile Lys Phe Ile
145 150 155 160

ata aag aaa aga aaa gat ata aaa aat tat ttc tca tta tgt tat caa 528
Ile Lys Lys Arg Lys Asp Ile Lys Asn Tyr Phe Ser Leu Cys Tyr Gln
165 170 175

aat tgt ata aat aaa tta gat aaa aat gat tat aat att tta aaa agt 576
Asn Cys Ile Asn Lys Leu Asp Lys Asn Asp Tyr Asn Ile Leu Lys Ser
180 185 190

aca ata aat aat agt aaa gaa aat ata att aat agt gct tat ata tat 624
Thr Ile Asn Asn Ser Lys Glu Asn Ile Ile Asn Ser Ala Tyr Ile Tyr
195 200 205

atg tat ata ata ttt ttc ttt tta tgt ata tat gta gaa aaa aat tta 672
Met Tyr Ile Ile Phe Phe Phe Leu Cys Ile Tyr Val Glu Lys Asn Leu
210 215 220

ttt tta tac ttt cct ata tta tta caa aag tat gaa ata cta aca aca 720
Phe Leu Tyr Phe Pro Ile Leu Leu Gln Lys Tyr Glu Ile Leu Thr Thr
225 230 235 240

tta ttt att tta ttt att cct cta att ctt ttt gtt ttt ttt tat ttt 768
Leu Phe Ile Leu Phe Ile Pro Leu Ile Leu Phe Val Phe Phe Tyr Phe
245 250 255

tat ttt act ata atc aag ttg ata tgt tct tgt cta gtt tta tat gta 816
Tyr Phe Thr Ile Ile Lys Leu Ile Cys Ser Cys Leu Val Leu Tyr Val
260 265 270

aca ttt caa tta att tat tat act caa ggt atg cct ata tat atg gaa 864
Thr Phe Gln Leu Ile Tyr Tyr Thr Gln Gly Met Pro Ile Tyr Met Glu
275 280 285

cat agc ata ttg aaa cat aaa gaa aaa gaa gaa att tgt gat gaa aaa 912
His Ser Ile Leu Lys His Lys Glu Lys Glu Glu Ile Cys Asp Glu Lys
290 295 300

gaa gaa att tgt gat gaa aaa gaa gaa att tgt gat gaa aaa gaa gaa 960

Glu Glu Ile Cys Asp Glu Lys Glu Glu Ile Cys Asp Glu Lys Glu Glu
305 310 315 320

att tgt gat gaa aaa gaa gaa att tgt gat gaa aaa gaa gaa att tgt 1008
Ile Cys Asp Glu Lys Glu Glu Ile Cys Asp Glu Lys Glu Glu Ile Cys
325 330 335

gat gaa aaa gaa gaa att ctt gat aaa aaa aaa aaa att cat gaa aaa 1056
Asp Glu Lys Glu Glu Ile Leu Asp Lys Lys Lys Lys Ile His Glu Lys
340 345 350

aaa aaa aaa att cat gat aaa aaa gaa gaa att gat gaa aaa aaa aaa 1104
Lys Lys Lys Ile His Asp Lys Lys Glu Glu Ile Asp Glu Lys Lys Lys
355 360 365

aaa att cat gat aaa aaa gac gaa agt cat gat aaa aat gaa gac ata 1152
Lys Ile His Asp Lys Lys Asp Glu Ser His Asp Lys Asn Glu Asp Ile
370 375 380

aca tat cct gtt caa tat aat ata gaa aat gat tta tgg tac agc tca 1200
Thr Tyr Pro Val Gln Tyr Asn Ile Glu Asn Asp Leu Trp Tyr Ser Ser
385 390 395 400

aaa aat gta gat att aaa atg tat tca tct tca aat aaa gga gaa gaa 1248
Lys Asn Val Asp Ile Lys Met Tyr Ser Ser Ser Asn Lys Gly Glu Glu
405 410 415

tat att ata cag aat aca tta aaa cat ttt aga tta atg aat atg tgt 1296
Tyr Ile Ile Gln Asn Thr Leu Lys His Phe Arg Leu Met Asn Met Cys
420 425 430

atg aca tat ata tgt atc ttt gct gtt gat ttt tat ttc ttt cca aat 1344
Met Thr Tyr Ile Cys Ile Phe Ala Val Asp Phe Tyr Phe Phe Pro Asn
435 440 445

cat ttt tgt aaa tcc tat tat tat gga aat aca cta atg gat ata ggg 1392
His Phe Cys Lys Ser Tyr Tyr Tyr Gly Asn Thr Leu Met Asp Ile Gly
450 455 460

ata ggt gct tct ata agc tcc agt gca tat tct caa gaa ata aaa aag 1440
Ile Gly Ala Ser Ile Ser Ser Ser Ala Tyr Ser Gln Glu Ile Lys Lys
465 470 475 480

ttt aca tat ata aaa gag aag aaa aga ata att gaa tta aaa cat ata 1488
Phe Thr Tyr Ile Lys Glu Lys Lys Arg Ile Ile Glu Leu Lys His Ile
485 490 495

gtt tta ttt att tta gga ata tct aga ttt att gga ata tat ctt ttt 1536
Val Leu Phe Ile Leu Gly Ile Ser Arg Phe Ile Gly Ile Tyr Leu Phe
500 505 510

aat tat aat tat aat ata agt gaa tat gga ata cat tgg aat ttc ttt 1584

Asn Tyr Asn Tyr Asn Ile Ser Glu Tyr Gly Ile His Trp Asn Phe Phe
515 520 525

tta aca tta tgt act aca ttt ctt ata tct aat ata tgt ttt att tta 1632
Leu Thr Leu Cys Thr Thr Phe Leu Ile Ser Asn Ile Cys Phe Ile Leu
530 535 540

tta aaa agg ata cgt tat att ttt ctt ttt agt ata atc tct ata att 1680
Leu Lys Arg Ile Arg Tyr Ile Phe Leu Phe Ser Ile Ile Ser Ile Ile
545 550 555 560

ctt ttt gaa ata gcc ata tac tat ttt gac tta cat aat tat ata tta 1728
Leu Phe Glu Ile Ala Ile Tyr Tyr Phe Asp Leu His Asn Tyr Ile Leu
565 570 575

tta aaa aat gat aga tta aat ttc ttt tca tca aac aaa gaa ggc tta 1776
Leu Lys Asn Asp Arg Leu Asn Phe Phe Ser Ser Asn Lys Glu Gly Leu
580 585 590

ttt aat att ata ggt tct gtt aat ttg tat tta ttt tct ttc tca tta 1824
Phe Asn Ile Ile Gly Ser Val Asn Leu Tyr Leu Phe Ser Phe Ser Leu
595 600 605

ttt aaa tat tta aca aaa caa agg aca tac ata aca acc tcg aac att 1872
Phe Lys Tyr Leu Thr Lys Gln Arg Thr Tyr Ile Thr Thr Ser Asn Ile
610 615 620

cca aaa aat aaa aag gat atg aat aat tct atg tat tca aag aac ggt 1920
Pro Lys Asn Lys Lys Asp Met Asn Asn Ser Met Tyr Ser Lys Asn Gly
625 630 635 640

aac cac aca aat agc aat ata aat aat agg aat cat aaa att gta att 1968
Asn His Thr Asn Ser Asn Ile Asn Asn Arg Asn His Lys Ile Val Ile
645 650 655

cgg aat aat cat ata aat aaa tat gaa caa gat aac aca aat aag tat 2016
Arg Asn Asn His Ile Asn Lys Tyr Glu Gln Asp Asn Thr Asn Lys Tyr
660 665 670

att aat aaa caa ata aat aat aat aag aat aaa ctt gat gaa gaa gaa 2064
Ile Asn Lys Gln Ile Asn Asn Asn Lys Asn Lys Leu Asp Glu Glu Glu
675 680 685

aaa tta aaa aaa tta aaa aaa tta aaa aac aaa aaa aaa aat tta aaa 2112
Lys Leu Lys Lys Leu Lys Lys Leu Lys Asn Lys Lys Lys Asn Leu Lys
690 695 700

aaa aaa att aaa tat tat ttg tta tac ctt caa tat ata ata aat ata 2160
Lys Lys Ile Lys Tyr Tyr Leu Leu Tyr Leu Gln Tyr Ile Ile Asn Ile
705 710 715 720

tat aaa gaa gaa tat tat act att tat tat aat ata aaa tta att ata 2208

Tyr Lys Glu Glu Tyr Tyr Thr Ile Tyr Tyr Asn Ile Lys Leu Ile Ile
725 730 735

tca tct ttt att ttt tat tta tta cat ata att ctt aat tta tat aaa 2256
Ser Ser Phe Ile Phe Tyr Leu Leu His Ile Ile Leu Asn Leu Tyr Lys
740 745 750

aat tat agt gtg cgt ata tta tgt aat gca aat tat att ttt tta ata 2304
Asn Tyr Ser Val Arg Ile Leu Cys Asn Ala Asn Tyr Ile Phe Leu Ile
755 760 765

aca tca ttg ggt ttg ttt tct tgt gcc ttg agt ttt tcc tta gaa gat 2352
Thr Ser Leu Gly Leu Phe Ser Cys Ala Leu Ser Phe Ser Leu Glu Asp
770 775 780

ata tta tta aga tat aaa aaa tat aaa ata aat att gat ata aca gta 2400
Ile Leu Leu Arg Tyr Lys Lys Tyr Lys Ile Asn Ile Asp Ile Thr Val
785 790 795 800

ttg gat aag ata aat aaa aat aca ttg ata gtt ttt ctt ttc tcg aat 2448
Leu Asp Lys Ile Asn Lys Asn Thr Leu Ile Val Phe Leu Phe Ser Asn
805 810 815

ata ctt gtg ggc atg ttc aat att cta ttt caa act tta tta tta cct 2496
Ile Leu Val Gly Met Phe Asn Ile Leu Phe Gln Thr Leu Leu Leu Pro
820 825 830

ctt ata ttt gta ata cct ata ttg gta ttt tat tct ttc tta ata ctg 2544

Leu Ile Phe Val Ile Pro Ile Leu Val Phe Tyr Ser Phe Leu Ile Leu

835 840 845

ctt ttt aca aaa tgc tta cca cct tcc ata cgc cat cca aaa aaa aaa 2592

Leu Phe Thr Lys Cys Leu Pro Pro Ser Ile Arg His Pro Lys Lys Lys

850 855 860

aca cat cat gag gaa aag caa aaa aaa gaa tga 2625

Thr His His Glu Glu Lys Gln Lys Lys Glu

865 870

<210> 2
<211> 874
<212> PRT
<213> Plasmodium falciparum
<400> 2

Met Ser Asn Met Asn Ile Leu Ala Tyr Leu Leu Ile Cys Pro Phe Asn

1 5 10 15

Leu Ile Tyr Ile Phe Asp Leu Pro Ser Tyr Ile Pro Glu Leu Asn Lys

20 25 30

Lys Leu Glu Asn Asp Glu Val Phe Ile Tyr Gly Lys Glu Ile Arg Lys
35 40 45

Asn Glu Ser Ala Tyr Ser Leu His Tyr Glu Lys Tyr Leu Tyr Glu Leu
50 55 60

Ser Arg Arg Tyr Tyr Glu Ile Ile Leu Lys Tyr Asn Lys Glu Leu Gly
65 70 75 80

Val Asn Gln Glu Lys Glu Tyr Asn Leu Ile Ile Ser Arg Glu Ile Asp
85 90 95

Lys Lys Lys Lys Lys Gln Lys Asn Ser Thr Gln Gly Glu Tyr Asn Asn
100 105 110

Asp Asp Asp Asn Asn Trp Lys Leu Phe Gln Ile Tyr Glu Lys Glu Glu
115 120 125

Pro Arg Ser Tyr Glu Leu Ile Arg Val Glu Ile Tyr Lys Lys Asp Ile
130 135 140

Leu Leu Ile Tyr Lys Asn Glu Lys Thr Lys Ser Ser Ile Lys Phe Ile
145 150 155 160

Ile Lys Lys Arg Lys Asp Ile Lys Asn Tyr Phe Ser Leu Cys Tyr Gln
165 170 175

Asn Cys Ile Asn Lys Leu Asp Lys Asn Asp Tyr Asn Ile Leu Lys Ser
180 185 190

Thr Ile Asn Asn Ser Lys Glu Asn Ile Ile Asn Ser Ala Tyr Ile Tyr
195 200 205

Met Tyr Ile Ile Phe Phe Phe Leu Cys Ile Tyr Val Glu Lys Asn Leu
210 215 220

Phe Leu Tyr Phe Pro Ile Leu Leu Gln Lys Tyr Glu Ile Leu Thr Thr
225 230 235 240

Leu Phe Ile Leu Phe Ile Pro Leu Ile Leu Phe Val Phe Phe Tyr Phe
245 250 255

Tyr Phe Thr Ile Ile Lys Leu Ile Cys Ser Cys Leu Val Leu Tyr Val
260 265 270

Thr Phe Gln Leu Ile Tyr Tyr Thr Gln Gly Met Pro Ile Tyr Met Glu
275 280 285

His Ser Ile Leu Lys His Lys Glu Lys Glu Glu Ile Cys Asp Glu Lys
290 295 300

Glu Glu Ile Cys Asp Glu Lys Glu Glu Ile Cys Asp Glu Lys Glu Glu

305 310 315 320

Ile Cys Asp Glu Lys Glu Glu Ile Cys Asp Glu Lys Glu Glu Ile Cys
325 330 335

Asp Glu Lys Glu Glu Ile Leu Asp Lys Lys Lys Lys Ile His Glu Lys
340 345 350

Lys Lys Lys Ile His Asp Lys Lys Glu Glu Ile Asp Glu Lys Lys Lys
355 360 365

Lys Ile His Asp Lys Lys Asp Glu Ser His Asp Lys Asn Glu Asp Ile
370 375 380

Thr Tyr Pro Val Gln Tyr Asn Ile Glu Asn Asp Leu Trp Tyr Ser Ser
385 390 395 400

Lys Asn Val Asp Ile Lys Met Tyr Ser Ser Ser Asn Lys Gly Glu Glu
405 410 415

Tyr Ile Ile Gln Asn Thr Leu Lys His Phe Arg Leu Met Asn Met Cys
420 425 430

Met Thr Tyr Ile Cys Ile Phe Ala Val Asp Phe Tyr Phe Phe Pro Asn
435 440 445

His Phe Cys Lys Ser Tyr Tyr Tyr Gly Asn Thr Leu Met Asp Ile Gly
450 455 460

Ile Gly Ala Ser Ile Ser Ser Ser Ala Tyr Ser Gln Glu Ile Lys Lys
465 470 475 480

Phe Thr Tyr Ile Lys Glu Lys Lys Arg Ile Ile Glu Leu Lys His Ile
485 490 495

Val Leu Phe Ile Leu Gly Ile Ser Arg Phe Ile Gly Ile Tyr Leu Phe
500 505 510

Asn Tyr Asn Tyr Asn Ile Ser Glu Tyr Gly Ile His Trp Asn Phe Phe
515 520 525

Leu Thr Leu Cys Thr Thr Phe Leu Ile Ser Asn Ile Cys Phe Ile Leu
530 535 540

Leu Lys Arg Ile Arg Tyr Ile Phe Leu Phe Ser Ile Ile Ser Ile Ile
545 550 555 560

Leu Phe Glu Ile Ala Ile Tyr Tyr Phe Asp Leu His Asn Tyr Ile Leu
565 570 575

Leu Lys Asn Asp Arg Leu Asn Phe Phe Ser Ser Asn Lys Glu Gly Leu
580 585 590

Phe Asn Ile Ile Gly Ser Val Asn Leu Tyr Leu Phe Ser Phe Ser Leu
595 600 605

Phe Lys Tyr Leu Thr Lys Gln Arg Thr Tyr Ile Thr Thr Ser Asn Ile
610 615 620

Pro Lys Asn Lys Lys Asp Met Asn Asn Ser Met Tyr Ser Lys Asn Gly
625 630 635 640

Asn His Thr Asn Ser Asn Ile Asn Asn Arg Asn His Lys Ile Val Ile
645 650 655

Arg Asn Asn His Ile Asn Lys Tyr Glu Gln Asp Asn Thr Asn Lys Tyr
660 665 670

Ile Asn Lys Gln Ile Asn Asn Asn Lys Asn Lys Leu Asp Glu Glu Glu
675 680 685

Lys Leu Lys Lys Leu Lys Lys Leu Lys Asn Lys Lys Lys Asn Leu Lys
690 695 700

Lys Lys Ile Lys Tyr Tyr Leu Leu Tyr Leu Gln Tyr Ile Ile Asn Ile
705 710 715 720

Tyr Lys Glu Glu Tyr Tyr Thr Ile Tyr Tyr Asn Ile Lys Leu Ile Ile

725 730 735

Ser Ser Phe Ile Phe Tyr Leu Leu His Ile Ile Leu Asn Leu Tyr Lys
740 745 750

Asn Tyr Ser Val Arg Ile Leu Cys Asn Ala Asn Tyr Ile Phe Leu Ile
755 760 765

Thr Ser Leu Gly Leu Phe Ser Cys Ala Leu Ser Phe Ser Leu Glu Asp
770 775 780

Ile Leu Leu Arg Tyr Lys Lys Tyr Lys Ile Asn Ile Asp Ile Thr Val
785 790 795 800

Leu Asp Lys Ile Asn Lys Asn Thr Leu Ile Val Phe Leu Phe Ser Asn
805 810 815

Ile Leu Val Gly Met Phe Asn Ile Leu Phe Gln Thr Leu Leu Leu Pro
820 825 830

Leu Ile Phe Val Ile Pro Ile Leu Val Phe Tyr Ser Phe Leu Ile Leu
835 840 845

Leu Phe Thr Lys Cys Leu Pro Pro Ser Ile Arg His Pro Lys Lys Lys
850 855 860

Thr His His Glu Glu Lys Gln Lys Lys Glu

865 870

<210> 3
<211> 1956
<212> DNA
<213> Plasmodium vivax
<220>
<221> CDS
<222> (1).. (1956)
<223>
<400>

atg gcg cat ttg aac ctc ctc gtc tac ctc atc atg tgc ccc ttc aat 48
Met Ala His Leu Asn Leu Leu Val Tyr Leu Ile Met Cys Pro Phe Asn
1 5 10 15

gtg agg cac atg ctg gat gcg ccc agc ttc cca ttc cgg tta gga agc 96
Val Arg His Met Leu Asp Ala Pro Ser Phe Pro Phe Arg Leu Gly Ser
20 25 30

aaa gca gca agt ggt gaa acc ttc acg tat gga gcg act gca aga gag 144
Lys Ala Ala Ser Gly Glu Thr Phe Thr Tyr Gly Ala Thr Ala Arg Glu
35 40 45

aac ctg ggg agt tac tct ccc gca cat gac gag cta tac atg tta gag 192
Asn Leu Gly Ser Tyr Ser Pro Ala His Asp Glu Leu Tyr Met Leu Glu
50 55 60

tta gcc aaa atg tac tat aaa att gtg tta aca tat aag aag gat gtt 240
Leu Ala Lys Met Tyr Tyr Lys Ile Val Leu Thr Tyr Lys Lys Asp Val
65 70 75 80

agg aaa gga cag gag gag agt tac aac ttg gtg gta ggc tcc ttt ggg 288
Arg Lys Gly Gln Glu Glu Ser Tyr Asn Leu Val Val Gly Ser Phe Gly
85 90 95

aag gaa gcc aaa ggg gag gtc tcc ctc caa aga gtt ctc atc aca aat 336
Lys Glu Ala Lys Gly Glu Val Ser Leu Gln Arg Val Leu Ile Thr Asn
100 105 110

gat gcc gtg tac ctg tcg tac cag gat gtg caa aac gaa cgt ggg atc 384
Asp Ala Val Tyr Leu Ser Tyr Gln Asp Val Gln Asn Glu Arg Gly Ile
115 120 125

caa gtt aag ata aaa agg ggg gaa ata tct tcc tat tta gac ctc cta 432
Gln Val Lys Ile Lys Arg Gly Glu Ile Ser Ser Tyr Leu Asp Leu Leu
130 135 140

tcg tgg gat tct tgt ttg tat aag ctt aac tca gac gat tat aat tta 480

Ser Trp Asp Ser Cys Leu Tyr Lys Leu Asn Ser Asp Asp Tyr Asn Leu
145 150 155 160

atg aag agc gca tcg gat cat agc aag cca atg gtg gtc agc aca tac 528
Met Lys Ser Ala Ser Asp His Ser Lys Pro Met Val Val Ser Thr Tyr
165 170 175

cac ata tac atg ctg ctg ctg gtg ttt tct ctt tgc act tac gtg gag 576
His Ile Tyr Met Leu Leu Leu Val Phe Ser Leu Cys Thr Tyr Val Glu
180 185 190

aag agc ctc ctg ctt gaa ttc cct gcg ttg aaa aag tgc caa gta ttt 624
Lys Ser Leu Leu Leu Glu Phe Pro Ala Leu Lys Lys Cys Gln Val Phe
195 200 205

cta acc cta tgt ttg gtg tac tgc ccg ata atc agt tac ctt ttt ttt 672
Leu Thr Leu Cys Leu Val Tyr Cys Pro Ile Ile Ser Tyr Leu Phe Phe
210 215 220

ttt tac tcc cat gtg agc cta ctt ggg gtg tta ctc gtc tat gtg ttt 720
Phe Tyr Ser His Val Ser Leu Leu Gly Val Leu Leu Val Tyr Val Phe
225 230 235 240

ttt tgc ggg ctc ttc agg ggc gtc tct tgc aga agg ggg ggg cag cac 768
Phe Cys Gly Leu Phe Arg Gly Val Ser Cys Arg Arg Gly Gly Gln His
245 250 255

atg ggg gag caa acg ggc caa cac acg ggc gat tgg cac acc atc cgc 816
Met Gly Glu Gln Thr Gly Gln His Thr Gly Asp Trp His Thr Ile Arg
260 265 270

ggc aac cca caa ggt gat gat acg caa gag gag aga cgc aag tgt ttg 864
Gly Asn Pro Gln Gly Asp Asp Thr Gln Glu Glu Arg Arg Lys Cys Leu
275 280 285

gtc cat atg agg cta gcc aac ctg tgc atc acc tac ata tgc ata ttc 912
Val His Met Arg Leu Ala Asn Leu Cys Ile Thr Tyr Ile Cys Ile Phe
290 295 300

gct gtg gac ttt tat ttt ttc cca agg caa ttt tcc aag tct ttt ttt 960
Ala Val Asp Phe Tyr Phe Phe Pro Arg Gln Phe Ser Lys Ser Phe Phe
305 310 315 320

ttt ggt aac act ttg atg gat tta ggg gtg ggg ggg tgc atc aca tcg 1008
Phe Gly Asn Thr Leu Met Asp Leu Gly Val Gly Gly Cys Ile Thr Ser
325 330 335

agc gcg tat tct cta aac agt aaa aag ctc cat tct gcg aac cgc aag 1056
Ser Ala Tyr Ser Leu Asn Ser Lys Lys Leu His Ser Ala Asn Arg Lys
340 345 350

gga cac cta atc gat tgg aag cat ttc att tta ttt ttc ctt gga ata 1104

Gly His Leu Ile Asp Trp Lys His Phe Ile Leu Phe Phe Leu Gly Ile
355 360 365

gct aga tac att gca gtg aag ctt ttc aat tat aat tac agc tta act 1152
Ala Arg Tyr Ile Ala Val Lys Leu Phe Asn Tyr Asn Tyr Ser Leu Thr
370 375 380

gag tat ggg atg cac tgg aat ttt ttt ctt act ctc ttt ttt act ctc 1200
Glu Tyr Gly Met His Trp Asn Phe Phe Leu Thr Leu Phe Phe Thr Leu
385 390 395 400

cta act tgt aac gcc cta ctc tgc ttg ata aga ggg gtt aaa cgc acc 1248
Leu Thr Cys Asn Ala Leu Leu Cys Leu Ile Arg Gly Val Lys Arg Thr
405 410 415

ttt cac ctg agc tgc gtc ctc atc tgt ttg tat gaa att ata att tgg 1296
Phe His Leu Ser Cys Val Leu Ile Cys Leu Tyr Glu Ile Ile Ile Trp
420 425 430

cgc ctg gac att acg agt tat tta gtg gtt gac gag gca gaa cgg agc 1344
Arg Leu Asp Ile Thr Ser Tyr Leu Val Val Asp Glu Ala Glu Arg Ser
435 440 445

ggc ttt ttt tcg cag aac aga gag ggc ctt atg aac gtc atc ggg tcc 1392
Gly Phe Phe Ser Gln Asn Arg Glu Gly Leu Met Asn Val Ile Gly Ser
450 455 460

gtc aat ttg tac ctc ttt tcg ttt tcg cta tgg aat ggc tat gtg ttt 1440
Val Asn Leu Tyr Leu Phe Ser Phe Ser Leu Trp Asn Gly Tyr Val Phe
465 470 475 480

ccg gat gag ggg cag cag tgg gag cga gga aag gcg gcg cga aga ccg 1488
Pro Asp Glu Gly Gln Gln Trp Glu Arg Gly Lys Ala Ala Arg Arg Pro
485 490 495

gat gag gcg gcg cga acg ccg ggg gag gga cat ggc cag cgc tcc cct 1536
Asp Glu Ala Ala Arg Thr Pro Gly Glu Gly His Gly Gln Arg Ser Pro
500 505 510

gtc cgc ctc acc ctg aag ttg ctt gcc ctg tcc ctc ctc ttc cac ctg 1584
Val Arg Leu Thr Leu Lys Leu Leu Ala Leu Ser Leu Leu Phe His Leu
515 520 525

ctg cac ctg ctg ttg aat tac tac cga aat tac agt gtg cgc atc ctt 1632
Leu His Leu Leu Leu Asn Tyr Tyr Arg Asn Tyr Ser Val Arg Ile Leu
530 535 540

tgc aac gcg aac tac ata tgt gtt gtc tcc tcc gtg agt ctc ttc gcg 1680
Cys Asn Ala Asn Tyr Ile Cys Val Val Ser Ser Val Ser Leu Phe Ala
545 550 555 560

gct gcc ctg agc tac ctc gta gag aag gta ctc ctc cgc gag aag acc 1728

Ala Ala Leu Ser Tyr Leu Val Glu Lys Val Leu Leu Arg Glu Lys Thr
565 570 575

acc acc atc cca gtt ttg caa caa atg aac cgg cac tcc ctg gca gtg 1776
Thr Thr Ile Pro Val Leu Gln Gln Met Asn Arg His Ser Leu Ala Val
580 585 590

ttc ctc ttt tgc aac gta aca atg ggc act ttc aac ctc ctc ttt cag 1824
Phe Leu Phe Cys Asn Val Thr Met Gly Thr Phe Asn Leu Leu Phe Gln
595 600 605

tct ctc ttg ttt ccc cta ttt ttt gcg tgc ctc gtt ttg gcg gcg tac 1872
Ser Leu Leu Phe Pro Leu Phe Phe Ala Cys Leu Val Leu Ala Ala Tyr
610 615 620

tcc tat ggc atg ttg cgc ttc gcc tcc ctg ttg ccc ggc ccc gcg cag 1920
Ser Tyr Gly Met Leu Arg Phe Ala Ser Leu Leu Pro Gly Pro Ala Gln
625 630 635 640

ggg gag aag gga gag aag cgg gag aag cag caa taa 1956
Gly Glu Lys Gly Glu Lys Arg Glu Lys Gln Gln
645 650

<210> 4
<211> 651
<212> PRT
<213> Plasmodium vivax
<400> 4

Met Ala His Leu Asn Leu Leu Val Tyr Leu Ile Met Cys Pro Phe Asn
1 5 10 15

Val Arg His Met Leu Asp Ala Pro Ser Phe Pro Phe Arg Leu Gly Ser
20 25 30

Lys Ala Ala Ser Gly Glu Thr Phe Thr Tyr Gly Ala Thr Ala Arg Glu
35 40 45

Asn Leu Gly Ser Tyr Ser Pro Ala His Asp Glu Leu Tyr Met Leu Glu
50 55 60

Leu Ala Lys Met Tyr Tyr Lys Ile Val Leu Thr Tyr Lys Lys Asp Val
65 70 75 80

Arg Lys Gly Gln Glu Glu Ser Tyr Asn Leu Val Val Gly Ser Phe Gly
85 90 95

Lys Glu Ala Lys Gly Glu Val Ser Leu Gln Arg Val Leu Ile Thr Asn
100 105 110

Asp Ala Val Tyr Leu Ser Tyr Gln Asp Val Gln Asn Glu Arg Gly Ile

115 120 125

Gln Val Lys Ile Lys Arg Gly Glu Ile Ser Ser Tyr Leu Asp Leu Leu
130 135 140

Ser Trp Asp Ser Cys Leu Tyr Lys Leu Asn Ser Asp Asp Tyr Asn Leu
145 150 155 160

Met Lys Ser Ala Ser Asp His Ser Lys Pro Met Val Val Ser Thr Tyr
165 170 175

His Ile Tyr Met Leu Leu Leu Val Phe Ser Leu Cys Thr Tyr Val Glu
180 185 190

Lys Ser Leu Leu Leu Glu Phe Pro Ala Leu Lys Lys Cys Gln Val Phe
195 200 205

Leu Thr Leu Cys Leu Val Tyr Cys Pro Ile Ile Ser Tyr Leu Phe Phe
210 215 220

Phe Tyr Ser His Val Ser Leu Leu Gly Val Leu Leu Val Tyr Val Phe
225 230 235 240

Phe Cys Gly Leu Phe Arg Gly Val Ser Cys Arg Arg Gly Gly Gln His
245 250 255

Met Gly Glu Gln Thr Gly Gln His Thr Gly Asp Trp His Thr Ile Arg
260 265 270

Gly Asn Pro Gln Gly Asp Asp Thr Gln Glu Glu Arg Arg Lys Cys Leu
275 280 285

Val His Met Arg Leu Ala Asn Leu Cys Ile Thr Tyr Ile Cys Ile Phe
290 295 300

Ala Val Asp Phe Tyr Phe Phe Pro Arg Gln Phe Ser Lys Ser Phe Phe
305 310 315 320

Phe Gly Asn Thr Leu Met Asp Leu Gly Val Gly Gly Cys Ile Thr Ser
325 330 335

Ser Ala Tyr Ser Leu Asn Ser Lys Lys Leu His Ser Ala Asn Arg Lys
340 345 350

Gly His Leu Ile Asp Trp Lys His Phe Ile Leu Phe Phe Leu Gly Ile
355 360 365

Ala Arg Tyr Ile Ala Val Lys Leu Phe Asn Tyr Asn Tyr Ser Leu Thr
370 375 380

Glu Tyr Gly Met His Trp Asn Phe Phe Leu Thr Leu Phe Phe Thr Leu
385 390 395 400

Leu Thr Cys Asn Ala Leu Leu Cys Leu Ile Arg Gly Val Lys Arg Thr
405 410 415

Phe His Leu Ser Cys Val Leu Ile Cys Leu Tyr Glu Ile Ile Ile Trp
420 425 430

Arg Leu Asp Ile Thr Ser Tyr Leu Val Val Asp Glu Ala Glu Arg Ser
435 440 445

Gly Phe Phe Ser Gln Asn Arg Glu Gly Leu Met Asn Val Ile Gly Ser
450 455 460

Val Asn Leu Tyr Leu Phe Ser Phe Ser Leu Trp Asn Gly Tyr Val Phe
465 470 475 480

Pro Asp Glu Gly Gln Gln Trp Glu Arg Gly Lys Ala Ala Arg Arg Pro
485 490 495

Asp Glu Ala Ala Arg Thr Pro Gly Glu Gly His Gly Gln Arg Ser Pro
500 505 510

Val Arg Leu Thr Leu Lys Leu Leu Ala Leu Ser Leu Leu Phe His Leu
515 520 525

Leu His Leu Leu Leu Asn Tyr Tyr Arg Asn Tyr Ser Val Arg Ile Leu

530 535 540

Cys Asn Ala Asn Tyr Ile Cys Val Val Ser Ser Val Ser Leu Phe Ala
545 550 555 560

Ala Ala Leu Ser Tyr Leu Val Glu Lys Val Leu Leu Arg Glu Lys Thr
565 570 575

Thr Thr Ile Pro Val Leu Gln Gln Met Asn Arg His Ser Leu Ala Val
580 585 590

Phe Leu Phe Cys Asn Val Thr Met Gly Thr Phe Asn Leu Leu Phe Gln
595 600 605

Ser Leu Leu Phe Pro Leu Phe Phe Ala Cys Leu Val Leu Ala Ala Tyr
610 615 620

Ser Tyr Gly Met Leu Arg Phe Ala Ser Leu Leu Pro Gly Pro Ala Gln
625 630 635 640

Gly Glu Lys Gly Glu Lys Arg Glu Lys Gln Gln
645 650

<210> 5
<211> 2625
<212> DNA
<213> Artificial
<220>

<223> an artificially synthesized sequence
<400> 5

atgagtaaca tgaacatcct ggcctacctg ctgatctgtc cattcaacct gatctacatc 60

ttcgacctgc ctagctacat ccctgagcta aacaagaagc tggagaacga cgaagtcttc 120

atctacggta aggagatccg taagaacgaa tccgcatact ctctacacta cgagaagtac 180

ctatacgaat tgtcacgaag atactacgag atcatcctga agtacaacaa ggagttggga 240

gtcaaccaag agaaggaata caacctgatt atctccagag agatcgataa gaagaagaag 300

aagcagaaga atagtaccca gggtgaatac aataacgacg atgataacaa ttggaagttg 360

ttccagattt acgagaagga agaacctagg agctatgaat tgatcagggt agagatatac 420

aagaaggaca ttctgttgat ctacaagaat gagaagacga agtcctctat caagttcatt 480

atcaagaagc gtaaggatat caagaattac ttctccttgt gttaccagaa ctgtatcaat 540

aagctggaca agaatgatta caacatcttg aagtctacca tcaacaattc caaggaaaac 600

attatcaact ctgcatacat ttacatgtac attatcttct tcttcctgtg catatacgtc 660

gagaagaacc tgttcttgta cttcccaata ttgcttcaga agtatgagat tctcactacg 720

ttgttcatcc tcttcatccc attgatccta ttcgtattct tctatttcta cttcacgatt 780

atcaagctga tttgctcatg cttagtccta tacgtgactt tccagttgat ctactatacg 840

cagggaatgc ctatttacat ggaacatagt attctcaagc acaaggagaa ggaagagatt 900

tgcgatgaga aggaggaaat ctgtgatgaa aaggaagaga tttgcgatga gaaggaagag 960

atttgcgatg agaaggaaga gatttgtgat gagaaggaag aaatctgcga tgagaaagaa 1020

gaaatccttg ataagaagaa gaagatccac gagaagaaga agaagatcca tgataagaaa 1080

gaggaaatcg atgagaagaa gaagaagatt catgacaaaa aggacgaaag tcatgataag 1140

aacgaggaca ttacgtatcc agtccagtac aatatcgaga atgacctatg gtattcatcc 1200

aagaacgtgg acatcaagat gtattcatcc agcaacaagg gtgaagaata cattatccag 1260

aacacgttga aacatttccg attgatgaac atgtgtatga cgtacatttg tatcttcgct 1320

gttgacttct acttcttccc taaccatttc tgcaagtcct actattacgg aaatacgttg 1380

atggacattg gaatcggtgc atccatttct tccagtgcat actcgcagga gatcaagaag 1440

ttcacgtaca ttaaggagaa gaaacgaatt atcgagttga aacatatcgt gttattcatt 1500

ctgggaatta gcagatttat cggtatctac ctattcaact ataactacaa catttctgag 1560

tatggaatcc attggaactt ctttcttacg ctatgtacaa cctttctgat tagcaacatt 1620

tgtttcatcc tcctcaagag gattcgttat atcttcctat tcagtattat ctcgatcatc 1680

ttattcgaaa tcgctattta ctacttcgat ctacataatt acatcctcct gaagaatgac 1740

cgtttaaact tcttctcttc taacaaggag ggtctattca acattatcgg ttccgtgaac 1800

ctttatttgt tcagtttctc actcttcaag taccttacga agcagcgtac gtatatcacg 1860

acgtccaata tccctaagaa caagaaagat atgaataact caatgtattc gaagaatgga 1920

aaccatacta attcgaatat caacaaccgt aaccataaga tcgtcatccg taataaccac 1980

attaacaagt atgagcagga caacacgaac aagtacatca acaagcaaat caataacaac 2040

aagaacaaat tggatgagga agagaagctg aagaaactca agaagcttaa gaataagaag 2100

aagaacctca agaagaaaat caagtactat ctattgtacc ttcagtatat catcaacatc 2160

tacaaggagg aatactatac gatctactat aacatcaagc taatcatttc gtcgtttata 2220

ttctacctcc ttcacataat ccttaatctg tacaagaact actctgtgcg tattctgtgt 2280

aatgcaaact acatcttcct gattacgagt ctgggtctgt tctcctgtgc attatccttc 2340

tccctggagg acatcctact ccgttataag aaatacaaga tcaatatcga tattactgtg 2400

ctagataaga ttaacaagaa caccttaatc gtgttcctgt ttagtaatat cctagtggga 2460

atgttcaaca tcctgttcca aactttgctc ctaccactga tattcgttat ccctattcta 2520

gtattctaca gcttcttgat cctgctgttc accaagtgtt tgccaccttc tatccgacat 2580

cctaagaaga agacgcatca cgaagagaag cagaagaaag agtga 2625

<210> 6
<211> 2010
<212> DNA
<213> Plasmodium falciparum
<400> 6

atgtgcacta caaaaaatga agacaataat aaagtgaatt atctgtatct catttattat 60

aataatatac ctatatttaa aaaaaaaagt ggaaatgaac aaaacataag tgcgctattt 120

attttatatg atgtaaaaaa gtatgtgtat aatatggttc atgatcacgt aaatacatta 180

gtcctagaag cttttagaag agaagacata ataaaaaaaa taaaagtaaa agaaaaacaa 240

aataataatg ataaaaataa agaaagtaat attgaaaaag ataaaaatga acaaaccaaa 300

tttacagata tatatgatac aaatagtaag agtgacaaag atatacaaaa gaataatatg 360

aacgatggtg atagtaataa taaaaatagt agtttattta ttgatccttt tgaaagtgat 420

tcatatgaaa agaataattt tagtaatgaa aaatgtgctt tccaaaatgt cgataaatca 480

aaaaaagata aagaacatat atattctgaa aatattactc ctagtagtag taataataat 540

aatgataata ataaagaaaa tgattgtgat aaggaacaat tagataaata taataaagat 600

aaagaaaata aattaaaatt aaatgataag gatgaatata tttctttcaa ttttattgaa 660

gataaattaa ccgaatcatt tcatatgaat caaataattc atttaattaa taaaaaatgt 720

gtatttacca aatgcctaga aaattataaa aatagatatt ttgtactgaa aaaagaagag 780

attttaaaaa aaaaaaaaaa gcaaaaaaaa atgtctatat tttcatatat tgtatcaatc 840

atattatttt ttacatatat catatcactt ataaatagtt gtttatatta tataatatgt 900

acaccaaaat tgttcagtga atatatattt tcaaaaaaat gtgatggata tctgcagaat 960

tcggcttacc ctaaatttat atttccttct gaatggcata atatattccg cagcttcatg 1020

aaaaataaac aaaacccatc tgaatattat aaatatagag aaatcttatt aattcgtatt 1080

atcaatttaa taatcgatat tttcttggga tttctgatat ttttactact ttattttaac 1140

gtaataaacc tacattatat atcagagaag gctcaaatat tttatggaac cagtacttta 1200

acttctatct tgggtacctt gttacagaat ccattaggat ttaaattaaa taataatttt 1260

acgtctttca ttggtagcat ccttgtttcg atattagaca aatgggattt atttacaaat 1320

accatccctg tgaataatag tacagttttg aattttgttg gatatacatc actgctgggt 1380

ttttcttttt ttttgtcttt tgttattgat tatttgagat tcgtaacagc acatgttacc 1440

attatttatt tatttttgaa aaaaatatgt acccttttttc ataaaaatat gtattcctta 1500

tacctattat tcaatgggaa aaaatggaac atactaaaac taagagttga tacaaattac 1560

tactcaaatg aagaagtact tttaggaacc atattattta ccattttaat ttttttgtac 1620

cctaccattt ttgttcttgt tttggttttt ggtcttatat atcttataat aaatagaatt 1680

atataccttt tgtgtgttat ggagaaaata attttgtaca ccccttttcta tattttcttt 1740

attcaaccga attgtaataa atatattagt aagggtttca agtttacaaa atatgaagtt 1800

ggggaacatg aactgttaaa aaggtatccg actaacagct acttgttgct agaaaagatt 1860

catttttat tttttgataa aataaaattg tttataaata ttttccttta ttttaaaaac 1920

ctcgagtcaa tgtcatcata ttcatatata tttatttctt tttgtttttg tcttttaaaa 1980

aaaaaatata tatatatata tataatataa 2010

<210> 7
<211> 669
<212> PRT
<213> Plasmodium falciparum
<400> 7

Met Cys Thr Thr Lys Asn Glu Asp Asn Asn Lys Val Asn Tyr Leu Tyr
1 5 10 15

Leu Ile Tyr Tyr Asn Asn Ile Pro Ile Phe Lys Lys Lys Ser Gly Asn
20 25 30

Glu Gln Asn Ile Ser Ala Leu Phe Ile Leu Tyr Asp Val Lys Lys Tyr
35 40 45

Val Tyr Asn Met Val His Asp His Val Asn Thr Leu Val Leu Glu Ala
50 55 60

Phe Arg Arg Glu Asp Ile Ile Lys Lys Ile Lys Val Lys Glu Lys Gln
65 70 75 80

Asn Asn Asn Asp Lys Asn Lys Glu Ser Asn Ile Glu Lys Asp Lys Asn
85 90 95

Glu Gln Thr Lys Phe Thr Asp Ile Tyr Asp Thr Asn Ser Lys Ser Asp
100 105 110

Lys Asp Ile Gln Lys Asn Asn Met Asn Asp Gly Asp Ser Asn Asn Lys
115 120 125

Asn Ser Ser Leu Phe Ile Asp Pro Phe Glu Ser Asp Ser Tyr Glu Lys
130 135 140

Asn Asn Phe Ser Asn Glu Lys Cys Ala Phe Gln Asn Val Asp Lys Ser
145 150 155 160

Lys Lys Asp Lys Glu His Ile Tyr Ser Glu Asn Ile Thr Pro Ser Ser

165 170 175

Ser Asn Asn Asn Asn Asp Asn Asn Lys Glu Asn Asp Cys Asp Lys Glu
180 185 190

Gln Leu Asp Lys Tyr Asn Lys Asp Lys Glu Asn Lys Leu Lys Leu Asn
195 200 205

Asp Lys Asp Glu Tyr Ile Ser Phe Asn Phe Ile Glu Asp Lys Leu Thr
210 215 220

Glu Ser Phe His Met Asn Gln Ile Ile His Leu Ile Asn Lys Lys Cys
225 230 235 240

Val Phe Thr Lys Cys Leu Glu Asn Tyr Lys Asn Arg Tyr Phe Val Leu
245 250 255

Lys Lys Glu Glu Ile Leu Lys Lys Lys Lys Lys Gln Lys Lys Met Ser
260 265 270

Ile Phe Ser Tyr Ile Val Ser Ile Ile Leu Phe Phe Thr Tyr Ile Ile
275 280 285

Ser Leu Ile Asn Ser Cys Leu Tyr Tyr Ile Ile Cys Thr Pro Lys Leu
290 295 300

Phe Ser Glu Tyr Ile Phe Ser Lys Lys Cys Asp Gly Tyr Leu Gln Asn
305 310 315 320

Ser Ala Tyr Pro Lys Phe Ile Phe Pro Ser Glu Trp His Asn Ile Phe
325 330 335

Arg Ser Phe Met Lys Asn Lys Gln Asn Pro Ser Glu Tyr Tyr Lys Tyr
340 345 350

Arg Glu Ile Leu Leu Ile Arg Ile Ile Asn Leu Ile Ile Asp Ile Phe
355 360 365

Leu Gly Phe Leu Ile Phe Leu Leu Leu Tyr Phe Asn Val Ile Asn Leu
370 375 380

His Tyr Ile Ser Glu Lys Ala Gln Ile Phe Tyr Gly Thr Ser Thr Leu
385 390 395 400

Thr Ser Ile Leu Gly Thr Leu Leu Gln Asn Pro Leu Gly Phe Lys Leu
405 410 415

Asn Asn Asn Phe Thr Ser Phe Ile Gly Ser Ile Leu Val Ser Ile Leu
420 425 430

Asp Lys Trp Asp Leu Phe Thr Asn Thr Ile Pro Val Asn Asn Ser Thr
435 440 445

Val Leu Asn Phe Val Gly Tyr Thr Ser Leu Leu Gly Phe Ser Phe Phe
450 455 460

Leu Ser Phe Val Ile Asp Tyr Leu Arg Phe Val Thr Ala His Val Thr
465 470 475 480

Ile Ile Tyr Leu Phe Leu Lys Lys Ile Cys Thr Leu Phe His Lys Asn
485 490 495

Met Tyr Ser Leu Tyr Leu Leu Phe Asn Gly Lys Lys Trp Asn Ile Leu
500 505 510

Lys Leu Arg Val Asp Thr Asn Tyr Tyr Ser Asn Glu Glu Val Leu Leu
515 520 525

Gly Thr Ile Leu Phe Thr Ile Leu Ile Phe Leu Tyr Pro Thr Ile Phe
530 535 540

Val Leu Val Leu Val Phe Gly Leu Ile Tyr Leu Ile Ile Asn Arg Ile
545 550 555 560

Ile Tyr Leu Leu Cys Val Met Glu Lys Ile Ile Leu Tyr Thr Pro Phe
565 570 575

Tyr Ile Phe Phe Ile Gln Pro Asn Cys Asn Lys Tyr Ile Ser Lys Gly

580 585 590

Phe Lys Phe Thr Lys Tyr Glu Val Gly Glu His Glu Leu Leu Lys Arg
595 600 605

Tyr Pro Thr Asn Ser Tyr Leu Leu Leu Glu Lys Ile His Phe Leu Phe
610 615 620

Phe Asp Lys Ile Lys Leu Phe Ile Asn Ile Phe Leu Tyr Phe Lys Asn
625 630 635 640

Leu Glu Ser Met Ser Ser Tyr Ser Tyr Ile Phe Ile Ser Phe Cys Phe
645 650 655

Cys Leu Leu Lys Lys Lys Tyr Ile Tyr Ile Tyr Ile Ile
660 665

<210> 8
<211> 1482
<212> DNA
<213> Plasmodium falciparum
<400> 8

atggggataa aaattataat ttatatattt tttctatcgt gggcgaaatg ggtgtgtggg 60

tctgttaatt ttaccgggtt tgataacaaa aatatgatag gtaagcacgt ggaactagaa 120

gggaggtata aaaaggaata tatagatagg ttttttttag aagaattaag aaaacacaat 180

tatatgaata acaatgttat attattaagt acatcaagac attattttaa ttatagacat 240

accactaatt tattgattgc atataaatat cttaaatatt tcggtgatac tatggataag 300

aatattttat taatgattcc atttgatcaa gcttgtgatt gtaggaatat aagagaaggt 360

caaatatttc gagaatatga attatttcct agtagtcata ataaagaaac aaaaatagaa 420

aatataaatt tatatgagaa tttaaatatt gattataaaa ataataatgt acgtgatgaa 480

caaattagaa gagtacttag acatagatat gatgctttta cacctaaaaa aaatagatta 540

tataataatg gaaataatga gaaaaattta tttctttata tgaccggaca tggtggtgtg 600

aatttttaa aaattcaaga atttaatatt attagttctt ctgaatttaa tatatatata 660

caagaattac ttatcaaaaa tttttataaa tatatattcg taattattga tacgtgtcaa 720

ggatatagtt tttatgatga tattctaaat tttgtatata aaaaaaaaat taataatatc 780

ttctttttat catcttctaa aagaaatgaa aatagttata gtttattttc cagtagttat 840

ttaagcgttt caacggtcga cagatttaca taccattttt ttaattatct tcaacaaata 900

cataaaatat atgaaaaaga accatctaaa aatataaaag ccttttcatt atataacatt 960

ttaaattatt taaaaacaca acatattatg tcagaaccta ctacaaataa ttctaaattt 1020

aattcgtcca ttttttttaca tgataaaaat attcttttct tcaattctaa tttgttaatt 1080

atacataaag atgatgtttc tataatatat caagataaac aaacacacaa tcacaaatat 1140

atatgtttgg ataatctatc taaatgtggt catataaaaa ataatgtaca taaaaaaatg 1200

caaactctat atgaacaaac gttatattat aataataatc aacagaattt cttttctaat 1260

catatgtcta attttacaga ttatttttt acacatgata tatataatat atataatata 1320

tataatgtat ataatatata taatgtatat aatatatata atgtatatga tatatataat 1380

gtatattctt ttcttatatt attgctctct ttatttttta ttatgtgttc tcttcttaca 1440

tattatattg ttttttttac agaaaaggct aaaatgacat aa 1482

<210> 9
<211> 493
<212> PRT
<213> Plasmodium falciparum
<400> 9

Met Gly Ile Lys Ile Ile Ile Tyr Ile Phe Phe Leu Ser Trp Ala Lys
1 5 10 15

Trp Val Cys Gly Ser Val Asn Phe Thr Gly Phe Asp Asn Lys Asn Met
20 25 30

Ile Gly Lys His Val Glu Leu Glu Gly Arg Tyr Lys Lys Glu Tyr Ile
35 40 45

Asp Arg Phe Phe Leu Glu Glu Leu Arg Lys His Asn Tyr Met Asn Asn
50 55 60

Asn Val Ile Leu Leu Ser Thr Ser Arg His Tyr Phe Asn Tyr Arg His
65 70 75 80

Thr Thr Asn Leu Leu Ile Ala Tyr Lys Tyr Leu Lys Tyr Phe Gly Asp
85 90 95

Thr Met Asp Lys Asn Ile Leu Leu Met Ile Pro Phe Asp Gln Ala Cys
100 105 110

Asp Cys Arg Asn Ile Arg Glu Gly Gln Ile Phe Arg Glu Tyr Glu Leu
115 120 125

Phe Pro Ser Ser His Asn Lys Glu Thr Lys Ile Glu Asn Ile Asn Leu
130 135 140

Tyr Glu Asn Leu Asn Ile Asp Tyr Lys Asn Asn Asn Val Arg Asp Glu
145 150 155 160

Gln Ile Arg Arg Val Leu Arg His Arg Tyr Asp Ala Phe Thr Pro Lys
165 170 175

Lys Asn Arg Leu Tyr Asn Asn Gly Asn Asn Glu Lys Asn Leu Phe Leu
180 185 190

Tyr Met Thr Gly His Gly Gly Val Asn Phe Leu Lys Ile Gln Glu Phe
195 200 205

Asn Ile Ile Ser Ser Ser Glu Phe Asn Ile Tyr Ile Gln Glu Leu Leu
210 215 220

Ile Lys Asn Phe Tyr Lys Tyr Ile Phe Val Ile Ile Asp Thr Cys Gln
225 230 235 240

Gly Tyr Ser Phe Tyr Asp Asp Ile Leu Asn Phe Val Tyr Lys Lys Lys
245 250 255

Ile Asn Asn Ile Phe Phe Leu Ser Ser Ser Lys Arg Asn Glu Asn Ser

260 265 270

Tyr Ser Leu Phe Ser Ser Ser Tyr Leu Ser Val Ser Thr Val Asp Arg
275 280 285

Phe Thr Tyr His Phe Phe Asn Tyr Leu Gln Gln Ile His Lys Ile Tyr
290 295 300

Glu Lys Glu Pro Ser Lys Asn Ile Lys Ala Phe Ser Leu Tyr Asn Ile
305 310 315 320

Leu Asn Tyr Leu Lys Thr Gln His Ile Met Ser Glu Pro Thr Thr Asn
325 330 335

Asn Ser Lys Phe Asn Ser Ser Ile Phe Leu His Asp Lys Asn Ile Leu
340 345 350

Phe Phe Asn Ser Asn Leu Leu Ile Ile His Lys Asp Asp Val Ser Ile
355 360 365

Ile Tyr Gln Asp Lys Gln Thr His Asn His Lys Tyr Ile Cys Leu Asp
370 375 380

Asn Leu Ser Lys Cys Gly His Ile Lys Asn Asn Val His Lys Lys Met
385 390 395 400

Gln Thr Leu Tyr Glu Gln Thr Leu Tyr Tyr Asn Asn Asn Gln Gln Asn
405 410 415

Phe Phe Ser Asn His Met Ser Asn Phe Thr Asp Tyr Phe Phe Thr His
420 425 430

Asp Ile Tyr Asn Ile Tyr Asn Ile Tyr Asn Val Tyr Asn Ile Tyr Asn
435 440 445

Val Tyr Asn Ile Tyr Asn Val Tyr Asp Ile Tyr Asn Val Tyr Ser Phe
450 455 460

Leu Ile Leu Leu Leu Ser Leu Phe Phe Ile Met Cys Ser Leu Leu Thr
465 470 475 480

Tyr Tyr Ile Val Phe Phe Thr Glu Lys Ala Lys Met Thr
485 490

<210> 10
<211> 1494
<212> DNA
<213> Plasmodium falciparum
<400> 10

atggaaagtg cagttagcga atgcaatata tacaaaaagg aaaaagataa aaatataatt 60

tacaaacaag aaagaaaatg ttgtatttgc atggtgagtg attttttta tccaaatttg 120

ggaggaatag aaactcacat ttttgaattg tctaagaatt tgataaaaaa gggtttcaag 180

gttatagttg taacaaattt taataataat aggcatggta taagatggat gggtaatggt 240

attaaggttt attatttgcc cttccagcct tttttagatg tagtgagttt tccaaatatt 300

atagggactt taccactatg tagaaatata ttatataggg aaaaagtcga catagtacat 360

ggtcaccagg ctacgtcagc attagctcat caattcattc ttcatgccaa aaccttagga 420

ataaaaacta tttatacaga tcactcatta tacagttttt cagacaaagg atgcatacat 480

gtaaacaaat tattgaaata ttgtataaac gatgttgatc attctatatg tgtttcccat 540

acgaatagag aaaatttagt tttgagaaca gaaagtaatc catataaaac gtcagttata 600

ggaaatgccc ttgatactac aaaatttgtt ccttgtatta gtaaaagacc aaagtttcca 660

agaataaata ttattgttat aagtaggtta acatatagaa aaggtataga tttgatagtt 720

aaggtaatac cattagtatg tcaaaaatat ccattcataa aatttattat agggggagaa 780

ggtcctaaaa gattgttatt agaagaaatg agagaaaagt atcacttaca taattctgtt 840

gtattattag gaaaagtaaa acaagaaaat gtaaaaaata ttttacaaac tggtcatata 900

ttcttaaata catctttaac agaagctttt tgtatagcca taattgaagc agctagttgt 960

ggtttgcttg tcatatctac ggatgtaggt ggaatatctg aagttttacc acacgatatg 1020

atgattttag ctaaaccaaa tcatatcgaa ttatgtaaag cagtcgataa agcattaaaa 1080

attgtacaaa aggtggactc aaatttattc cacgaaaggg taaacatgag tttattaaca 1140

tatgtaaata tatatatata tatatatata tatatatata taatatatat gaataatttt 1200

atttataatc taaccaaaat gtactcttgg gaaaaagtag cggaaaagac ggtaaaatca 1260

cataatacat atattatgaa tattgaaaag gtgtatatga acgtattaaa ttatgcaaat 1320

ccaagcttgt ttaatagaat aagaaaaata tacgaaatta atacacctat tcatgtttcc 1380

ttttttttt ttttagacaa aatattgaag aggtcgttag ctttcctcat ttttatgatg 1440

acgaaaataa aaatgaaaaa taagagtttt aaaatgtcga tatataccac ataa 1494

<210> 11
<211> 497
<212> PRT
<213> Plasmodium falciparum
<400> 11

Met Glu Ser Ala Val Ser Glu Cys Asn Ile Tyr Lys Lys Glu Lys Asp
1 5 10 15

Lys Asn Ile Ile Tyr Lys Gln Glu Arg Lys Cys Cys Ile Cys Met Val
20 25 30

Ser Asp Phe Phe Tyr Pro Asn Leu Gly Gly Ile Glu Thr His Ile Phe
35 40 45

Glu Leu Ser Lys Asn Leu Ile Lys Lys Gly Phe Lys Val Ile Val Val
50 55 60

Thr Asn Phe Asn Asn Asn Arg His Gly Ile Arg Trp Met Gly Asn Gly
65 70 75 80

Ile Lys Val Tyr Tyr Leu Pro Phe Gln Pro Phe Leu Asp Val Val Ser
85 90 95

Phe Pro Asn Ile Ile Gly Thr Leu Pro Leu Cys Arg Asn Ile Leu Tyr
100 105 110

Arg Glu Lys Val Asp Ile Val His Gly His Gln Ala Thr Ser Ala Leu

115 120 125

Ala His Gln Phe Ile Leu His Ala Lys Thr Leu Gly Ile Lys Thr Ile
130 135 140

Tyr Thr Asp His Ser Leu Tyr Ser Phe Ser Asp Lys Gly Cys Ile His
145 150 155 160

Val Asn Lys Leu Leu Lys Tyr Cys Ile Asn Asp Val Asp His Ser Ile
165 170 175

Cys Val Ser His Thr Asn Arg Glu Asn Leu Val Leu Arg Thr Glu Ser
180 185 190

Asn Pro Tyr Lys Thr Ser Val Ile Gly Asn Ala Leu Asp Thr Thr Lys
195 200 205

Phe Val Pro Cys Ile Ser Lys Arg Pro Lys Phe Pro Arg Ile Asn Ile
210 215 220

Ile Val Ile Ser Arg Leu Thr Tyr Arg Lys Gly Ile Asp Leu Ile Val
225 230 235 240

Lys Val Ile Pro Leu Val Cys Gln Lys Tyr Pro Phe Ile Lys Phe Ile
245 250 255

Ile Gly Gly Glu Gly Pro Lys Arg Leu Leu Leu Glu Glu Met Arg Glu
260 265 270

Lys Tyr His Leu His Asn Ser Val Val Leu Leu Gly Lys Val Lys Gln
275 280 285

Glu Asn Val Lys Asn Ile Leu Gln Thr Gly His Ile Phe Leu Asn Thr
290 295 300

Ser Leu Thr Glu Ala Phe Cys Ile Ala Ile Ile Glu Ala Ala Ser Cys
305 310 315 320

Gly Leu Leu Val Ile Ser Thr Asp Val Gly Gly Ile Ser Glu Val Leu
325 330 335

Pro His Asp Met Met Ile Leu Ala Lys Pro Asn His Ile Glu Leu Cys
340 345 350

Lys Ala Val Asp Lys Ala Leu Lys Ile Val Gln Lys Val Asp Ser Asn
355 360 365

Leu Phe His Glu Arg Val Asn Met Ser Leu Leu Thr Tyr Val Asn Ile
370 375 380

Tyr Ile Tyr Ile Tyr Ile Tyr Ile Tyr Ile Ile Tyr Met Asn Asn Phe
385 390 395 400

Ile Tyr Asn Leu Thr Lys Met Tyr Ser Trp Glu Lys Val Ala Glu Lys
405 410 415

Thr Val Lys Ser His Asn Thr Tyr Ile Met Asn Ile Glu Lys Val Tyr
420 425 430

Met Asn Val Leu Asn Tyr Ala Asn Pro Ser Leu Phe Asn Arg Ile Arg
435 440 445

Lys Ile Tyr Glu Ile Asn Thr Pro Ile His Val Ser Phe Phe Phe Phe
450 455 460

Leu Asp Lys Ile Leu Lys Arg Ser Leu Ala Phe Leu Ile Phe Met Met
465 470 475 480

Thr Lys Ile Lys Met Lys Asn Lys Ser Phe Lys Met Ser Ile Tyr Thr
485 490 495

Thr

<210> 12
<211> 2361
<212> DNA
<213> Plasmodium falciparum
<400> 12

atgatttaca atgacatttt aacattatgt gcaaataaat taagaggact aattgattca 60

aagatattta tttggttgtt aatatttttt agaatattta attgtttatt tgttgtaaca 120

tcattttatc ctgatgaata ttttcaatct gtagaaattg ctcatttttg ggcttatgga 180

tatggacata tgtcatggga atgggaacct tgtgtagcat taagatcagt gataactcct 240

tttatttatt atgtattatt tttatttttа aaacttatta acatagatca tcctgtttgt 300

gtattataca ttcctaaatt atgtcatggt atatgtgctg ctttgtgtga tttaggtatt 360

tataaattat tgatatattg gtatgttgaa ttgtataatg acgcatggat aaatgaagat 420

aatataaaac gtaatgagaa agatgaaaat aatggaaata acaacaacaa taataataat 480

aacaataata ataacaataa taataataat tattattatc ataataatat attatacaac 540

acaaatgaca ttatttctac aattctatgt tgtcattttt tttgttggtt ttatttttat 600

tccatatgta ggacatcctc gcattccttt gaatgcttgt ttaatatatg gggtgtatat 660

tttttatcac aaaattatta ccccttgaaa aatcaatcaa acaaaataga aaagatagac 720

ttattattac agaacgatgt aatcatacaa aaaggaaaga aacatttaaa tgaatggaca 780

aatttaaaag aaagaaggaa tgatcatcat tttgatacat acgaaaataa ttttatatat 840

cataaaggaa cacaaaattg taaacaatat gataaaaata tggttgatca aaatgtttgt 900

ggtcaaaata tggttgatca cataattcag aacaggaaca atttgtgtag gacacatttt 960

tattcctcca aatttaacaa aatacaagag gcaaaaaatt tattatttag tttattcttt 1020

agctccttgt ctgttatatt tcgtccaaac gctttagtat tttggttatc tttatatata 1080

ctatatatta taaagaatat atttgaaaaa caaaataaaa taaattataa agaaatattc 1140

aaaataggta ttacgtacac ttttttttte ttaactatta ttattataat tgattcttat 1200

tattttgggc acattacatt tccctttgg aatttttttg tttataattt tttaagtgga 1260

aacaataaat attttggagg gcattctttt ttttttact ttgtatgtgt tataccttct 1320

atatatttaa ctttaacacc ttttttgttt tatggttatt acattatata taataatata 1380

ttgaataagg tgaagtataa gacaattaat atatatatgt atatattgaa acgaattgat 1440

tggatagtat atttagttac acacttagaa atcctatctt tatctttcag taagcataag 1500

gaacataaaa ttgttatagg atatataccg tttcttacaa tttttgttgg atatgcatta 1560

tatataataa aattacatta taaaaaatat aatggcaaaa atggaaagaa tatatataat 1620

aataataaaa tccaatatgg taatataacc ataaagggaa gaaataaata tatttttta 1680

atttcatctt ctctttttac aaatataagt tttttacttc aatttttatg tattcttttt 1740

ttctgcctta tacataacag atcacctgaa catgtagcct cttattttag aaacttagaa 1800

acgaaagatg atcaaaatat ttatatattt ataacaaatt gttatgatat acctttatat 1860

tcgcatatac atagaaaatt caatatagga tttttagact gttctcctta tgacacgagt 1920

aatgatgaag ctaccaaaaa ttggagaaaa cgtatatatg aagataaatt taaggaacaa 1980

ttttttaata tttttcaaga aaaaaaaaat aataatcatc atataaatag tacatatgga 2040

gatacaatta ctccatatat aataccagat aaatcatttt attggtttgg tcatcatcat 2100

tttaataaaa aaaataattt tcaatatatt tatcaaaaca ttaatttgtc atgtttaaat 2160

tatagatttc atataccttt acaaggacaa ttacctactt atatagttac aacaactatt 2220

gaacttacac atttacaatt atttctgagt acatataatt ataaacttga aacaaagcct 2280

tttttttctt attttatgat aagtgaagca aaaggaatag ttccagtata tcattacata 2340

ttcaagaggg ttccttccta a 2361

<210> 13
<211> 786
<212> PRT
<213> Plasmodium falciparum
<400> 13

Met Ile Tyr Asn Asp Ile Leu Thr Leu Cys Ala Asn Lys Leu Arg Gly
1 5 10 15

Leu Ile Asp Ser Lys Ile Phe Ile Trp Leu Leu Ile Phe Phe Arg Ile
20 25 30

Phe Asn Cys Leu Phe Val Val Thr Ser Phe Tyr Pro Asp Glu Tyr Phe
35 40 45

Gln Ser Val Glu Ile Ala His Phe Trp Ala Tyr Gly Tyr Gly His Met
50 55 60

Ser Trp Glu Trp Glu Pro Cys Val Ala Leu Arg Ser Val Ile Thr Pro
65 70 75 80

Phe Ile Tyr Tyr Val Leu Phe Leu Phe Leu Lys Leu Ile Asn Ile Asp
85 90 95

His Pro Val Cys Val Leu Tyr Ile Pro Lys Leu Cys His Gly Ile Cys
100 105 110

Ala Ala Leu Cys Asp Leu Gly Ile Tyr Lys Leu Leu Ile Tyr Trp Tyr
115 120 125

Val Glu Leu Tyr Asn Asp Ala Trp Ile Asn Glu Asp Asn Ile Lys Arg
130 135 140

Asn Glu Lys Asp Glu Asn Asn Gly Asn Asn Asn Asn Asn Asn Asn Asn
145 150 155 160

Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Tyr Tyr Tyr His Asn Asn
165 170 175

Ile Leu Tyr Asn Thr Asn Asp Ile Ile Ser Thr Ile Leu Cys Cys His
180 185 190

Phe Phe Cys Trp Phe Tyr Phe Tyr Ser Ile Cys Arg Thr Ser Ser His
195 200 205

Ser Phe Glu Cys Leu Phe Asn Ile Trp Gly Val Tyr Phe Leu Ser Gln
210 215 220

Asn Tyr Tyr Pro Leu Lys Asn Gln Ser Asn Lys Ile Glu Lys Ile Asp
225 230 235 240

Leu Leu Leu Gln Asn Asp Val Ile Ile Gln Lys Gly Lys Lys His Leu
245 250 255

Asn Glu Trp Thr Asn Leu Lys Glu Arg Arg Asn Asp His His Phe Asp
260 265 270

Thr Tyr Glu Asn Asn Phe Ile Tyr His Lys Gly Thr Gln Asn Cys Lys
275 280 285

Gln Tyr Asp Lys Asn Met Val Asp Gln Asn Val Cys Gly Gln Asn Met
290 295 300

Val Asp His Ile Ile Gln Asn Arg Asn Asn Leu Cys Arg Thr His Phe
305 310 315 320

Tyr Ser Ser Lys Phe Asn Lys Ile Gln Glu Ala Lys Asn Leu Leu Phe
325 330 335

Ser Leu Phe Phe Ser Ser Leu Ser Val Ile Phe Arg Pro Asn Ala Leu
340 345 350

Val Phe Trp Leu Ser Leu Tyr Ile Leu Tyr Ile Ile Lys Asn Ile Phe

355 360 365

Glu Lys Gln Asn Lys Ile Asn Tyr Lys Glu Ile Phe Lys Ile Gly Ile
370 375 380

Thr Tyr Thr Phe Phe Phe Leu Thr Ile Ile Ile Ile Ile Asp Ser Tyr
385 390 395 400

Tyr Phe Gly His Ile Thr Phe Pro Phe Trp Asn Phe Phe Val Tyr Asn
405 410 415

Phe Leu Ser Gly Asn Asn Lys Tyr Phe Gly Gly His Ser Phe Phe Phe
420 425 430

Tyr Phe Val Cys Val Ile Pro Ser Ile Tyr Leu Thr Leu Thr Pro Phe
435 440 445

Leu Phe Tyr Gly Tyr Tyr Ile Ile Tyr Asn Asn Ile Leu Asn Lys Val
450 455 460

Lys Tyr Lys Thr Ile Asn Ile Tyr Met Tyr Ile Leu Lys Arg Ile Asp
465 470 475 480

Trp Ile Val Tyr Leu Val Thr His Leu Glu Ile Leu Ser Leu Ser Phe
485 490 495

Ser Lys His Lys Glu His Lys Ile Val Ile Gly Tyr Ile Pro Phe Leu
500 505 510

Thr Ile Phe Val Gly Tyr Ala Leu Tyr Ile Ile Lys Leu His Tyr Lys
515 520 525

Lys Tyr Asn Gly Lys Asn Gly Lys Asn Ile Tyr Asn Asn Asn Lys Ile
530 535 540

Gln Tyr Gly Asn Ile Thr Ile Lys Gly Arg Asn Lys Tyr Ile Phe Leu
545 550 555 560

Ile Ser Ser Ser Leu Phe Thr Asn Ile Ser Phe Leu Leu Gln Phe Leu
565 570 575

Cys Ile Leu Phe Phe Cys Leu Ile His Asn Arg Ser Pro Glu His Val
580 585 590

Ala Ser Tyr Phe Arg Asn Leu Glu Thr Lys Asp Asp Gln Asn Ile Tyr
595 600 605

Ile Phe Ile Thr Asn Cys Tyr Asp Ile Pro Leu Tyr Ser His Ile His
610 615 620

Arg Lys Phe Asn Ile Gly Phe Leu Asp Cys Ser Pro Tyr Asp Thr Ser
625 630 635 640

Asn Asp Glu Ala Thr Lys Asn Trp Arg Lys Arg Ile Tyr Glu Asp Lys
645 650 655

Phe Lys Glu Gln Phe Phe Asn Ile Phe Gln Glu Lys Lys Asn Asn Asn
660 665 670

His His Ile Asn Ser Thr Tyr Gly Asp Thr Ile Thr Pro Tyr Ile Ile
675 680 685

Pro Asp Lys Ser Phe Tyr Trp Phe Gly His His His Phe Asn Lys Lys
690 695 700

Asn Asn Phe Gln Tyr Ile Tyr Gln Asn Ile Asn Leu Ser Cys Leu Asn
705 710 715 720

Tyr Arg Phe His Ile Pro Leu Gln Gly Gln Leu Pro Thr Tyr Ile Val
725 730 735

Thr Thr Thr Ile Glu Leu Thr His Leu Gln Leu Phe Leu Ser Thr Tyr
740 745 750

Asn Tyr Lys Leu Glu Thr Lys Pro Phe Phe Ser Tyr Phe Met Ile Ser
755 760 765

Glu Ala Lys Gly Ile Val Pro Val Tyr His Tyr Ile Phe Lys Arg Val

770 775 780

Pro Ser

785

<210> 14
<211> 1233
<212> DNA
<213> Plasmodium falciparum
<400> 14

atggggcata cacataaaga atataaaaac aatgagaaga gtgcaatatt ttttgagtgg 60

ttgatttttt ttgtgggtat aataattcgt ataattattt attattatgg aaggtggcaa 120

gataaaaact ttaatgttaa gtttacagat gtagattatt atgtttttc tgatgctgca 180

aaatatgtac ttatgaacaa atcaccatat gaaagatata catatagata tacaccttta 240

ttagcatata taatgatacc aaatttttt gttcattttt cttttgggaa aatattattt 300

tcatttatcg atattcttgt tactattctt ataaatcaaa ttataaaaat caaatatact 360

aattgtaaaa attatatatt ttatacttgt ttatggtttt taaatccatt agtcataatt 420

atatcccttc gaggtaatgc agatgttatc ccatgcttct taataatagt aacaatcttt 480

tgtatatata aaaaacatat ctttttgtct tcgatttttt atggactagc tgtgaacttt 540

aaaatatata caattattta tgcactacca ttcatgttat atttaaataa aaattattta 600

cttggggaaa atatttttca attaaatgaa aaaaaaaaaa aaaaaaaaaa tgacttccta 660

ttaaacacat ttttttatat ttttcgtatt atatctaatt tttttgtgga attatttaaa 720

ttaaattatg aacagttttt atttgccata tgtagttcct cggtatttct aattttaaac 780

tgtgtattct atatcatata tggatatgaa tttttgtatg agtcttttat atatcatatt 840

attagacgtg atcataggca taacttttcc ctttttttt accttatgta tttaagtatt 900

gagaagaatt caaagattat tcccttaata acctttgtac cacaaataat tttagtagcc 960

ttatttggat ttaaatatgc aagaacgaat ttggaattat ccatgttttt acaaactatt 1020

tcttttattg cattgaataa agtgtgcaca tctcagtatt tcatttggtg tattccattt 1080

ttaccaatta tactttgtgc cataacctta agcaagagaa atatgtttct tataatatcc 1140

tccattttat tttttattgt ggcaaaagtg ggctcaaaaa gatttctttt attatataaa 1200

tatgtctttt catatattat ttttttttca tga 1233

<210> 15
<211> 410
<212> PRT
<213> Plasmodium falciparum
<400> 15

Met Gly His Thr His Lys Glu Tyr Lys Asn Asn Glu Lys Ser Ala Ile
1 5 10 15

Phe Phe Glu Trp Leu Ile Phe Phe Val Gly Ile Ile Ile Arg Ile Ile
20 25 30

Ile Tyr Tyr Tyr Gly Arg Trp Gln Asp Lys Asn Phe Asn Val Lys Phe
35 40 45

Thr Asp Val Asp Tyr Tyr Val Phe Ser Asp Ala Ala Lys Tyr Val Leu
50 55 60

Met Asn Lys Ser Pro Tyr Glu Arg Tyr Thr Tyr Arg Tyr Thr Pro Leu
65 70 75 80

Leu Ala Tyr Ile Met Ile Pro Asn Phe Phe Val His Phe Ser Phe Gly
85 90 95

Lys Ile Leu Phe Ser Phe Ile Asp Ile Leu Val Thr Ile Leu Ile Asn
100 105 110

Gln Ile Ile Lys Ile Lys Tyr Thr Asn Cys Lys Asn Tyr Ile Phe Tyr
115 120 125

Thr Cys Leu Trp Phe Leu Asn Pro Leu Val Ile Ile Ile Ser Leu Arg
130 135 140

Gly Asn Ala Asp Val Ile Pro Cys Phe Leu Ile Ile Val Thr Ile Phe
145 150 155 160

Cys Ile Tyr Lys Lys His Ile Phe Leu Ser Ser Ile Phe Tyr Gly Leu
165 170 175

Ala Val Asn Phe Lys Ile Tyr Thr Ile Ile Tyr Ala Leu Pro Phe Met
180 185 190

Leu Tyr Leu Asn Lys Asn Tyr Leu Leu Gly Glu Asn Ile Phe Gln Leu
195 200 205

Asn Glu Lys Lys Lys Lys Lys Lys Asn Asp Phe Leu Leu Asn Thr Phe
210 215 220

Phe Tyr Ile Phe Arg Ile Ile Ser Asn Phe Phe Val Glu Leu Phe Lys

225 230 235 240

Leu Asn Tyr Glu Gln Phe Leu Phe Ala Ile Cys Ser Ser Ser Val Phe
245 250 255

Leu Ile Leu Asn Cys Val Phe Tyr Ile Ile Tyr Gly Tyr Glu Phe Leu
260 265 270

Tyr Glu Ser Phe Ile Tyr His Ile Ile Arg Arg Asp His Arg His Asn
275 280 285

Phe Ser Leu Phe Phe Tyr Leu Met Tyr Leu Ser Ile Glu Lys Asn Ser
290 295 300

Lys Ile Ile Pro Leu Ile Thr Phe Val Pro Gln Ile Ile Leu Val Ala
305 310 315 320

Leu Phe Gly Phe Lys Tyr Ala Arg Thr Asn Leu Glu Leu Ser Met Phe
325 330 335

Leu Gln Thr Ile Ser Phe Ile Ala Leu Asn Lys Val Cys Thr Ser Gln
340 345 350

Tyr Phe Ile Trp Cys Ile Pro Phe Leu Pro Ile Ile Leu Cys Ala Ile
355 360 365

Thr Leu Ser Lys Arg Asn Met Phe Leu Ile Ile Ser Ser Ile Leu Phe
370 375 380

Phe Ile Val Ala Lys Val Gly Ser Lys Arg Phe Leu Leu Leu Tyr Lys
385 390 395 400

Tyr Val Phe Ser Tyr Ile Ile Phe Phe Ser
405 410

<210> 16
<211> 3852
<212> DNA
<213> Plasmodium falciparum
<400> 16

atgaaaatta aaaataatat taaaaaaaaa aatgataacc tacatcattt cataagtaat 60

catacgctaa tattttctat tatcctactt ataaatctat tgatttttt ctcatttatc 120

aatggctatt tttatgcaag acaaaaactt gaagaaaaat cagaaaacct tgagcttttt 180

agtaggaaag tatttggaga tgaatacgta gaaagtttga aaaagaaaaa aaatactttt 240

tcgattatta atgcaccata tgataaagtt gttatacttt taatagattc cttaagattt 300

gattttaccc tatacgatac taattatgaa aaggaattca taggaaaaga aaaaaataca 360

gatatctaca ataatatatc tagcgaaaaa aaaaatatat caaatgatgg ggaaaaaaaa 420

aactcattat ttttttaaa taatatgata aatgtacatc acattttaca aaatgaaaaa 480

aacaacactt tattattccg gtttgatgca gatgccccta caataacaac ttcaaggata 540

aaatctatat ttatgggtac cataccaaat tatatggaag taaatgaaaa ctttagtcct 600

acgactagtg ttgaagataa ttttttgaa cagcttcatt taaataataa aaaagtaatt 660

gctatcggtg ataataccat tactcatttg atgaaacatt tttctaaaga attagtttat 720

gagagcttta atgtttttga tttttattca ttagatattg ctgcaaagaa acatttttat 780

gaagaatacg aatcaaatga ttgggatatt atgtatatac atatgttggg agttgatcat 840

attggacata taaaaacacc caactcaaaa atcatgggag atgccttaaa agattttgat 900

acattcatat atgatattat aaataaaata aaattagata atcttaaaaa tattagcaca 960

gaagaaaaag aaaaaatgaa aataataaaa aaaaaaatat ataaaactta tcgaaacggt 1020

catcacatac aaaatgaaaa tgatcatatt attgataata tacaaaatga aaatgatcat 1080

attattgata atatacaaaa tgaaaatgat catactattg ataatataca aagtgaaaat 1140

gatcatacta ttgataatat acaaaatgaa aatgatcata ctattgaaga tatacaaatt 1200

gataatgatc atactattga agatattgaa aatcaaagtg aacaaaaaaa tgatgataaa 1260

aaaacactgt tcatattttt tggtgatcat ggacagctag atacaggaga tcacggagga 1320

tacagcttgg acgaaaccca tagtgctctt tttgcatatt caccettaaa ctttatatct 1380

ttagataatg acatcattca aaataatttt gttttatatg ataaagataa attaaaaaaa 1440

aatgtgaata cactgaatga agaaaataat aataatgaga atatagataa ttataaaaaa 1500

tatcattcat atttaaaaga tagaaataaa aaatattctt accattataa tgttaaatat 1560

acaaaacaag taaatttaat gagtacctta tccttattaa ttggatcaac attaccttat 1620

ggaaatatag gaaatattat tatggatttc attcccaatg catatataaa aaataataat 1680

aaaaaaaaaa ataataataa taataataat aataataatt cttcattacc taatgaacag 1740

acaaatttat attatgatct tttaaattta cattatattg ctgaattaaa ttatgctaac 1800

ttatggcaat tgaatagata cctgaatgaa tatgaaaaaa agtataatat aataaaaaat 1860

gaagattatc attttattaa atcctcatgg catattatac aaaaagacaa aaaagaattg 1920

tttttttcaac caaataaaaa atttattaaa aatgacattt tattaaaaaa agaaaaagaa 1980

tcatatatag aattcataaa tgaaatgaca actctaatgg atatcacaca aaaatatttt 2040

tactatatat tcaacataaa agaaaaatat ttcttaattt tatctattgt tttaaatata 2100

ttcttattat tatttttaaa acatttttat tattattcta aattaaatta ttaccataaa 2160

ttaattaaag taacctttaa tgattttaat aaaaatattt atttattact ttgtatatgt 2220

gcattacttt tatatttttt tatcttctgt ttatcaatta aagaatataa agatatattc 2280

cgaatatttt ctcatgctaa aatcattttc ataagcaata atatagatat gataatacct 2340

agtataaaaa attaccatat gagcgctaaa cgtaacatga atattacgaa taatgacacc 2400

taccatacat cacataagga tcggaaatca ttcacaaata aagaagagaa acaaaataat 2460

acacttatga atatattcta taatattatt tatttcttaa gaataattcg aaaaaaaatt 2520

gttcagtata taatctttat acatttgaca atatacaatc taactatagg taatattatc 2580

tttattctat ttaaattatt tccgaaaatt ataactaatt catttcaaat attaagaagt 2640

aattatttcc ttttgtttgt tattatatgg agctgttgtg aaatgtcctt taattatata 2700

gataaagaaa gatattatat tcattacatt ttaattgtat atgttatatt tgggatgctt 2760

aaatggaagt atcaccgtgt ctttaatata ctaaaagcct tcattttgtt ggtgcttcta 2820

ataattaatg ctttgtatag ccatacaccc gaatattttg accatggtaa agaaaaaata 2880

tatttaaaag aatctgtact aaaatcagtt tttccaatat catcttatat tcttagctta 2940

atattaataa atagtggtat taataattta ctgaaaaaac gaataaaaat aataataacc 3000

caaatatgga cattacaata tatcctcgtt tttttgttct taaataatat ataccataga 3060

tatattcaat ttataacacc cccaagtatt tatttcttaa ccatttcaac cttcatattc 3120

atattcaata caaatttagg tgtattattt ctcttttata tgacatttct ttttttctac 3180

tttattctta taagttccaa ttgttcagaa aatatgatcc aaatgaatga cataacatcg 3240

acatggataa atgaaaatat acataataga aatgatccta taattacaaa aggaaatttg 3300

gagaataaag aaaagtgtac ttcatgtaat acatctataa aagaaaaatt ttattataaa 3360

ttaatgatag aaaaattcaa attattaaat acatgctctg tattaaatga agaagaaata 3420

atgggaatac aaatttataa attaattaga gatatttctt atttttatat aaatgaaaca 3480

gatttttata ttttatcatg tgtactttta atatattctt tttttataac gggacataaa 3540

tttatttttaa ataacttacc actagtttca ggttatgttg gattgtataa atatgtgtgg 3600

ccaataagtc agttttatat ttttaatcat atttttttc cattcttctt ttcgttattt 3660

tttatcattt atatttataa cataagaagg ataaaaatta taaattcttt taagcaattt 3720

gatttgtatt atttttatgt ttatccacta atgaactttt ccttcaaggc ctccttttg 3780

ttttgttgca agtttattat atctgtatgg gtttcatatt acttgaatct gcacataatg 3840

gtaaaaatat aa 3852

<210> 17
<211> 1283
<212> PRT
<213> Plasmodium falciparum
<400> 17

Met Lys Ile Lys Asn Asn Ile Lys Lys Lys Asn Asp Asn Leu His His
1 5 10 15

Phe Ile Ser Asn His Thr Leu Ile Phe Ser Ile Ile Leu Leu Ile Asn
20 25 30

Leu Leu Ile Phe Phe Ser Phe Ile Asn Gly Tyr Phe Tyr Ala Arg Gln
35 40 45

Lys Leu Glu Glu Lys Ser Glu Asn Leu Glu Leu Phe Ser Arg Lys Val
50 55 60

Phe Gly Asp Glu Tyr Val Glu Ser Leu Lys Lys Lys Lys Asn Thr Phe
65 70 75 80

Ser Ile Ile Asn Ala Pro Tyr Asp Lys Val Val Ile Leu Leu Ile Asp
85 90 95

Ser Leu Arg Phe Asp Phe Thr Leu Tyr Asp Thr Asn Tyr Glu Lys Glu
100 105 110

Phe Ile Gly Lys Glu Lys Asn Thr Asp Ile Tyr Asn Asn Ile Ser Ser
115 120 125

Glu Lys Lys Asn Ile Ser Asn Asp Gly Glu Lys Lys Asn Ser Leu Phe
130 135 140

Phe Leu Asn Asn Met Ile Asn Val His His Ile Leu Gln Asn Glu Lys
145 150 155 160

Asn Asn Thr Leu Leu Phe Arg Phe Asp Ala Asp Ala Pro Thr Ile Thr
165 170 175

Thr Ser Arg Ile Lys Ser Ile Phe Met Gly Thr Ile Pro Asn Tyr Met
180 185 190

Glu Val Asn Glu Asn Phe Ser Pro Thr Thr Ser Val Glu Asp Asn Phe
195 200 205

Phe Glu Gln Leu His Leu Asn Asn Lys Lys Val Ile Ala Ile Gly Asp
210 215 220

Asn Thr Ile Thr His Leu Met Lys His Phe Ser Lys Glu Leu Val Tyr
225 230 235 240

Glu Ser Phe Asn Val Phe Asp Phe Tyr Ser Leu Asp Ile Ala Ala Lys
245 250 255

Lys His Phe Tyr Glu Glu Tyr Glu Ser Asn Asp Trp Asp Ile Met Tyr
260 265 270

Ile His Met Leu Gly Val Asp His Ile Gly His Ile Lys Thr Pro Asn
275 280 285

Ser Lys Ile Met Gly Asp Ala Leu Lys Asp Phe Asp Thr Phe Ile Tyr

290 295 300

Asp Ile Ile Asn Lys Ile Lys Leu Asp Asn Leu Lys Asn Ile Ser Thr
305 310 315 320

Glu Glu Lys Glu Lys Met Lys Ile Ile Lys Lys Lys Ile Tyr Lys Thr
325 330 335

Tyr Arg Asn Gly His His Ile Gln Asn Glu Asn Asp His Ile Ile Asp
340 345 350

Asn Ile Gln Asn Glu Asn Asp His Ile Ile Asp Asn Ile Gln Asn Glu
355 360 365

Asn Asp His Thr Ile Asp Asn Ile Gln Ser Glu Asn Asp His Thr Ile
370 375 380

Asp Asn Ile Gln Asn Glu Asn Asp His Thr Ile Glu Asp Ile Gln Ile
385 390 395 400

Asp Asn Asp His Thr Ile Glu Asp Ile Glu Asn Gln Ser Glu Gln Lys
405 410 415

Asn Asp Asp Lys Lys Thr Leu Phe Ile Phe Phe Gly Asp His Gly Gln
420 425 430

Leu Asp Thr Gly Asp His Gly Gly Tyr Ser Leu Asp Glu Thr His Ser
435 440 445

Ala Leu Phe Ala Tyr Ser Pro Leu Asn Phe Ile Ser Leu Asp Asn Asp
450 455 460

Ile Ile Gln Asn Asn Phe Val Leu Tyr Asp Lys Asp Lys Leu Lys Lys
465 470 475 480

Asn Val Asn Thr Leu Asn Glu Glu Asn Asn Asn Asn Glu Asn Ile Asp
485 490 495

Asn Tyr Lys Lys Tyr His Ser Tyr Leu Lys Asp Arg Asn Lys Lys Tyr
500 505 510

Ser Tyr His Tyr Asn Val Lys Tyr Thr Lys Gln Val Asn Leu Met Ser
515 520 525

Thr Leu Ser Leu Leu Ile Gly Ser Thr Leu Pro Tyr Gly Asn Ile Gly
530 535 540

Asn Ile Ile Met Asp Phe Ile Pro Asn Ala Tyr Ile Lys Asn Asn Asn
545 550 555 560

Lys Lys Lys Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Ser Ser Leu
565 570 575

Pro Asn Glu Gln Thr Asn Leu Tyr Tyr Asp Leu Leu Asn Leu His Tyr
580 585 590

Ile Ala Glu Leu Asn Tyr Ala Asn Leu Trp Gln Leu Asn Arg Tyr Leu
595 600 605

Asn Glu Tyr Glu Lys Lys Tyr Asn Ile Ile Lys Asn Glu Asp Tyr His
610 615 620

Phe Ile Lys Ser Ser Trp His Ile Ile Gln Lys Asp Lys Lys Glu Leu
625 630 635 640

Phe Phe Gln Pro Asn Lys Lys Phe Ile Lys Asn Asp Ile Leu Leu Lys
645 650 655

Lys Glu Lys Glu Ser Tyr Ile Glu Phe Ile Asn Glu Met Thr Thr Leu
660 665 670

Met Asp Ile Thr Gln Lys Tyr Phe Tyr Tyr Ile Phe Asn Ile Lys Glu
675 680 685

Lys Tyr Phe Leu Ile Leu Ser Ile Val Leu Asn Ile Phe Leu Leu Leu
690 695 700

Phe Leu Lys His Phe Tyr Tyr Tyr Ser Lys Leu Asn Tyr Tyr His Lys

705 710 715 720

Leu Ile Lys Val Thr Phe Asn Asp Phe Asn Lys Asn Ile Tyr Leu Leu
725 730 735

Leu Cys Ile Cys Ala Leu Leu Leu Tyr Phe Phe Ile Phe Cys Leu Ser
740 745 750

Ile Lys Glu Tyr Lys Asp Ile Phe Arg Ile Phe Ser His Ala Lys Ile
755 760 765

Ile Phe Ile Ser Asn Asn Ile Asp Met Ile Ile Pro Ser Ile Lys Asn
770 775 780

Tyr His Met Ser Ala Lys Arg Asn Met Asn Ile Thr Asn Asn Asp Thr
785 790 795 800

Tyr His Thr Ser His Lys Asp Arg Lys Ser Phe Thr Asn Lys Glu Glu
805 810 815

Lys Gln Asn Asn Thr Leu Met Asn Ile Phe Tyr Asn Ile Ile Tyr Phe
820 825 830

Leu Arg Ile Ile Arg Lys Lys Ile Val Gln Tyr Ile Ile Phe Ile His
835 840 845

Leu Thr Ile Tyr Asn Leu Thr Ile Gly Asn Ile Ile Phe Ile Leu Phe
850 855 860

Lys Leu Phe Pro Lys Ile Ile Thr Asn Ser Phe Gln Ile Leu Arg Ser
865 870 875 880

Asn Tyr Phe Leu Leu Phe Val Ile Ile Trp Ser Cys Cys Glu Met Ser
885 890 895

Phe Asn Tyr Ile Asp Lys Glu Arg Tyr Tyr Ile His Tyr Ile Leu Ile
900 905 910

Val Tyr Val Ile Phe Gly Met Leu Lys Trp Lys Tyr His Arg Val Phe
915 920 925

Asn Ile Leu Lys Ala Phe Ile Leu Leu Val Leu Leu Ile Ile Asn Ala
930 935 940

Leu Tyr Ser His Thr Pro Glu Tyr Phe Asp His Gly Lys Glu Lys Ile
945 950 955 960

Tyr Leu Lys Glu Ser Val Leu Lys Ser Val Phe Pro Ile Ser Ser Tyr
965 970 975

Ile Leu Ser Leu Ile Leu Ile Asn Ser Gly Ile Asn Asn Leu Leu Lys
980 985 990

Lys Arg Ile Lys Ile Ile Ile Thr Gln Ile Trp Thr Leu Gln Tyr Ile
995 1000 1005

Leu Val Phe Leu Phe Leu Asn Asn Ile Tyr His Arg Tyr Ile Gln
1010 1015 1020

Phe Ile Thr Pro Pro Ser Ile Tyr Phe Leu Thr Ile Ser Thr Phe
1025 1030 1035

Ile Phe Ile Phe Asn Thr Asn Leu Gly Val Leu Phe Leu Phe Tyr
1040 1045 1050

Met Thr Phe Leu Phe Phe Tyr Phe Ile Leu Ile Ser Ser Asn Cys
1055 1060 1065

Ser Glu Asn Met Ile Gln Met Asn Asp Ile Thr Ser Thr Trp Ile
1070 1075 1080

Asn Glu Asn Ile His Asn Arg Asn Asp Pro Ile Ile Thr Lys Gly
1085 1090 1095

Asn Leu Glu Asn Lys Glu Lys Cys Thr Ser Cys Asn Thr Ser Ile
1100 1105 1110

Lys Glu Lys Phe Tyr Tyr Lys Leu Met Ile Glu Lys Phe Lys Leu

1115 1120 1125

Leu Asn Thr Cys Ser Val Leu Asn Glu Glu Glu Ile Met Gly Ile
1130 1135 1140

Gln Ile Tyr Lys Leu Ile Arg Asp Ile Ser Tyr Phe Tyr Ile Asn
1145 1150 1155

Glu Thr Asp Phe Tyr Ile Leu Ser Cys Val Leu Leu Ile Tyr Ser
1160 1165 1170

Phe Phe Ile Thr Gly His Lys Phe Ile Leu Asn Asn Leu Pro Leu
1175 1180 1185

Val Ser Gly Tyr Val Gly Leu Tyr Lys Tyr Val Trp Pro Ile Ser
1190 1195 1200

Gln Phe Tyr Ile Phe Asn His Ile Phe Phe Pro Phe Phe Phe Ser
1205 1210 1215

Leu Phe Phe Ile Ile Tyr Ile Tyr Asn Ile Arg Arg Ile Lys Ile
1220 1225 1230

Ile Asn Ser Phe Lys Gln Phe Asp Leu Tyr Tyr Phe Tyr Val Tyr
1235 1240 1245

Pro Leu Met Asn Phe Ser Phe Lys Ala Ser Phe Leu Phe Cys Cys
1250 1255 1260

Lys Phe Ile Ile Ser Val Trp Val Ser Tyr Tyr Leu Asn Leu His
1265 1270 1275

Ile Met Val Lys Ile
1280

<210> 18
<211> 2433
<212> DNA
<213> Plasmodium falciparum
<400> 18

atgggatttt cagaaaatcc caaattctgc ctgctcataa ataagcttat caagaaatct 60

aaagttatag gcgttttctt atcaattatt ggtgtgattt tctttttggt gtttaataag 120

tttaataaga atgctgaatt agacgctagg acatttaccc aatttgttgg taattcagta 180

ttgaacaaaa agaatgagaa gttttataat gatacaaatt cttatttcat gaactataca 240

tatgaaggga aagaagatat aataaagttg atatatgatt atattagaaa aaatatatta 300

gtaaatgtag agaatgagat ggttaaaata aaattaacgg atagaattga acagaatata 360

ttgataagta atgtaggatg taaatattgt aataatatgg aaagtttagt tgtggtaata 420

aattttgatt ttaaagaaag gaaatatttt catagcgtaa ttatcggttt aacgttaatg 480

gaacattttt ctaaatgtaa ctatatgagt aaggatgtga ctttttttatt taccaataaa 540

gaattattat attctttagg tgttcaagaa tttatacaaa aatattttta taataatact 600

aatagaattg gaaaaaaaat tattagatct tctactatta ttgaatttga ttctatttat 660

ccttcttata ttaaaattaa ttatgaagga ttaaatggta tgttacctaa tcaagactta 720

atattattat taacaaatga acttcatttt tattctattc ctattaaaat ggagcttact 780

catggttcca tatttgatat ggccctagaa aagaattatg aaaatggtca catatacttt 840

ctgaggtaca aaaaaaaata tgaatatata cgtgatgata atgatgaaat caagaacatt 900

cccgcattta ctgcaacggg gggtagcaaa gtacccataa gaaataaaat gattaatttg 960

ttcaacttaa ccaaagcatt acaaagttat ttaagaagtc agagtaatac acatgaaggc 1020

ttttgtcatt cttcaaattt ttatttttttt aatacattca gaaggcatat accaataagt 1080

atatattgtt atagtgttta tttaatatgc gcatatagca taatgaaatt atttaaatca 1140

acgatattta gaagctacat aaatttttta acaggtttct acacttattt gattacaata 1200

ttaattattt ccctacctat atatttaatt tcaacaaata aaaaatttta tgagttgttg 1260

aattttgaag aaaattatat tccttcatgt tatgaatggc atcctgataa ttttgataaa 1320

tatataaaaa ttgcaaatat atggtggaat gttttatttt tctcaatttt tggtgcattt 1380

ttttttaatt tatttatttc ttttttagtt aataaaaaaa gaaaagttat accaaaaaaa 1440

aatgatcaaa atgaatcatt tgatggctat aaaaaggtag agaaggtaga acgaatttta 1500

atattagaaa aaatcaaaga attgcaaaat gaaataatga aacgaaaagg tattacaaat 1560

aatcataata atattaaaaa ttataatatt tatacaaatg aaaatatata caataataat 1620

ataaataata taaataataa taataatatt tatgaaaact tatatgataa tggagaagta 1680

aaaaaaaaca ttctggttaa accaaaaatt ataaatagcg atgatgaaga ttttcttctt 1740

gaaaaaaaaa attccgaatt cattaaaaaa atagaaaaac aaatagaaat attagaagaa 1800

aaattggaat ttttaagtaa tgatgaaaat gtaaaatata ttttttataa taattctata 1860

gcaccattta atacaatgat gatatatatg aatatttttt atttcatatt agtagcgcta 1920

ttaagttcgt tatataattg gtcctattct gtattattta gcctgctatt tgtaattcct 1980

atatcaattt tacataattt aaaaacaaaa ccagtcagaa tttttaagaa gattattctt 2040

tcacttttta ttctttgtat gtttatttat atgtatccta atgataatca tctttggaat 2100

ataagacaga agctaactaa tttatttagg aataatatat caaaatgttg taaatattta 2160

gacaagcaca aaatattaca aagcaaatat ttcccagaaa gtttgcaatt tatttgttcg 2220

aataggttat ttgattcatt ttactcaaat aaatattttt tggataatct aaatattaaa 2280

tttagttatg tcttggatat tcaaaatgga ttcttattaa ctttatacaa tttagcaaga 2340

aatcattttt gtattggtac agctacctat cctttaatat gctttacctt attcccaata 2400

gtattttata tagtttttt atttttttgt taa 2433

<210> 19
<211> 810
<212> PRT
<213> Plasmodium falciparum
<400> 19

Met Gly Phe Ser Glu Asn Pro Lys Phe Cys Leu Leu Ile Asn Lys Leu
1 5 10 15

Ile Lys Lys Ser Lys Val Ile Gly Val Phe Leu Ser Ile Ile Gly Val
20 25 30

Ile Phe Phe Leu Val Phe Asn Lys Phe Asn Lys Asn Ala Glu Leu Asp
35 40 45

Ala Arg Thr Phe Thr Gln Phe Val Gly Asn Ser Val Leu Asn Lys Lys
50 55 60

Asn Glu Lys Phe Tyr Asn Asp Thr Asn Ser Tyr Phe Met Asn Tyr Thr
65 70 75 80

Tyr Glu Gly Lys Glu Asp Ile Ile Lys Leu Ile Tyr Asp Tyr Ile Arg
85 90 95

Lys Asn Ile Leu Val Asn Val Glu Asn Glu Met Val Lys Ile Lys Leu
100 105 110

Thr Asp Arg Ile Glu Gln Asn Ile Leu Ile Ser Asn Val Gly Cys Lys
115 120 125

Tyr Cys Asn Asn Met Glu Ser Leu Val Val Val Ile Asn Phe Asp Phe

130 135 140

Lys Glu Arg Lys Tyr Phe His Ser Val Ile Ile Gly Leu Thr Leu Met
145 150 155 160

Glu His Phe Ser Lys Cys Asn Tyr Met Ser Lys Asp Val Thr Phe Leu
165 170 175

Phe Thr Asn Lys Glu Leu Leu Tyr Ser Leu Gly Val Gln Glu Phe Ile
180 185 190

Gln Lys Tyr Phe Tyr Asn Asn Thr Asn Arg Ile Gly Lys Lys Ile Ile
195 200 205

Arg Ser Ser Thr Ile Ile Glu Phe Asp Ser Ile Tyr Pro Ser Tyr Ile
210 215 220

Lys Ile Asn Tyr Glu Gly Leu Asn Gly Met Leu Pro Asn Gln Asp Leu
225 230 235 240

Ile Leu Leu Leu Thr Asn Glu Leu His Phe Tyr Ser Ile Pro Ile Lys
245 250 255

Met Glu Leu Thr His Gly Ser Ile Phe Asp Met Ala Leu Glu Lys Asn
260 265 270

Tyr Glu Asn Gly His Ile Tyr Phe Leu Arg Tyr Lys Lys Lys Tyr Glu
275 280 285

Tyr Ile Arg Asp Asp Asn Asp Glu Ile Lys Asn Ile Pro Ala Phe Thr
290 295 300

Ala Thr Gly Gly Ser Lys Val Pro Ile Arg Asn Lys Met Ile Asn Leu
305 310 315 320

Phe Asn Leu Thr Lys Ala Leu Gln Ser Tyr Leu Arg Ser Gln Ser Asn
325 330 335

Thr His Glu Gly Phe Cys His Ser Ser Asn Phe Tyr Phe Phe Asn Thr
340 345 350

Phe Arg Arg His Ile Pro Ile Ser Ile Tyr Cys Tyr Ser Val Tyr Leu
355 360 365

Ile Cys Ala Tyr Ser Ile Met Lys Leu Phe Lys Ser Thr Ile Phe Arg
370 375 380

Ser Tyr Ile Asn Phe Leu Thr Gly Phe Tyr Thr Tyr Leu Ile Thr Ile
385 390 395 400

Leu Ile Ile Ser Leu Pro Ile Tyr Leu Ile Ser Thr Asn Lys Lys Phe
405 410 415

Tyr Glu Leu Leu Asn Phe Glu Glu Asn Tyr Ile Pro Ser Cys Tyr Glu
420 425 430

Trp His Pro Asp Asn Phe Asp Lys Tyr Ile Lys Ile Ala Asn Ile Trp
435 440 445

Trp Asn Val Leu Phe Phe Ser Ile Phe Gly Ala Phe Phe Phe Asn Leu
450 455 460

Phe Ile Ser Phe Leu Val Asn Lys Lys Arg Lys Val Ile Pro Lys Lys
465 470 475 480

Asn Asp Gln Asn Glu Ser Phe Asp Gly Tyr Lys Lys Val Glu Lys Val
485 490 495

Glu Arg Ile Leu Ile Leu Glu Lys Ile Lys Glu Leu Gln Asn Glu Ile
500 505 510

Met Lys Arg Lys Gly Ile Thr Asn Asn His Asn Asn Ile Lys Asn Tyr
515 520 525

Asn Ile Tyr Thr Asn Glu Asn Ile Tyr Asn Asn Asn Ile Asn Asn Ile
530 535 540

Asn Asn Asn Asn Asn Ile Tyr Glu Asn Leu Tyr Asp Asn Gly Glu Val

545 550 555 560

Lys Lys Asn Ile Leu Val Lys Pro Lys Ile Ile Asn Ser Asp Asp Glu
565 570 575

Asp Phe Leu Leu Glu Lys Lys Asn Ser Glu Phe Ile Lys Lys Ile Glu
580 585 590

Lys Gln Ile Glu Ile Leu Glu Glu Lys Leu Glu Phe Leu Ser Asn Asp
595 600 605

Glu Asn Val Lys Tyr Ile Phe Tyr Asn Asn Ser Ile Ala Pro Phe Asn
610 615 620

Thr Met Met Ile Tyr Met Asn Ile Phe Tyr Phe Ile Leu Val Ala Leu
625 630 635 640

Leu Ser Ser Leu Tyr Asn Trp Ser Tyr Ser Val Leu Phe Ser Leu Leu
645 650 655

Phe Val Ile Pro Ile Ser Ile Leu His Asn Leu Lys Thr Lys Pro Val
660 665 670

Arg Ile Phe Lys Lys Ile Ile Leu Ser Leu Phe Ile Leu Cys Met Phe
675 680 685

Ile Tyr Met Tyr Pro Asn Asp Asn His Leu Trp Asn Ile Arg Gln Lys
690 695 700

Leu Thr Asn Leu Phe Arg Asn Asn Ile Ser Lys Cys Cys Lys Tyr Leu
705 710 715 720

Asp Lys His Lys Ile Leu Gln Ser Lys Tyr Phe Pro Glu Ser Leu Gln
725 730 735

Phe Ile Cys Ser Asn Arg Leu Phe Asp Ser Phe Tyr Ser Asn Lys Tyr
740 745 750

Phe Leu Asp Asn Leu Asn Ile Lys Phe Ser Tyr Val Leu Asp Ile Gln
755 760 765

Asn Gly Phe Leu Leu Thr Leu Tyr Asn Leu Ala Arg Asn His Phe Cys
770 775 780

Ile Gly Thr Ala Thr Tyr Pro Leu Ile Cys Phe Thr Leu Phe Pro Ile
785 790 795 800

Val Phe Tyr Ile Val Phe Leu Phe Phe Cys
805 810

<210> 20
<211> 780
<212> DNA
<213> Plasmodium falciparum
<400> 20

atggttattc gatttttcct gtttgtcatt acactcttag gcttatgcat aaatatggtg 60

tgttgtaatt ttaaatattc gattatatta cctacttaca atgaaaaaga aaacttacca 120

tatcttattt atatgataat tgatgaatta ataaaacatg aaattaaatt tgaaataatt 180

gtaatagatg ataatagtca agatggtact gcagatgtgt acaaaaagtt acaaaacatt 240

tttaaggatg aagaattatt attaatacaa agaaaaggaa aattagggtt aggttctgca 300

tatatggaag gtttaaaaaa tgtaacagga gattttgtta taataatgga tgctgattta 360

tcacatcatc ctaaatatat ttataacttt attaaaaaac aaagagaaaa aaattgtgac 420

attgttacag gcacaagata taagaaccaa ggtggaatat caggatggtc atttaataga 480

attataataa gtagagtagc aaatttttta gctcaatttc tattattcat taatctatca 540

gatttaaccg ggtcttttag attatataaa actaatgtac tgaaggaact tatgcaatct 600

attaataata caggttatgt ttttcaaatg gaagttcttg taagagcata taaaatggga 660

aaatctatag aagaagttgg ttacgttttt gttgatagat tatttggaaa atcaaaactg 720

gaaactacag atattttaca atacttatca ggtcttttca agttattctg gtcaatataa 780

<210> 21
<211> 259
<212> PRT

<213> Plasmodium falciparum
<400> 21

Met Val Ile Arg Phe Phe Leu Phe Val Ile Thr Leu Leu Gly Leu Cys
1 5 10 15

Ile Asn Met Val Cys Cys Asn Phe Lys Tyr Ser Ile Ile Leu Pro Thr
20 25 30

Tyr Asn Glu Lys Glu Asn Leu Pro Tyr Leu Ile Tyr Met Ile Ile Asp
35 40 45

Glu Leu Asn Lys His Glu Ile Lys Phe Glu Ile Ile Val Ile Asp Asp
50 55 60

Asn Ser Gln Asp Gly Thr Ala Asp Val Tyr Lys Lys Leu Gln Asn Ile
65 70 75 80

Phe Lys Asp Glu Glu Leu Leu Leu Ile Gln Arg Lys Gly Lys Leu Gly
85 90 95

Leu Gly Ser Ala Tyr Met Glu Gly Leu Lys Asn Val Thr Gly Asp Phe
100 105 110

Val Ile Ile Met Asp Ala Asp Leu Ser His His Pro Lys Tyr Ile Tyr
115 120 125

Asn Phe Ile Lys Lys Gln Arg Glu Lys Asn Cys Asp Ile Val Thr Gly
130 135 140

Thr Arg Tyr Lys Asn Gln Gly Gly Ile Ser Gly Trp Ser Phe Asn Arg
145 150 155 160

Ile Ile Ile Ser Arg Val Ala Asn Phe Leu Ala Gln Phe Leu Leu Phe
165 170 175

Ile Asn Leu Ser Asp Leu Thr Gly Ser Phe Arg Leu Tyr Lys Thr Asn
180 185 190

Val Leu Lys Glu Leu Met Gln Ser Ile Asn Asn Thr Gly Tyr Val Phe
195 200 205

Gln Met Glu Val Leu Val Arg Ala Tyr Lys Met Gly Lys Ser Ile Glu

210 215 220

Glu Val Gly Tyr Val Phe Val Asp Arg Leu Phe Gly Lys Ser Lys Leu
225 230 235 240

Glu Thr Thr Asp Ile Leu Gln Tyr Leu Ser Gly Leu Phe Lys Leu Phe
245 250 255

Trp Ser Ile

<210> 22
<211> 843
<212> DNA
<213> Saccharomyces cerevisiae
<400> 22

atgacaagat ctccctggaa gcgcctacta tggttgaaac aggagtaccc agataattat 60

acagatccaa gttttattga gttgagagca agacaaaagg ctgagagtaa ccagaagtct 120

gatagaaaat tatcagaagc tgctcgcgct caaattaggt tggattttat aagtttctac 180

caaaccatat tgaacacttc tttcatttac atcactttta catatattta ctattatggc 240

ttcgatccta ttccgccaac tattttcctt tcatttataa cattgattat atcaaggacg 300

aaagtcgacc ctctattgtc ctcattcatg gacgtaaagt cttcgctgat tatcacattt 360

gcaatgttga ctctctctcc agtcctcaaa tctctttcta aaacaactgc atctgattcc 420

atatggacat tgtctttttg gctgacccta tggtacattt tcgttatttc gtcaacaaag 480

tccaaagata aaccctctaa cctttccacc aatatacttg tcgcccttgt tgctgtccta 540

tcatcgaggc tttcgaccac aatcgacgta ttctgttttc ttttaatttg tattcagttg 600

aatatcattc tacccactta tttatcggtg acgaataagg tagtaccaat aatttcaaat 660

attattgtat actcattttt gaatgttgct ctaggttgga tttatatgct gttgattttc 720

tttgcttcag tattttatat tactgtttta cctaagtggt tcatctactg gaaaatcaat 780

tatcataaac gggataacga tctactaagt acatgggatg caagaacacc aatattggat 840

tag 843

<210> 23
<211> 280
<212> PRT
<213> Saccharomyces cerevisiae
<400> 23

Met Thr Arg Ser Pro Trp Lys Arg Leu Leu Trp Leu Lys Gln Glu Tyr
1 5 10 15

Pro Asp Asn Tyr Thr Asp Pro Ser Phe Ile Glu Leu Arg Ala Arg Gln
20 25 30

Lys Ala Glu Ser Asn Gln Lys Ser Asp Arg Lys Leu Ser Glu Ala Ala
35 40 45

Arg Ala Gln Ile Arg Leu Asp Phe Ile Ser Phe Tyr Gln Thr Ile Leu
50 55 60

Asn Thr Ser Phe Ile Tyr Ile Thr Phe Thr Tyr Ile Tyr Tyr Tyr Gly
65 70 75 80

Phe Asp Pro Ile Pro Pro Thr Ile Phe Leu Ser Phe Ile Thr Leu Ile
85 90 95

Ile Ser Arg Thr Lys Val Asp Pro Leu Leu Ser Ser Phe Met Asp Val
100 105 110

Lys Ser Ser Leu Ile Ile Thr Phe Ala Met Leu Thr Leu Ser Pro Val
115 120 125

Leu Lys Ser Leu Ser Lys Thr Thr Ala Ser Asp Ser Ile Trp Thr Leu
130 135 140

Ser Phe Trp Leu Thr Leu Trp Tyr Ile Phe Val Ile Ser Ser Thr Lys
145 150 155 160

Ser Lys Asp Lys Pro Ser Asn Leu Ser Thr Asn Ile Leu Val Ala Leu
165 170 175

Val Ala Val Leu Ser Ser Arg Leu Ser Thr Thr Ile Asp Val Phe Cys
180 185 190

Phe Leu Leu Ile Cys Ile Gln Leu Asn Ile Ile Leu Pro Thr Tyr Leu
195 200 205

Ser Val Thr Asn Lys Val Val Pro Ile Ile Ser Asn Ile Ile Val Tyr
210 215 220

Ser Phe Leu Asn Val Ala Leu Gly Trp Ile Tyr Met Leu Leu Ile Phe
225 230 235 240

Phe Ala Ser Val Phe Tyr Ile Thr Val Leu Pro Lys Trp Phe Ile Tyr
245 250 255

Trp Lys Ile Asn Tyr His Lys Arg Asp Asn Asp Leu Leu Ser Thr Trp

260 265 270

Asp Ala Arg Thr Pro Ile Leu Asp

275 280

<210> 24
<211> 764
<212> DNA
<213> Saccharomyces cerevisiae
<400> 24

atgattagta aagagtatga atttggtaag actagtatac tgaatagaaa gaagtataca 60

ttagttatcg atgaagacaa gaatggcaat tttataagat ttaccgtttt acctgtatct 120

aaccgaaagt tcaaaaaagt caagcaaaat gggagggtag agattaacat gggcatacaa 180

tatcaccaaa ttgtacttat tttactactg aatattttgt tctatgtaat ttgcctaaga 240

tcaagatttc tcgaacatat taatagaact tttgaagtga caatcgcgcg aagtttccag 300

atcttaatta taatgggatt gtttgcctta ggtacaatta tacttgtgag gggacctagt 360

gtggaaactg taacaatttt caaagaaagt ggactacagc tgtccagagt gaagggtatg 420

gttatatttc ctcaacaatg gaatcggaag ttctttgaac aagtagagtt tatatccaat 480

gaaagaatta ttgatgtagt gatcaatgaa ggattctgtc ggggatttcg agtgatattc 540

tatcttgcag caattgtacg taaatcgtct acgcttaagc tattatttcc agtatgtatt 600

caagcgaatt taagattgtt tcttacttca acgatctgat tagaaatact aacacaacaa 660

tgcagtcaaa tttgcccagt atcgatgacc aacgtctaat atacaacata tctagaaaat 720

atctcagtaa gcaagaaaaa cccctgagca gaccaaaaga ttga 764

<210> 25
<211> 229
<212> PRT
<213> Saccharomyces cerevisiae
<400> 25

Met Ile Ser Lys Glu Tyr Glu Phe Gly Lys Thr Ser Ile Leu Asn Arg
1 5 10 15

Lys Lys Tyr Thr Leu Val Ile Asp Glu Asp Lys Asn Gly Asn Phe Ile
20 25 30

Arg Phe Thr Val Leu Pro Val Ser Asn Arg Lys Phe Lys Lys Val Lys

35 40 45

Gln Asn Gly Arg Val Glu Ile Asn Met Gly Ile Gln Tyr His Gln Ile
50 55 60

Val Leu Ile Leu Leu Leu Asn Ile Leu Phe Tyr Val Ile Cys Leu Arg
65 70 75 80

Ser Arg Phe Leu Glu His Ile Asn Arg Thr Phe Glu Val Thr Ile Ala
85 90 95

Arg Ser Phe Gln Ile Leu Ile Ile Met Gly Leu Phe Ala Leu Gly Thr
100 105 110

Ile Ile Leu Val Arg Gly Pro Ser Val Glu Thr Val Thr Ile Phe Lys
115 120 125

Glu Ser Gly Leu Gln Leu Ser Arg Val Lys Gly Met Val Ile Phe Pro
130 135 140

Gln Gln Trp Asn Arg Lys Phe Phe Glu Gln Val Glu Phe Ile Ser Asn
145 150 155 160

Glu Arg Ile Ile Asp Val Val Ile Asn Glu Gly Phe Cys Arg Gly Phe
165 170 175

Arg Val Ile Phe Tyr Leu Ala Ala Ile Val Arg Lys Ser Ser Thr Leu
180 185 190

Lys Leu Leu Phe Pro Ser Asn Leu Pro Ser Ile Asp Asp Gln Arg Leu
195 200 205

Ile Tyr Asn Ile Ser Arg Lys Tyr Leu Ser Lys Gln Glu Lys Pro Leu
210 215 220

Ser Arg Pro Lys Asp
225

<210> 26
<211> 423
<212> DNA
<213> Saccharomyces cerevisiae
<400> 26

atgtatacaa aagagtacta ctggttttca caatatatga taataacaag cactttggtg 60

ctcaccataa tatggtccat cttaccatca tcgctgggtg aggctgcacc aaagcagttt 120

atcaacacgc tattggacat cttcccacaa agaagatgga ttattacctt ggagagcata 180

atgctgatgg gcatgctatg cacatacatc ggccttctga tgtacaatga agatacatta 240

acaccgccgc tagattctct atctacagta acggatgccg gtggtcaact tgtaatagag 300

gacgacccgg acgtattcgt taagaaatgg gcctttaaag aaacaagtgg tatttacgat 360

ctgtctctga tggatgcctg ccaacttctc tacctatatg ataacgacca taccagcaca 420

tag 423

<210> 27
<211> 140
<212> PRT
<213> Saccharomyces cerevisiae
<400> 27

Met Tyr Thr Lys Glu Tyr Tyr Trp Phe Ser Gln Tyr Met Ile Ile Thr
1 5 10 15

Ser Thr Leu Val Leu Thr Ile Ile Trp Ser Ile Leu Pro Ser Ser Leu
20 25 30

Gly Glu Ala Ala Pro Lys Gln Phe Ile Asn Thr Leu Leu Asp Ile Phe
35 40 45

Pro Gln Arg Arg Trp Ile Ile Thr Leu Glu Ser Ile Met Leu Met Gly

50 55 60

Met Leu Cys Thr Tyr Ile Gly Leu Leu Met Tyr Asn Glu Asp Thr Leu
65 70 75 80

Thr Pro Pro Leu Asp Ser Leu Ser Thr Val Thr Asp Ala Gly Gly Gln
85 90 95

Leu Val Ile Glu Asp Asp Pro Asp Val Phe Val Lys Lys Trp Ala Phe
100 105 110

Lys Glu Thr Ser Gly Ile Tyr Asp Leu Ser Leu Met Asp Ala Cys Gln
115 120 125

Leu Leu Tyr Leu Tyr Asp Asn Asp His Thr Ser Thr
130 135 140

<210> 28
<211> 915
<212> DNA
<213> Saccharomyces cerevisiae
<400> 28

atgaagatgt tgaggcgtac aaaggtaaat ttttcaaaat tgctttacaa gattactaaa 60

ctagcaatag tactgacgat cctatatatt tattttacgc ccaaaatcgt ctcccgaaac 120

aatgcatcat tgcagcatat ttttcctcat aaatatggcg attatgaaat caatttggtc 180

atagcgcacc ctgacgacga agttatgttt ttttcccccа taatttctca actgaattcg 240

tactttccga gaaccgtccc atttaacata atctgcttat caaagggcaa cgccgaaggt 300

cttggcgaaa ccagggtaag agaattaaat gagtcggccg ctttattgct acacaatgaa 360

agagcagtct ccgtacaggt gatggatttc caggatggta tggacgaaat atgggatatt 420

gattctataa cttcttctct ttcacaaaag atagatataa agaatcataa cttgaaccag 480

attatcgtta cctttgattc atatggtgta tcaaatcata tcaaccacaa aagctgttat 540

gctgccgtta aaaagttggt ggatgattat gctcaaccta agaccaaaag aaatgaacaa 600

ccacctcatg tcactgcgct ttatttgaga agctacaaga acaacatcgt tttaaagtac 660

aactccttta tttgggaaat cctaaaaata ctttacgacc tgatttctcc attccgtaga 720

ataattcagg cgcttccgcc taacacagcc gccgaaaaag acaagctttc acttatgaat 780

acacatgcac aatacgtact agcgtttgcc actatgctaa atgctcacga atcccaagtt 840

gtgtggttta gatacggatg gtggatattt tccagatttg tcttcgttaa tgaatttgat 900

gtttatacat attag 915

<210> 29
<211> 304
<212> PRT
<213> Saccharomyces cerevisiae
<400> 29

Met Lys Met Leu Arg Arg Thr Lys Val Asn Phe Ser Lys Leu Leu Tyr
1 5 10 15

Lys Ile Thr Lys Leu Ala Ile Val Leu Thr Ile Leu Tyr Ile Tyr Phe
20 25 30

Thr Pro Lys Ile Val Ser Arg Asn Asn Ala Ser Leu Gln His Ile Phe
35 40 45

Pro His Lys Tyr Gly Asp Tyr Glu Ile Asn Leu Val Ile Ala His Pro
50 55 60

Asp Asp Glu Val Met Phe Phe Ser Pro Ile Ile Ser Gln Leu Asn Ser
65 70 75 80

Tyr Phe Pro Arg Thr Val Pro Phe Asn Ile Ile Cys Leu Ser Lys Gly
85 90 95

Asn Ala Glu Gly Leu Gly Glu Thr Arg Val Arg Glu Leu Asn Glu Ser
100 105 110

Ala Ala Leu Leu Leu His Asn Glu Arg Ala Val Ser Val Gln Val Met
115 120 125

Asp Phe Gln Asp Gly Met Asp Glu Ile Trp Asp Ile Asp Ser Ile Thr
130 135 140

Ser Ser Leu Ser Gln Lys Ile Asp Ile Lys Asn His Asn Leu Asn Gln
145 150 155 160

Ile Ile Val Thr Phe Asp Ser Tyr Gly Val Ser Asn His Ile Asn His
165 170 175

Lys Ser Cys Tyr Ala Ala Val Lys Lys Leu Val Asp Asp Tyr Ala Gln
180 185 190

Pro Lys Thr Lys Arg Asn Glu Gln Pro Pro His Val Thr Ala Leu Tyr
195 200 205

Leu Arg Ser Tyr Lys Asn Asn Ile Val Leu Lys Tyr Asn Ser Phe Ile
210 215 220

Trp Glu Ile Leu Lys Ile Leu Tyr Asp Leu Ile Ser Pro Phe Arg Arg
225 230 235 240

Ile Ile Gln Ala Leu Pro Pro Asn Thr Ala Ala Glu Lys Asp Lys Leu
245 250 255

Ser Leu Met Asn Thr His Ala Gln Tyr Val Leu Ala Phe Ala Thr Met
260 265 270

Leu Asn Ala His Glu Ser Gln Val Val Trp Phe Arg Tyr Gly Trp Trp
275 280 285

Ile Phe Ser Arg Phe Val Phe Val Asn Glu Phe Asp Val Tyr Thr Tyr
290 295 300

<210> 30
<211> 2760
<212> DNA
<213> Saccharomyces cerevisiae
<400> 30

atgtggaaca aaaccagaac gacgcttctg gctgttggtg tcttatttca tttattttac 60

ctatggtcta tttttgatat ctatttcatt tcaccgctcg ttcatggtat gagcccatat 120

caaagtactc caacccctcc tgcaaagaga ttgtttttga ttgtcggtga tggtttacgt 180

gcagatacca cttttgataa agtcactcat ccagtatccg gaaaaacaga atttctggca 240

ccttttatta gatctttggt aatgaataat gccacctacg gtatatcaca taccagaatg 300

ccaactgaat cccgtcctgg tcatgttgct atgattgctg ggttttacga agatgttagt 360

gccgtcacaa aaggttggaa gtcaaaccct gtcaatttcg atagtttttt caaccaatct 420

actcatactt attcattcgg ttcacctgac attttaccta tgttcaaaga tggcgcttct 480

gacccaaata aagttgacac ttggatgtat gatcatactt tcgaggattt tacgcaatct 540

tccatcgagc tggatgcttt tgtctttaga cacttggatc aattattcca caattccaca 600

ctgaactcaa cattggatta tgaaattagg caagacggta atgtattctt tctacatcta 660

ctaggttgcg atactgccgg acattcttat agaccatatt ctgccgagta ttatgacaat 720

gtcaaatata ttgatgatca aatccctatc cttatagaca aagtcaacaa gtttttgcg 780

gacgacaaaa ccgcatttat ttttacagca gatcatggta tgagtgcatt tggatcacat 840

ggtgacggtc atcctaacaa cacaaggacc cctcttgttg cttggggtgc gggtttgaat 900

aaaccagtac ataatccttt tccggtatcc gacaactata ctgaaaattg ggagctttcg 960

agcattaaaa gaaatgatgt caagcaagca gatattgctt ctttaatgtc atacttgatt 1020

ggtgtgaact atcctaaaaa ttcagttggt gagttaccaa tagcatatat cgatggaaaa 1080

gaaagtgaca agcttgccgc attgtacaac aacgcaagaa gcattttaga gcagtactta 1140

gtcaagcaag atgaggtaat agactctcaa ttttttttata aggaatactt caagtttgtt 1200

gaaaagtctc attcacatta cttagaagag atagaaacct taattcagcg tatatctgaa 1260

ggagaaaact atttggaaca agaagcaatc acccttacag aggaattaat gcagataaca 1320

ttggaaggtt tacattattt gacaacctat aattggagat tcattagaac tattgttaca 1380

tttgggtttg ttgggtggat ctttttttct tttataatat ttttgaaatc attcatatta 1440

gagaatgtaa ttgatgacca aaaagcgtca ccattaagcc atgcagtatt tggttccata 1500

ggaattttac taaattggat tttgttctac caacattctc cgttcaattt ttacatgtac 1560

cttcttttcc cattatactt ttggagctat atttttacaa atagatccgt actacgttca 1620

ggtatcaagg aattcttcaa aggtacctct ccttggaaaa gagttttaat aacaatctct 1680

attatatcag tttatgaggg aattgtatat ggatttttcc atagatggac gtttacgcta 1740

attacaaata tattggcgtt ttacccgttt atttgtgggg tgagagagct atccgtgaat 1800

atattgtgga tcataactag tgttctttta tctacattta ccttatttga cgctgttaaa 1860

attgaggact tgaaccagat acatctagca gggttattaa tcattctcag tgccttttat 1920

gctctttaca aaatacattc caggataaat tcctacacgc gtgctatatt tgccattcaa 1980

atttccttgg tggctgccat gttggcggtt actcatcgtt cagttatctc tttacagcta 2040

agacaagggt taccaagaga gtcacaggtc gctggatgga taatttttt tgtatctctt 2100

tttgtaatgc caattttaca ttataggaag cccaacaatg attacaaagt gagattattg 2160

atcatttatt taaccttcgc accatccttt atcattttga ctatatcatt cgaatccctt 2220

ttctacttct tgttcactag ttacatggta caatggattg aaattgagaa caaaatcaaa 2280

gaaatgaaga cccaaaaaga tgaaaattgg ttacaagtgc taagagtttc agtaatcggg 2340

ttctttttac ttcaagtcgc attctttgga actggtaacg tcgcttcaat ctcttcattt 2400

tcattggagt ctgtttgtag attgttgcca atttttgatc ctttcctgat gggcgcatta 2460

ttgatgttga aattgataat tccctacggg ctattgtcca catgcctagg tatactgaat 2520

ttaaaactta acttcaagga ctacacaatc tcatcattaa ttatttccat gagtgatatt 2580

ctgtcgttga atttttttcta ccttttaaga acggaggggt cgtggttgga tattggcata 2640

accatttcca actattgttt ggcgatccta tcatctttgt tcatgcttat tttggaagta 2700

ctcggtcatg tgttgctaaa aaatgtcatc atacaggata aaaccaaaaa aacacaatag 2760

<210> 31
<211> 919
<212> PRT
<213> Saccharomyces cerevisiae
<400> 31

Met Trp Asn Lys Thr Arg Thr Thr Leu Leu Ala Val Gly Val Leu Phe
1 5 10 15

His Leu Phe Tyr Leu Trp Ser Ile Phe Asp Ile Tyr Phe Ile Ser Pro
20 25 30

Leu Val His Gly Met Ser Pro Tyr Gln Ser Thr Pro Thr Pro Pro Ala
35 40 45

Lys Arg Leu Phe Leu Ile Val Gly Asp Gly Leu Arg Ala Asp Thr Thr
50 55 60

Phe Asp Lys Val Thr His Pro Val Ser Gly Lys Thr Glu Phe Leu Ala
65 70 75 80

Pro Phe Ile Arg Ser Leu Val Met Asn Asn Ala Thr Tyr Gly Ile Ser
85 90 95

His Thr Arg Met Pro Thr Glu Ser Arg Pro Gly His Val Ala Met Ile
100 105 110

Ala Gly Phe Tyr Glu Asp Val Ser Ala Val Thr Lys Gly Trp Lys Ser
115 120 125

Asn Pro Val Asn Phe Asp Ser Phe Phe Asn Gln Ser Thr His Thr Tyr
130 135 140

Ser Phe Gly Ser Pro Asp Ile Leu Pro Met Phe Lys Asp Gly Ala Ser
145 150 155 160

Asp Pro Asn Lys Val Asp Thr Trp Met Tyr Asp His Thr Phe Glu Asp
165 170 175

Phe Thr Gln Ser Ser Ile Glu Leu Asp Ala Phe Val Phe Arg His Leu

180 185 190

Asp Gln Leu Phe His Asn Ser Thr Leu Asn Ser Thr Leu Asp Tyr Glu
195 200 205

Ile Arg Gln Asp Gly Asn Val Phe Phe Leu His Leu Leu Gly Cys Asp
210 215 220

Thr Ala Gly His Ser Tyr Arg Pro Tyr Ser Ala Glu Tyr Tyr Asp Asn
225 230 235 240

Val Lys Tyr Ile Asp Asp Gln Ile Pro Ile Leu Ile Asp Lys Val Asn
245 250 255

Lys Phe Phe Ala Asp Asp Lys Thr Ala Phe Ile Phe Thr Ala Asp His
260 265 270

Gly Met Ser Ala Phe Gly Ser His Gly Asp Gly His Pro Asn Asn Thr
275 280 285

Arg Thr Pro Leu Val Ala Trp Gly Ala Gly Leu Asn Lys Pro Val His
290 295 300

Asn Pro Phe Pro Val Ser Asp Asn Tyr Thr Glu Asn Trp Glu Leu Ser
305 310 315 320

Ser Ile Lys Arg Asn Asp Val Lys Gln Ala Asp Ile Ala Ser Leu Met
325 330 335

Ser Tyr Leu Ile Gly Val Asn Tyr Pro Lys Asn Ser Val Gly Glu Leu
340 345 350

Pro Ile Ala Tyr Ile Asp Gly Lys Glu Ser Asp Lys Leu Ala Ala Leu
355 360 365

Tyr Asn Asn Ala Arg Ser Ile Leu Glu Gln Tyr Leu Val Lys Gln Asp
370 375 380

Glu Val Ile Asp Ser Gln Phe Phe Tyr Lys Glu Tyr Phe Lys Phe Val
385 390 395 400

Glu Lys Ser His Ser His Tyr Leu Glu Glu Ile Glu Thr Leu Ile Gln
405 410 415

Arg Ile Ser Glu Gly Glu Asn Tyr Leu Glu Gln Glu Ala Ile Thr Leu
420 425 430

Thr Glu Glu Leu Met Gln Ile Thr Leu Glu Gly Leu His Tyr Leu Thr
435 440 445

Thr Tyr Asn Trp Arg Phe Ile Arg Thr Ile Val Thr Phe Gly Phe Val
450 455 460

Gly Trp Ile Phe Phe Ser Phe Ile Ile Phe Leu Lys Ser Phe Ile Leu
465 470 475 480

Glu Asn Val Ile Asp Asp Gln Lys Ala Ser Pro Leu Ser His Ala Val
485 490 495

Phe Gly Ser Ile Gly Ile Leu Leu Asn Trp Ile Leu Phe Tyr Gln His
500 505 510

Ser Pro Phe Asn Phe Tyr Met Tyr Leu Leu Phe Pro Leu Tyr Phe Trp
515 520 525

Ser Tyr Ile Phe Thr Asn Arg Ser Val Leu Arg Ser Gly Ile Lys Glu
530 535 540

Phe Phe Lys Gly Thr Ser Pro Trp Lys Arg Val Leu Ile Thr Ile Ser
545 550 555 560

Ile Ile Ser Val Tyr Glu Gly Ile Val Tyr Gly Phe Phe His Arg Trp
565 570 575

Thr Phe Thr Leu Ile Thr Asn Ile Leu Ala Phe Tyr Pro Phe Ile Cys
580 585 590

Gly Val Arg Glu Leu Ser Val Asn Ile Leu Trp Ile Ile Thr Ser Val

595 600 605

Leu Leu Ser Thr Phe Thr Leu Phe Asp Ala Val Lys Ile Glu Asp Leu
610 615 620

Asn Gln Ile His Leu Ala Gly Leu Leu Ile Ile Leu Ser Ala Phe Tyr
625 630 635 640

Ala Leu Tyr Lys Ile His Ser Arg Ile Asn Ser Tyr Thr Arg Ala Ile
645 650 655

Phe Ala Ile Gln Ile Ser Leu Val Ala Ala Met Leu Ala Val Thr His
660 665 670

Arg Ser Val Ile Ser Leu Gln Leu Arg Gln Gly Leu Pro Arg Glu Ser
675 680 685

Gln Val Ala Gly Trp Ile Ile Phe Phe Val Ser Leu Phe Val Met Pro
690 695 700

Ile Leu His Tyr Arg Lys Pro Asn Asn Asp Tyr Lys Val Arg Leu Leu
705 710 715 720

Ile Ile Tyr Leu Thr Phe Ala Pro Ser Phe Ile Ile Leu Thr Ile Ser
725 730 735

Phe Glu Ser Leu Phe Tyr Phe Leu Phe Thr Ser Tyr Met Val Gln Trp
740 745 750

Ile Glu Ile Glu Asn Lys Ile Lys Glu Met Lys Thr Gln Lys Asp Glu
755 760 765

Asn Trp Leu Gln Val Leu Arg Val Ser Val Ile Gly Phe Phe Leu Leu
770 775 780

Gln Val Ala Phe Phe Gly Thr Gly Asn Val Ala Ser Ile Ser Ser Phe
785 790 795 800

Ser Leu Glu Ser Val Cys Arg Leu Leu Pro Ile Phe Asp Pro Phe Leu
805 810 815

Met Gly Ala Leu Leu Met Leu Lys Leu Ile Ile Pro Tyr Gly Leu Leu
820 825 830

Ser Thr Cys Leu Gly Ile Leu Asn Leu Lys Leu Asn Phe Lys Asp Tyr
835 840 845

Thr Ile Ser Ser Leu Ile Ile Ser Met Ser Asp Ile Leu Ser Leu Asn
850 855 860

Phe Phe Tyr Leu Leu Arg Thr Glu Gly Ser Trp Leu Asp Ile Gly Ile
865 870 875 880

Thr Ile Ser Asn Tyr Cys Leu Ala Ile Leu Ser Ser Leu Phe Met Leu
885 890 895

Ile Leu Glu Val Leu Gly His Val Leu Leu Lys Asn Val Ile Ile Gln
900 905 910

Asp Lys Thr Lys Lys Thr Gln
915

<210> 32
<211> 660
<212> DNA
<213> Saccharomyces cerevisiae
<400> 32

atgccagcta aaaaaaggac tagaaagaca gtgaaaaaaa ccgtatcatt ctccgatgac 60

acaacattaa caacgcacca aaatcgtgag aaaaagaacg tagatcatga tcgtccacct 120

gtgtatgtga ggaaaacccc tctgatgaca tttccatacc atttagtagc actactttat 180

tactacgttt ttgtatcttc aaatttcaat acggtgaagt tgctaagttt tttgattcct 240

acacaagttg cttatttagt tttacaattc aataaatgca cagtttacgg taacaaaatc 300

attaagatca attactcatt gaccattatt tgtctaggtg ttacattttt gttgagcttt 360

cccacaatgt tattaactat attatttggt gcgccattaa tggacttatt gtgggaaacc 420

tggctgttgt cactgcattt tgcattttta gcataccctg cagtttattc tgtatttaat 480

tgtgatttca aagtgggatt atggaagaag tattttatct ttatcgttgt agggggttgg 540

attagttgtg ttgtcattcc tttggattgg gatagagatt ggcagaattg gccaattcct 600

attgttgttg gaggttattt gggcgctttg gtgggctata ctatcggtgc ctatatataa 660

<210> 33
<211> 219
<212> PRT
<213> Saccharomyces cerevisiae
<400> 33

Met Pro Ala Lys Lys Arg Thr Arg Lys Thr Val Lys Lys Thr Val Ser
1 5 10 15

Phe Ser Asp Asp Thr Thr Leu Thr Thr His Gln Asn Arg Glu Lys Lys
20 25 30

Asn Val Asp His Asp Arg Pro Pro Val Tyr Val Arg Lys Thr Pro Leu
35 40 45

Met Thr Phe Pro Tyr His Leu Val Ala Leu Leu Tyr Tyr Tyr Val Phe
50 55 60

Val Ser Ser Asn Phe Asn Thr Val Lys Leu Leu Ser Phe Leu Ile Pro
65 70 75 80

Thr Gln Val Ala Tyr Leu Val Leu Gln Phe Asn Lys Cys Thr Val Tyr
85 90 95

Gly Asn Lys Ile Ile Lys Ile Asn Tyr Ser Leu Thr Ile Ile Cys Leu
100 105 110

Gly Val Thr Phe Leu Leu Ser Phe Pro Thr Met Leu Leu Thr Ile Leu
115 120 125

Phe Gly Ala Pro Leu Met Asp Leu Leu Trp Glu Thr Trp Leu Leu Ser
130 135 140

Leu His Phe Ala Phe Leu Ala Tyr Pro Ala Val Tyr Ser Val Phe Asn
145 150 155 160

Cys Asp Phe Lys Val Gly Leu Trp Lys Lys Tyr Phe Ile Phe Ile Val
165 170 175

Val Gly Gly Trp Ile Ser Cys Val Val Ile Pro Leu Asp Trp Asp Arg
180 185 190

Asp Trp Gln Asn Trp Pro Ile Pro Ile Val Val Gly Gly Tyr Leu Gly
195 200 205

Ala Leu Val Gly Tyr Thr Ile Gly Ala Tyr Ile
210 215

<210> 34
<211> 2493
<212> DNA
<213> Saccharomyces cerevisiae
<400> 34

atgaacttga agcagttcac gtgcctatca tgcgctcaat tactcgctat tctgctcttt 60

atctttgctt ttttcccctag aaaaatcgtg ctgacaggta tatcaaagca agatccggat 120

caagaccgtg atctccagcg cgataggccc ttccagaaat tggtgtttgt gatcattgat 180

gctctcagat cagactttct ttttgattcg cagatttccc acttcaacaa cgtgcaccaa 240

tggctcaata cgggcgaagc atggggttac acgtcatttg ctaatccgcc taccgtgacg 300

ctgcctagac tcaaaagtat tactacggga tctacaccta gcttcattga cttgctgctg 360

aatgtagccc aggacataga ttccaacgat ctttcggagc acgattcctg gctgcagcag 420

ttcatccaac ataataacac gattcgtttc atgggcgatg acacctggct gaaactgttc 480

ccacagcaat ggtttgactt cgctgacccg acacactcgt tctttgtcag tgatttcact 540

caagtcgata ataatgtgac gaggaacttg cccgggaaat tatttcagga atgggcccag 600

tgggacgtgg ctatcctgca ttacttgggt cttgaccata tcgggcataa agatggcccg 660

cattcaaagt ttatggctgc taaacatcaa gaaatggaca gcattctgaa gtcaatatat 720

gatgaagtgt tggaacatga agatgacgat gatacactga tttgtgttct tggcgaccat 780

ggaatgaacg aactgggcaa ccatggtggc tcttcagccg gcgaaacatc agcaggattg 840

ttgtttttgt cacctaagct ggcgcaattt gctaggccag aatcgcaagt aaactacaca 900

ttgcccatca acgctagtcc ggactggaat ttccagtatt tagagactgt tcaacaaatt 960

gatatcgtcc ccaccatagc agcactgttt ggtatgccaa tccccatgaa cagtgttggg 1020

ataataatac ctgacttttt acaactgttg cccaataagt tggcaagtat gaaagaaaat 1080

tttatgcatt tgtggaaatt atcagaccat cacggcgagg ttgctcttga cgatttcact 1140

gccgaagata tttatacaaa gatgtacact attcaagaaa cgttaaccaa gtctgcaaca 1200

aattataatt atcctctttt gacactggct tttgttggtt tcctcataat aacaatcatc 1260

gccatttatg tattattacg ttattctggg cctgattttt ggcagttgcg cgtttcttcc 1320

ctgtctgttc tgttagtttc cattatacta ggcgtttcca catttgcaag tagtttcatt 1380

gaagaggagc accaactgtg gtggtggata gtaactgcat tctcggcggt ccctctgttc 1440

gtataccgat tgaatgtgct cataatcgtg cgctggttta taatgatggc atgcgtacgc 1500

tcaatcaagt tttggaataa cagtggccag aaattcattt attctaacgt tatgtccaat 1560

ctacttaatc agaatccttc ctggaagtgg tgcttaaata tgttgacatt tctagtgctg 1620

ataatggcat ctgctggttt tcaagtacta cattttattg tcactactat tttggtgggg 1680

ttgtgtttca cgtacaaaat ctcgtgggaa atcgtcaatg gtaaccaggc agaaataccg 1740

ctctttatgc atgatttact ggctaagata gactttgcac caactgaaag taacttgatt 1800

gtacttgcgc gcgttttctt ccaagcttgg gctattgttg tcatttcaag gttggtcctg 1860

acgaaattga aagtacttaa caagaactac ctcattaaag atatgaaagt ttatataaca 1920

attcttttga tgttccaaac ttcttctcag aacataggtc aatttctcgt tttccaaata 1980

ttagagtccc aaatttttta ctttttccaa aatattccaa ccgcctcatt aacatcaaca 2040

agtaagattt atttttcgaa tttggtgtcc ttaattttac aaaattttac atttttccaa 2100

ttcggtggca caaattccat ttctactata gaccttggaa acgcatacca tggtgtttcc 2160

tcagactaca acatctacgt agtggggata ttaatgtccg ttgccaattt cgcgccggca 2220

atatactggt ccatgctacc gtggtcaata aactacgcct ctattccagc acaagttaag 2280

ttgcaaacgt tcatcagaag taagttacct gccttcacct atcattgtat atttggaact 2340

tgtttgatga cggcatgcgt cgttttgaga tttcatctct ttatttggtc cgttttcagt 2400

ccaaaattat gttattttct tgggtggaat tttgtgatgg gattgctgaa tggctggtta 2460

cctgaattgg ccctcctttg cgctcttgat taa 2493

<210> 35
<211> 830
<212> PRT
<213> Saccharomyces cerevisiae
<400> 35

```
Met Asn Leu Lys Gln Phe Thr Cys Leu Ser Cys Ala Gln Leu Leu Ala
1               5                  10                  15

Ile Leu Leu Phe Ile Phe Ala Phe Phe Pro Arg Lys Ile Val Leu Thr
            20                  25                  30

Gly Ile Ser Lys Gln Asp Pro Asp Gln Asp Arg Asp Leu Gln Arg Asp
        35                  40                  45

Arg Pro Phe Gln Lys Leu Val Phe Val Ile Ile Asp Ala Leu Arg Ser
    50                  55                  60

Asp Phe Leu Phe Asp Ser Gln Ile Ser His Phe Asn Asn Val His Gln
65                  70                  75                  80

Trp Leu Asn Thr Gly Glu Ala Trp Gly Tyr Thr Ser Phe Ala Asn Pro
                85                  90                  95

Pro Thr Val Thr Leu Pro Arg Leu Lys Ser Ile Thr Thr Gly Ser Thr
            100                 105                 110

Pro Ser Phe Ile Asp Leu Leu Leu Asn Val Ala Gln Asp Ile Asp Ser
```

115 120 125

Asn Asp Leu Ser Glu His Asp Ser Trp Leu Gln Gln Phe Ile Gln His
130 135 140

Asn Asn Thr Ile Arg Phe Met Gly Asp Asp Thr Trp Leu Lys Leu Phe
145 150 155 160

Pro Gln Gln Trp Phe Asp Phe Ala Asp Pro Thr His Ser Phe Phe Val
165 170 175

Ser Asp Phe Thr Gln Val Asp Asn Asn Val Thr Arg Asn Leu Pro Gly
180 185 190

Lys Leu Phe Gln Glu Trp Ala Gln Trp Asp Val Ala Ile Leu His Tyr
195 200 205

Leu Gly Leu Asp His Ile Gly His Lys Asp Gly Pro His Ser Lys Phe
210 215 220

Met Ala Ala Lys His Gln Glu Met Asp Ser Ile Leu Lys Ser Ile Tyr
225 230 235 240

Asp Glu Val Leu Glu His Glu Asp Asp Asp Asp Thr Leu Ile Cys Val
245 250 255

Leu Gly Asp His Gly Met Asn Glu Leu Gly Asn His Gly Gly Ser Ser
260 265 270

Ala Gly Glu Thr Ser Ala Gly Leu Leu Phe Leu Ser Pro Lys Leu Ala
275 280 285

Gln Phe Ala Arg Pro Glu Ser Gln Val Asn Tyr Thr Leu Pro Ile Asn
290 295 300

Ala Ser Pro Asp Trp Asn Phe Gln Tyr Leu Glu Thr Val Gln Gln Ile
305 310 315 320

Asp Ile Val Pro Thr Ile Ala Ala Leu Phe Gly Met Pro Ile Pro Met
325 330 335

Asn Ser Val Gly Ile Ile Ile Pro Asp Phe Leu Gln Leu Leu Pro Asn
340 345 350

Lys Leu Ala Ser Met Lys Glu Asn Phe Met His Leu Trp Lys Leu Ser
355 360 365

Asp His His Gly Glu Val Ala Leu Asp Asp Phe Thr Ala Glu Asp Ile
370 375 380

Tyr Thr Lys Met Tyr Thr Ile Gln Glu Thr Leu Thr Lys Ser Ala Thr
385 390 395 400

Asn Tyr Asn Tyr Pro Leu Leu Thr Leu Ala Phe Val Gly Phe Leu Ile
405 410 415

Ile Thr Ile Ile Ala Ile Tyr Val Leu Leu Arg Tyr Ser Gly Pro Asp
420 425 430

Phe Trp Gln Leu Arg Val Ser Ser Leu Ser Val Leu Leu Val Ser Ile
435 440 445

Ile Leu Gly Val Ser Thr Phe Ala Ser Ser Phe Ile Glu Glu Glu His
450 455 460

Gln Leu Trp Trp Trp Ile Val Thr Ala Phe Ser Ala Val Pro Leu Phe
465 470 475 480

Val Tyr Arg Leu Asn Val Leu Ile Ile Val Arg Trp Phe Ile Met Met
485 490 495

Ala Cys Val Arg Ser Ile Lys Phe Trp Asn Asn Ser Gly Gln Lys Phe
500 505 510

Ile Tyr Ser Asn Val Met Ser Asn Leu Leu Asn Gln Asn Pro Ser Trp
515 520 525

Lys Trp Cys Leu Asn Met Leu Thr Phe Leu Val Leu Ile Met Ala Ser

530 535 540

Ala Gly Phe Gln Val Leu His Phe Ile Val Thr Thr Ile Leu Val Gly
545 550 555 560

Leu Cys Phe Thr Tyr Lys Ile Ser Trp Glu Ile Val Asn Gly Asn Gln
565 570 575

Ala Glu Ile Pro Leu Phe Met His Asp Leu Leu Ala Lys Ile Asp Phe
580 585 590

Ala Pro Thr Glu Ser Asn Leu Ile Val Leu Ala Arg Val Phe Phe Gln
595 600 605

Ala Trp Ala Ile Val Val Ile Ser Arg Leu Val Leu Thr Lys Leu Lys
610 615 620

Val Leu Asn Lys Asn Tyr Leu Ile Lys Asp Met Lys Val Tyr Ile Thr
625 630 635 640

Ile Leu Leu Met Phe Gln Thr Ser Ser Gln Asn Ile Gly Gln Phe Leu
645 650 655

Val Phe Gln Ile Leu Glu Ser Gln Ile Phe Tyr Phe Phe Gln Asn Ile
660 665 670

Pro Thr Ala Ser Leu Thr Ser Thr Ser Lys Ile Tyr Phe Ser Asn Leu
675 680 685

Val Ser Leu Ile Leu Gln Asn Phe Thr Phe Phe Gln Phe Gly Gly Thr
690 695 700

Asn Ser Ile Ser Thr Ile Asp Leu Gly Asn Ala Tyr His Gly Val Ser
705 710 715 720

Ser Asp Tyr Asn Ile Tyr Val Val Gly Ile Leu Met Ser Val Ala Asn
725 730 735

Phe Ala Pro Ala Ile Tyr Trp Ser Met Leu Pro Trp Ser Ile Asn Tyr
740 745 750

Ala Ser Ile Pro Ala Gln Val Lys Leu Gln Thr Phe Ile Arg Ser Lys
755 760 765

Leu Pro Ala Phe Thr Tyr His Cys Ile Phe Gly Thr Cys Leu Met Thr
770 775 780

Ala Cys Val Val Leu Arg Phe His Leu Phe Ile Trp Ser Val Phe Ser
785 790 795 800

Pro Lys Leu Cys Tyr Phe Leu Gly Trp Asn Phe Val Met Gly Leu Leu
805 810 815

Asn Gly Trp Leu Pro Glu Leu Ala Leu Leu Cys Ala Leu Asp

820 825 830

<210> 36
<211> 1605
<212> DNA
<213> Saccharomyces cerevisiae
<400> 36

atgtccaatg caaatctaag aaaatgggtt ggtttttgct ttgttgccat ttatctcttt 60

ttaggtgttc cactgtggta caagctaact acagtttata gagcatcact accaataaat 120

tacattgagt cacttcaaaa taacaaattc caagatattc atctcgtaat accggtgtat 180

gttaagtcag atacttacag atttcctgac gttcatgacg ctatccaagt acaagttaac 240

catttattga attctcagga gcaacgggtc ccttggtctt tacaagttct tccatataat 300

gagactattg agcagatgga aagtgaaggc aaccagtttc atgtcgttac tttgaagtta 360

gacgaattta ttggttactc atcagcttac gacaccaaag aaacactagt atattacgac 420

gatgctgccg ttttaagtaa tgatctaccg ttttttgttg ctcaaacatt ggtagagcac 480

actttccaat tggaatggac gcatttgaat aaaacgtgtg aaggcgtttc tacaaacaac 540

gatgtcgcaa tatcttatga tccaaacatt catttaagtg taactttatt gtcaggtgat 600

gggaatcctg ttgcatggga aattgagcct acattaactg actactttc acctttagg 660

aagttcttat caccactggt aaattttaca gtagattcat ccattgttta tcataatgat 720

ttgaatttgc attcattaaa tggatcatgt acaagcgtta cgtggtttga tctctctcat 780

actattgatc tttctgaact ttcttcaatg gcctattacc cagaagattc tgcactgaat 840

ttagccatag tctttcctag tgcttcttca agtcccgatg gtctggcgtt cattaatggc 900

actcggattt cagacgaaat aaccacatta gattggaata gttatctagt tcctcaatgg 960

ggggttataa taataaataa aatgccgttg aagccaaatt cagtcattag cgaagattat 1020

ttagaaccta tgatgtaccg ttttgcgaca gatatttttc aactattggg attaacggag 1080

ggctcgcaag atttgttatc accttatatt accatagatt cattcaaaag gttgacaatt 1140

ttacagaatc tagataaagc tacggaaaca ttatggtcgt tagtgaaatt aactcaacaa 1200

tttcagggca tgtctatccc acgcgaagta tcggataatg ttatcgaagc tttagactta 1260

aggctacaga ttattgattt attaaatgat cctggaaagg gtggagatat cgtctggaac 1320

aatgccctgc atctaagtaa tgaattggtt aaactatgcg aaaaggcatt tttcaatgga 1380

gaaatggttc aacaaaattt cttcccacaa gagcacatga tagctgtgta tttaccttta 1440

ttaggcccaa tatcggcagt catgttcttt ggtttctaca acgtgatgaa ggaaaagaat 1500

caaaagagta aaaagaatgg aaccgagaga gaagttgcta aagaaaaatt agagttgaaa 1560

gaggctcaaa aattacatgc tattgatggt gaagatgaat tatga 1605

<210> 37
<211> 534
<212> PRT
<213> Saccharomyces cerevisiae
<400> 37

Met Ser Asn Ala Asn Leu Arg Lys Trp Val Gly Phe Cys Phe Val Ala
1 5 10 15

Ile Tyr Leu Phe Leu Gly Val Pro Leu Trp Tyr Lys Leu Thr Thr Val
20 25 30

Tyr Arg Ala Ser Leu Pro Ile Asn Tyr Ile Glu Ser Leu Gln Asn Asn
35 40 45

Lys Phe Gln Asp Ile His Leu Val Ile Pro Val Tyr Val Lys Ser Asp
50 55 60

Thr Tyr Arg Phe Pro Asp Val His Asp Ala Ile Gln Val Gln Val Asn
65 70 75 80

His Leu Leu Asn Ser Gln Glu Gln Arg Val Pro Trp Ser Leu Gln Val
85 90 95

Leu Pro Tyr Asn Glu Thr Ile Glu Gln Met Glu Ser Glu Gly Asn Gln
100 105 110

Phe His Val Val Thr Leu Lys Leu Asp Glu Phe Ile Gly Tyr Ser Ser
115 120 125

Ala Tyr Asp Thr Lys Glu Thr Leu Val Tyr Tyr Asp Asp Ala Ala Val
130 135 140

Leu Ser Asn Asp Leu Pro Phe Phe Val Ala Gln Thr Leu Val Glu His
145 150 155 160

Thr Phe Gln Leu Glu Trp Thr His Leu Asn Lys Thr Cys Glu Gly Val
165 170 175

Ser Thr Asn Asn Asp Val Ala Ile Ser Tyr Asp Pro Asn Ile His Leu
180 185 190

Ser Val Thr Leu Leu Ser Gly Asp Gly Asn Pro Val Ala Trp Glu Ile
195 200 205

Glu Pro Thr Leu Thr Asp Tyr Phe Ser Pro Phe Arg Lys Phe Leu Ser
210 215 220

Pro Leu Val Asn Phe Thr Val Asp Ser Ser Ile Val Tyr His Asn Asp
225 230 235 240

Leu Asn Leu His Ser Leu Asn Gly Ser Cys Thr Ser Val Thr Trp Phe
245 250 255

Asp Leu Ser His Thr Ile Asp Leu Ser Glu Leu Ser Ser Met Ala Tyr
260 265 270

Tyr Pro Glu Asp Ser Ala Leu Asn Leu Ala Ile Val Phe Pro Ser Ala
275 280 285

Ser Ser Ser Pro Asp Gly Leu Ala Phe Ile Asn Gly Thr Arg Ile Ser
290 295 300

Asp Glu Ile Thr Thr Leu Asp Trp Asn Ser Tyr Leu Val Pro Gln Trp

305 310 315 320

Gly Val Ile Ile Ile Asn Lys Met Pro Leu Lys Pro Asn Ser Val Ile
325 330 335

Ser Glu Asp Tyr Leu Glu Pro Met Met Tyr Arg Phe Ala Thr Asp Ile
340 345 350

Phe Gln Leu Leu Gly Leu Thr Glu Gly Ser Gln Asp Leu Leu Ser Pro
355 360 365

Tyr Ile Thr Ile Asp Ser Phe Lys Arg Leu Thr Ile Leu Gln Asn Leu
370 375 380

Asp Lys Ala Thr Glu Thr Leu Trp Ser Leu Val Lys Leu Thr Gln Gln
385 390 395 400

Phe Gln Gly Met Ser Ile Pro Arg Glu Val Ser Asp Asn Val Ile Glu
405 410 415

Ala Leu Asp Leu Arg Leu Gln Ile Ile Asp Leu Leu Asn Asp Pro Gly
420 425 430

Lys Gly Gly Asp Ile Val Trp Asn Asn Ala Leu His Leu Ser Asn Glu
435 440 445

Leu Val Lys Leu Cys Glu Lys Ala Phe Phe Asn Gly Glu Met Val Gln
450 455 460

Gln Asn Phe Phe Pro Gln Glu His Met Ile Ala Val Tyr Leu Pro Leu
465 470 475 480

Leu Gly Pro Ile Ser Ala Val Met Phe Phe Gly Phe Tyr Asn Val Met
485 490 495

Lys Glu Lys Asn Gln Lys Ser Lys Lys Asn Gly Thr Glu Arg Glu Val
500 505 510

Ala Lys Glu Lys Leu Glu Leu Lys Glu Ala Gln Lys Leu His Ala Ile
515 520 525

Asp Gly Glu Asp Glu Leu
530

<210> 38
<211> 1833
<212> DNA
<213> Saccharomyces cerevisiae
<400> 38

atgatcctca cactggccta tttcatgctg ggcactctac tactgggtgt gttcgcagaa 60

gacacggtgt cgcagattgg tataaatgac agtttatggt atccgtacga cgaagcactg 120

gtgttgaagc cgctgcccaa caatgatctg ctactctcat ttgcattcca actgcaatcg 180

gaaccgtttg acccggccgt atcatccatg tcatatgatg cgtatgagca ctacacgact 240

ttcccacggg ccatcccacc attgttggaa tctactgcca cgcgtcagtt tcatttaaga 300

tttaccagag gattctggga tgccctgtcg tggggacagt tgccacatgc tggaaaagag 360

gcaggtgcct caggtgtgga attgtggtcg caagtgcagg ccatggatca ggaacaggcg 420

ttccataatt ggaaaaaact gtccaattca ttgagcggat tgttttgttc ttctttaaat 480

tttatcgacg agtcaaggac gacctttccc cggcggtcat atgcttctga tataggagct 540

cctcttttca atagcaccga gaaactgtac ctgatgcgag catcgttgcc caatgaaccc 600

atctgtaccg agaacttgac gccgttcata aaactattgc ctactagggg caaatccggt 660

ttgacatctc tcttggatgg tcataaattg ttcgactctc tatggaatag tatttccttg 720

gatattgcca ctatttgttc tgaagatgaa gatgctcttt gtcactacga gatggacgca 780

cgcatagaaa tggtaacaca cgttccctcc gccttggcaa gaggtgagag acctatcccc 840

aaacctttgg atgggaacac attgcgttgt gacacggata aacccttga ttcttaccaa 900

tgcttccctc taccggaacc ttcgcagact cacttcaagc tgtctcagct gtttgccaga 960

ccaataaaca atggcaacct gtttgctaat aggcccacaa gaatttgtgc agaagttgac 1020

cgttctacct ggactgcgtt tttgtcagtt gacgatacta ttttcagcac acatgataat 1080

tgctttgact tatcaaacga tcaaaatgag ggtggttcgg gctacgactt tattttagaa 1140

tcgacggaca ctactaaagt tactcccata gttcctgtcc caattcacgt aagcagatct 1200

ctgactggta atggacaaga tcgtggtgga atgcgtattg ttttccataa cgacaatgat 1260

acccctgtga agttgattta tttcgaatca ttgccatggt tcatgagagt ttacctatcc 1320

tctcttcaaa ttacttctac tacctctccg caattgcaag aaaacgatat catcttagat 1380

aaatactatt tacaagcggc cgatagaaaa agacctggcc acttggagtt cacgatgtta 1440

attccagcta atacggacat tgtaatgact tatcaattcg ataaagctct tctgcaattt 1500

gccgagtatc caccagatgc aaaccatggt tttgaaatcg atgcagctgt aatcaccgtg 1560

ctatctttgg agtcctcatc gtctctttat gaaatgagaa cctctaccct attgttatcc 1620

ctgtctacac cggattttag tatgccgtat aacgtcatca ttctaacatc tacaatcatg 1680

ggactcatat tcggtatgct atacaatttg atggtgaaga gaatggtcac cgtcgaagag 1740

gccgataaga ttacgttgca atctggctta aaatacaaat tgctaaagct aaaggaaaag 1800

ttcctaggga aaaaaaagac taaaacagac taa 1833

<210> 39
<211> 610
<212> PRT
<213> Saccharomyces cerevisiae
<400> 39

Met Ile Leu Thr Leu Ala Tyr Phe Met Leu Gly Thr Leu Leu Leu Gly
1 5 10 15

Val Phe Ala Glu Asp Thr Val Ser Gln Ile Gly Ile Asn Asp Ser Leu
20 25 30

Trp Tyr Pro Tyr Asp Glu Ala Leu Val Leu Lys Pro Leu Pro Asn Asn
35 40 45

Asp Leu Leu Leu Ser Phe Ala Phe Gln Leu Gln Ser Glu Pro Phe Asp

50 55 60

Pro Ala Val Ser Ser Met Ser Tyr Asp Ala Tyr Glu His Tyr Thr Thr
65 70 75 80

Phe Pro Arg Ala Ile Pro Pro Leu Leu Glu Ser Thr Ala Thr Arg Gln
85 90 95

Phe His Leu Arg Phe Thr Arg Gly Phe Trp Asp Ala Leu Ser Trp Gly
100 105 110

Gln Leu Pro His Ala Gly Lys Glu Ala Gly Ala Ser Gly Val Glu Leu
115 120 125

Trp Ser Gln Val Gln Ala Met Asp Gln Glu Gln Ala Phe His Asn Trp
130 135 140

Lys Lys Leu Ser Asn Ser Leu Ser Gly Leu Phe Cys Ser Ser Leu Asn
145 150 155 160

Phe Ile Asp Glu Ser Arg Thr Thr Phe Pro Arg Arg Ser Tyr Ala Ser
165 170 175

Asp Ile Gly Ala Pro Leu Phe Asn Ser Thr Glu Lys Leu Tyr Leu Met
180 185 190

Arg Ala Ser Leu Pro Asn Glu Pro Ile Cys Thr Glu Asn Leu Thr Pro
195 200 205

Phe Ile Lys Leu Leu Pro Thr Arg Gly Lys Ser Gly Leu Thr Ser Leu
210 215 220

Leu Asp Gly His Lys Leu Phe Asp Ser Leu Trp Asn Ser Ile Ser Leu
225 230 235 240

Asp Ile Ala Thr Ile Cys Ser Glu Asp Glu Asp Ala Leu Cys His Tyr
245 250 255

Glu Met Asp Ala Arg Ile Glu Met Val Thr His Val Pro Ser Ala Leu
260 265 270

Ala Arg Gly Glu Arg Pro Ile Pro Lys Pro Leu Asp Gly Asn Thr Leu
275 280 285

Arg Cys Asp Thr Asp Lys Pro Phe Asp Ser Tyr Gln Cys Phe Pro Leu
290 295 300

Pro Glu Pro Ser Gln Thr His Phe Lys Leu Ser Gln Leu Phe Ala Arg
305 310 315 320

Pro Ile Asn Asn Gly Asn Leu Phe Ala Asn Arg Pro Thr Arg Ile Cys
325 330 335

Ala Glu Val Asp Arg Ser Thr Trp Thr Ala Phe Leu Ser Val Asp Asp
340 345 350

Thr Ile Phe Ser Thr His Asp Asn Cys Phe Asp Leu Ser Asn Asp Gln
355 360 365

Asn Glu Gly Gly Ser Gly Tyr Asp Phe Ile Leu Glu Ser Thr Asp Thr
370 375 380

Thr Lys Val Thr Pro Ile Val Pro Val Pro Ile His Val Ser Arg Ser
385 390 395 400

Leu Thr Gly Asn Gly Gln Asp Arg Gly Gly Met Arg Ile Val Phe His
405 410 415

Asn Asp Asn Asp Thr Pro Val Lys Leu Ile Tyr Phe Glu Ser Leu Pro
420 425 430

Trp Phe Met Arg Val Tyr Leu Ser Ser Leu Gln Ile Thr Ser Thr Thr
435 440 445

Ser Pro Gln Leu Gln Glu Asn Asp Ile Ile Leu Asp Lys Tyr Tyr Leu
450 455 460

Gln Ala Ala Asp Arg Lys Arg Pro Gly His Leu Glu Phe Thr Met Leu

465 470 475 480

Ile Pro Ala Asn Thr Asp Ile Val Met Thr Tyr Gln Phe Asp Lys Ala
485 490 495

Leu Leu Gln Phe Ala Glu Tyr Pro Pro Asp Ala Asn His Gly Phe Glu
500 505 510

Ile Asp Ala Ala Val Ile Thr Val Leu Ser Leu Glu Ser Ser Ser Ser
515 520 525

Leu Tyr Glu Met Arg Thr Ser Thr Leu Leu Leu Ser Leu Ser Thr Pro
530 535 540

Asp Phe Ser Met Pro Tyr Asn Val Ile Ile Leu Thr Ser Thr Ile Met
545 550 555 560

Gly Leu Ile Phe Gly Met Leu Tyr Asn Leu Met Val Lys Arg Met Val
565 570 575

Thr Val Glu Glu Ala Asp Lys Ile Thr Leu Gln Ser Gly Leu Lys Tyr
580 585 590

Lys Leu Leu Lys Leu Lys Glu Lys Phe Leu Gly Lys Lys Lys Thr Lys
595 600 605

Thr Asp

610

<210> 40
<211> 1185
<212> DNA
<213> Saccharomyces cerevisiae
<400> 40

atggattcca cagcacttaa ggtagctcta ggctgtattg caattcgttt ggctgtgaac 60

agccttttc cctctctaca acaacaactg gaccagtctg tagaattctc aactcccgta 120

acttcattta ggtcactaca ggaaggtata tacctactgc ggaacaacat ccaagtatat 180

aatcatgggg ttgttcacca tcctccaatt ttgatttttt ttctttccct ctttaattcc 240

gacaggttaa tttccctcat atacgcttta attgatggat taattgcgta tcagctgaca 300

gaggtaacaa aggctttcaa aaacttgaaa ctgaaagttt ggctacctgg acttctttat 360

gccgtgaatc ctttgaccct tttatcgtgc attagtcggt catcaatcat attcacaaat 420

tttgctattt catcgtcatt gtattgcata ttagctgaag gaaacgttct tttgtcctct 480

gttatgattt ctatatctgg atatttgtca gtatacccta ttctcctctt aattccgcta 540

ttaggtatgc tgaaaagttg gaggcaaaga atattatctg ccattgtttc catactatct 600

ttattaattc tgctattatt cagctacagt atattaggca gccaaagttg gtcatttttg 660

acacaggttt atggatctat tataaccttt gagaaggttt ttccaaatct gggtttgtgg 720

tggtacttct tcattgaaat gtttgacacc ttcataccgt tcttcaaggc tgtattcaac 780

atttttattg cagtattcat tacaccattt actttgcgct atcataagca gccattctac 840

gcattcattt tatgcattgg gtggattgtc cttacaaagc catatccctc actaggtgac 900

gctggttttt tcttcagctt cctacctttc ttcacgccac tatttggata tttaagatac 960

cccatcatat cagcattact gtttttacac gcaattgttt tggcgccaat tttctatcat 1020

ctttgggttg ttttaggttc agggaatagt aatttttttct atgctatttc cctagtttat 1080

gctctggcta tagcatctat attagttgac ttgaactggg cgatgctgag aattgaatac 1140

gataacggta tcccaaattt caaattgaag gtaacacaaa tttaa 1185

<210> 41
<211> 394
<212> PRT
<213> Saccharomyces cerevisiae
<400> 41

Met Asp Ser Thr Ala Leu Lys Val Ala Leu Gly Cys Ile Ala Ile Arg
1 5 10 15

Leu Ala Val Asn Ser Leu Phe Pro Ser Leu Gln Gln Gln Leu Asp Gln
20 25 30

Ser Val Glu Phe Ser Thr Pro Val Thr Ser Phe Arg Ser Leu Gln Glu
35 40 45

Gly Ile Tyr Leu Leu Arg Asn Asn Ile Gln Val Tyr Asn His Gly Val
50 55 60

Val His His Pro Pro Ile Leu Ile Phe Phe Leu Ser Leu Phe Asn Ser
65 70 75 80

Asp Arg Leu Ile Ser Leu Ile Tyr Ala Leu Ile Asp Gly Leu Ile Ala
85 90 95

Tyr Gln Leu Thr Glu Val Thr Lys Ala Phe Lys Asn Leu Lys Leu Lys
100 105 110

Val Trp Leu Pro Gly Leu Leu Tyr Ala Val Asn Pro Leu Thr Leu Leu
115 120 125

Ser Cys Ile Ser Arg Ser Ser Ile Ile Phe Thr Asn Phe Ala Ile Ser
130 135 140

Ser Ser Leu Tyr Cys Ile Leu Ala Glu Gly Asn Val Leu Leu Ser Ser
145 150 155 160

Val Met Ile Ser Ile Ser Gly Tyr Leu Ser Val Tyr Pro Ile Leu Leu
165 170 175

Leu Ile Pro Leu Leu Gly Met Leu Lys Ser Trp Arg Gln Arg Ile Leu
180 185 190

Ser Ala Ile Val Ser Ile Leu Ser Leu Leu Ile Leu Leu Leu Phe Ser
195 200 205

Tyr Ser Ile Leu Gly Ser Gln Ser Trp Ser Phe Leu Thr Gln Val Tyr
210 215 220

Gly Ser Ile Ile Thr Phe Glu Lys Val Phe Pro Asn Leu Gly Leu Trp
225 230 235 240

Trp Tyr Phe Phe Ile Glu Met Phe Asp Thr Phe Ile Pro Phe Phe Lys
245 250 255

Ala Val Phe Asn Ile Phe Ile Ala Val Phe Ile Thr Pro Phe Thr Leu
260 265 270

Arg Tyr His Lys Gln Pro Phe Tyr Ala Phe Ile Leu Cys Ile Gly Trp
275 280 285

Ile Val Leu Thr Lys Pro Tyr Pro Ser Leu Gly Asp Ala Gly Phe Phe
290 295 300

Phe Ser Phe Leu Pro Phe Phe Thr Pro Leu Phe Gly Tyr Leu Arg Tyr
305 310 315 320

Pro Ile Ile Ser Ala Leu Leu Phe Leu His Ala Ile Val Leu Ala Pro
325 330 335

Ile Phe Tyr His Leu Trp Val Val Leu Gly Ser Gly Asn Ser Asn Phe
340 345 350

Phe Tyr Ala Ile Ser Leu Val Tyr Ala Leu Ala Ile Ala Ser Ile Leu
355 360 365

Val Asp Leu Asn Trp Ala Met Leu Arg Ile Glu Tyr Asp Asn Gly Ile
370 375 380

Pro Asn Phe Lys Leu Lys Val Thr Gln Ile

385 390

<210> 42
<211> 255
<212> DNA
<213> Homo sapiens
<400> 42

atggccacgg ggacagacca ggtggtggga ctcggcctcg tcgccgttag cctgatcatc 60

ttcacctact acaccgcctg ggtgattctc ttgccattca tcgacagtca gcatgtcatc 120

cacaagtatt tcctgccccg agcctatgct gtcgccatcc cactggctgc aggcctcctg 180

ctgctcctgt ttgtgggact gttcatctcc tatgtgatgc tgaagaccaa gagagtgacc 240

aagaaggctc agtga 255

<210> 43
<211> 84
<212> PRT
<213> Homo sapiens
<400> 43

Met Ala Thr Gly Thr Asp Gln Val Val Gly Leu Gly Leu Val Ala Val
1 5 10 15

Ser Leu Ile Ile Phe Thr Tyr Tyr Thr Ala Trp Val Ile Leu Leu Pro
20 25 30

Phe Ile Asp Ser Gln His Val Ile His Lys Tyr Phe Leu Pro Arg Ala
35 40 45

Tyr Ala Val Ala Ile Pro Leu Ala Ala Gly Leu Leu Leu Leu Leu Phe
50 55 60

Val Gly Leu Phe Ile Ser Tyr Val Met Leu Lys Thr Lys Arg Val Thr
65 70 75 80

Lys Lys Ala Gln

<210> 44
<211> 369
<212> DNA
<213> Homo sapiens
<400> 44

atgctctccg tgggcgggct tcggttgagt ttggtccgct ttcctttct gctcctcagg 60

ggagcattgc ttccttctct cgcagtgacc atgacgaaat tagcgcagtg gctttgggga 120

ctagcgatcc tgggctccac ctgggtggcc ctgaccacgg gagccttggg cctggagctg 180

cccttgtcct gccaggaagt cctgtggcca ctgcccgcct acttgctggt gtccgccggc 240

tgctatgccc tgggcactgt gggctatcgt gtggccactt ttcatgactg cgaggacgcc 300

gcacgcgagc tgcagagcca gatacaggag gcccgagccg acttagcccg caggggctg 360

cgcttctga 369

<210> 45
<211> 122
<212> PRT
<213> Homo sapiens
<400> 45

Met Leu Ser Val Gly Gly Leu Arg Leu Ser Leu Val Arg Phe Ser Phe
1 5 10 15

Leu Leu Leu Arg Gly Ala Leu Leu Pro Ser Leu Ala Val Thr Met Thr
20 25 30

Lys Leu Ala Gln Trp Leu Trp Gly Leu Ala Ile Leu Gly Ser Thr Trp
35 40 45

Val Ala Leu Thr Thr Gly Ala Leu Gly Leu Glu Leu Pro Leu Ser Cys
50 55 60

Gln Glu Val Leu Trp Pro Leu Pro Ala Tyr Leu Leu Val Ser Ala Gly
65 70 75 80

Cys Tyr Ala Leu Gly Thr Val Gly Tyr Arg Val Ala Thr Phe His Asp
85 90 95

Cys Glu Asp Ala Ala Arg Glu Leu Gln Ser Gln Ile Gln Glu Ala Arg
100 105 110

Ala Asp Leu Ala Arg Arg Gly Leu Arg Phe
115 120

<210> 46
<211> 744
<212> DNA
<213> Homo sapiens
<400> 46

atggcggccg aggcggacgg accgcttaaa cggctgctcg tgccgattct tttacctgag 60

aaatgctacg accaactttt cgttcagtgg gacttgcttc acgtcccctg cctcaagatt 120

ctcctcagca aaggcctggg gctgggcatt gtggctggct cacttctagt aaagctgccc 180

caggtgttta aaatccgggg agccaagagt gctgaagggt tgagtctcca gtctgtaatg 240

ctggagctag tggcattgac tgggaccatg gtctacagca tcactaacaa cttcccattc 300

agctcttggg gtgaagcctt attcctgatg ctccagacga tcaccatctg cttcctggtc 360

atgcactaca gaggacagac tgtgaaaggt gtcgctttcc tcgcttgcta cggcctggtc 420

ctgctggtgc ttctctcacc tctgacgccc ttgactgtag tcaccctgct ccaggcctcc 480

aatgtgcctg ctgtggtggt ggggaggctt ctccaggcag ccaccaacta ccacaacggg 540

tacacaggcc agctctcagc catcacagtc ttcctgctgt ttgggggctc cctggcccga 600

atcttcactt ccattcagga aaccggagat cccctgatgg ctgggacctt tgtggtctcc 660

tctctctgca acggcctcat cgccgcccag ctgctcttct actggaatgc aaagcctccc 720

cacaagcaga aaaaggcgca gtag 744

<210> 47
<211> 247
<212> PRT
<213> Homo sapiens
<400> 47

```
Met Ala Ala Glu Ala Asp Gly Pro Leu Lys Arg Leu Leu Val Pro Ile
1               5                  10                  15

Leu Leu Pro Glu Lys Cys Tyr Asp Gln Leu Phe Val Gln Trp Asp Leu
            20                  25                  30

Leu His Val Pro Cys Leu Lys Ile Leu Leu Ser Lys Gly Leu Gly Leu
        35                  40                  45

Gly Ile Val Ala Gly Ser Leu Leu Val Lys Leu Pro Gln Val Phe Lys
    50                  55                  60

Ile Arg Gly Ala Lys Ser Ala Glu Gly Leu Ser Leu Gln Ser Val Met
65                  70                  75                  80

Leu Glu Leu Val Ala Leu Thr Gly Thr Met Val Tyr Ser Ile Thr Asn
                85                  90                  95

Asn Phe Pro Phe Ser Ser Trp Gly Glu Ala Leu Phe Leu Met Leu Gln
            100                 105                 110
```

Thr Ile Thr Ile Cys Phe Leu Val Met His Tyr Arg Gly Gln Thr Val
115 120 125

Lys Gly Val Ala Phe Leu Ala Cys Tyr Gly Leu Val Leu Leu Val Leu
130 135 140

Leu Ser Pro Leu Thr Pro Leu Thr Val Val Thr Leu Leu Gln Ala Ser
145 150 155 160

Asn Val Pro Ala Val Val Val Gly Arg Leu Leu Gln Ala Ala Thr Asn
165 170 175

Tyr His Asn Gly Tyr Thr Gly Gln Leu Ser Ala Ile Thr Val Phe Leu
180 185 190

Leu Phe Gly Gly Ser Leu Ala Arg Ile Phe Thr Ser Ile Gln Glu Thr
195 200 205

Gly Asp Pro Leu Met Ala Gly Thr Phe Val Val Ser Ser Leu Cys Asn
210 215 220

Gly Leu Ile Ala Ala Gln Leu Leu Phe Tyr Trp Asn Ala Lys Pro Pro
225 230 235 240

His Lys Gln Lys Lys Ala Gln

245

<210> 48
<211> 25
<212> DNA
<213> Artificial
<220>
<223> an artificially synthesized primer sequence
<400> 48
atgacaatgt ggggaagtca acggg 25
<210> 49
<211> 30
<212> DNA
<213> Artificial
<220>
<223> an artificially synthesized primer sequence
<400> 49
tgtgtggtta ccgttctttg aatacataga 30
<210> 50
<211> 29
<212> DNA
<213> Artificial
<220>
<223> an artificially synthesized primer sequence
<400> 50
atagaaaatg atttatggta cagctcaaa 29
<210> 51
<211> 30
<212> DNA
<213> Artificial
<220>
<223> an artificially synthesized primer sequence
<400> 51
agaccaaatt aattatgcct ttacatgtac 30
<210> 52
<211> 40
<212> DNA
<213> Artificial
<220>
<223> an artificially synthesized primer sequence
<400> 52
agaattcacc atgagcaaca tgaatatact tgcgtatctt 40
<210> 53
<211> 30
<212> DNA
<213> Artificial
<220>
<223> an artificially synthesized primer sequence
<400> 53
gaaattccaa tgtattccat attcacttat 30
<210> 54
<211> 42
<212> DNA
<213> Artificial
<220>
<223> an artificially synthesized primer sequence

<400> 54
aagatctaat acattaaaac attttagatt aatgaatatg tg 42
<210> 55
<211> 34
<212> DNA
<213> Artificial
<220>
<223> an artificially synthesized primer sequence
<400> 55
aggtaccgta cactccactc tatgatgatc attc 34

Claims

1. A DNA encoding a protein that has the activity of complementing the phenotype of a GPI synthase gene-deficient yeast, which is a degenerate mutant of a DNA according to any one of (a) to (c), and which has an AT content of 70% or less of the original DNA according to any one of (a) to (c):

   (a) a DNA encoding a protein that comprises the amino acid sequence of SEQ ID NO: 2;
   (b) a DNA hybridizing under stringent conditions to the DNA that comprises the nucleotide sequence of SEQ ID NO: 1, wherein the DNA encodes a protein involved in GPI biosynthesis in malaria parasites and has at least 80% identity to the amino acid sequence of SEQ ID NO: 2;
   (c) a DNA encoding a protein which comprises the amino acid sequence of SEQ ID NO: 2, in which one or more amino acids have been added, deleted, substituted and/or inserted, wherein the DNA encodes a protein involved in GPI biosynthesis in malaria parasites and has at least 80% identity to the amino acid sequence of SEQ ID NO: 2.

2. The DNA of claim 1, comprising the nucleotide sequence of SEQ ID NO: 5.

3. A vector into which the DNA according to claim 1 or 2 is inserted.

4. A transformant which retains, in an expressible state, the DNA according to claim 1 or 2, or the vector according to claim 3.

5. The transformant according to claim 4, which is

   (a) a GPI synthase gene-deficient fungus; or
   (b) a GPI synthase gene-deficient yeast.

6. A method for producing a protein encoded by the DNA according to claim 1 or 2, which comprises the steps of culturing the transformant according to claim 4 or 5, and recovering the expressed protein from the transformant or the culture supernatant.

7. A method of screening for a compound having antimalarial activity, which comprises the steps of:

   (a) contacting a test sample with a GPI synthase gene-deficient fungus that expresses the DNA according to claim 1 or 2;
   (b) assaying the growth of that fungus; and
   (c) selecting a test compound that inhibits the growth of that fungus.

8. A method of screening for a compound having antimalarial activity, which comprises the steps of:

   (a) contacting a test sample with a GPI synthase gene-deficient fungus expressing the DNA according to claim 1 or 2;
   (b) determining the amount of a GPI-anchored protein transported to the fungal cell wall; and
   (c) selecting a test sample that decreases the amount of the GPI-anchored protein transported to the cell wall, as determined in step (b).

9. A method of screening for a compound having antimalarial activity, which comprises the steps of:

(a) introducing the DNA according to claim 1 or 2 into a GPI synthase gene-deficient fungus and expressing the protein encoded by the DNA;
(b) preparing the protein expressed in step (a);
(c) contacting the prepared protein with a test sample and a labeled compound that has the activity of binding to the protein;
(d) detecting the labeled compound that binds to the protein; and
(e) selecting a test sample that decreases the amount of labeled compound that binds to the protein.

10. A method of screening for a compound having antimalarial activity, which comprises the steps of:

(a) introducing the DNA according to claim 1 or 2 into a GWT1-deficient fungus, and expressing the protein encoded by the degenerate mutant DNA;
(b) preparing the protein expressed in step (a);
(c) contacting the prepared protein with a test sample;
(d) detecting GlcN-(acyl)PI; and
(e) selecting a test compound that decreases the level of GlcN-(acyl)PI.

Patentansprüche

1. DNA, die ein Protein codiert, das die Aktivität zur Komplementierung des Phänotyps einer GPI-Synthasegen-defizienten Hefe hat, die eine degenerierte Mutante einer DNA nach einem von (a) bis (c) ist, und die einen AT-Gehalt von 70% oder weniger der ursprünglichen DNA nach einem von (a) bis (c) hat:

(a) DNA, die ein Protein codiert, das die Aminosäuresequenz von SEQ ID NO: 2 umfasst;
(b) DNA, die unter stringenten Bedingungen an die DNA hybridisiert, die die Nucleotidsequenz von SEQ ID NO: 1 umfasst, wobei die DNA ein Protein codiert, das in der GPI-Biosynthese in Malariaparasiten involviert ist und mindestens 80% Identität mit der Aminosäuresequenz von SEQ ID NO: 2 besitzt;
(c) DNA, die ein Protein codiert, das die Aminosäuresequenz von SEQ ID NO: 2 umfasst, in der eine oder mehrere Aminosäuren hinzugefügt, entfernt, ausgetauscht und/oder eingefügt wurden, wobei die DNA ein Protein codiert, das in der GPI-Biosynthese in Malariaparasiten involviert ist und mindestens 80% Identität mit der Aminosäuresequenz von SEQ ID NO: 2 besitzt.

2. DNA nach Anspruch 1, umfassend die Nucleotidsequenz von SEQ ID NO: 5.

3. Vektor, in den die DNA nach Anspruch 1 oder 2 eingefügt ist.

4. Transformante, die die DNA nach Anspruch 1 oder 2 oder den Vektor nach Anspruch 3 in einem exprimierbaren Zustand bewahrt.

5. Transformante nach Anspruch 4, die

(a) ein GPI-Synthasegen-defizienter Pilz; oder
(b) eine GPI-Synthasegen-defiziente Hefe ist.

6. Verfahren zur Herstellung eines Proteins, das durch die DNA nach Anspruch 1 oder 2 codiert wird, umfassend die Schritte des Züchtens der Transformante nach Anspruch 4 oder 5 und des Gewinnens des exprimierten Proteins von der Transformante oder dem Kulturüberstand.

7. Verfahren zum Screenen nach einer Verbindung, die Anti-Malaria-Aktivität hat, das die Schritte umfasst:

(a) Inkontaktbringen einer Testprobe mit einem GPI-Synthasegen-defizienten Pilz, der die DNA nach Anspruch 1 oder 2 exprimiert;
(b) Testen des Wachstums des Pilzes; und
(c) Auswählen einer Testverbindung, die das Wachstum des Pilzes hemmt.

8. Verfahren zum Screenen nach einer Verbindung, die Anti-Malaria-Aktivität hat, das die Schritte umfasst:

(a) Inkontaktbringen einer Testprobe mit einem GPI-Synthasegen-defizienten Pilz, der die DNA nach Anspruch 1 oder 2 exprimiert;
(b) Bestimmen der Menge an GPI-verankertem Protein, das zur Pilzzellwand transportiert wurde; und
(c) Auswählen einer Testprobe, welche die Menge des GPI-verankerten, an die Zellwand transportierten Proteins herabsetzt, wie in Schritt (b) bestimmt.

9. Verfahren zum Screenen nach einer Verbindung, die Anti-Malaria-Aktivität hat, das die Schritte umfasst:

(a) Einführen der DNA nach Anspruch 1 oder 2 in einen GPI-Synthasegen-defizienten Pilz und Exprimieren des durch die DNA codierten Proteins;
(b) Herstellen des in (a) exprimierten Proteins;
(c) Inkontaktbringen des hergestellten Proteins mit einer Testprobe und einer markierten Verbindung, welche die Aktivität zur Bindung an das Protein hat;
(d) Nachweisen der markierten Verbindung, die an das Protein bindet; und
(e) Auswählen einer Testprobe, die die Menge der markierten Verbindung, die an das Protein bindet, herabsetzt.

10. Verfahren zum Screenen nach einer Verbindung, die Anti-Malaria-Aktivität hat, das die Schritte umfasst:

(a) Einführen der DNA nach Anspruch 1 oder 2 in einen GWT1-defizienten Pilz, und Exprimieren des Proteins, das durch die degenerierte Mutanten-DNA codiert wird;
(b) Herstellen des in (a) exprimierten Proteins;
(c) Inkontaktbringen des hergestellten Proteins mit einer Testprobe;
(d) Nachweisen von GlcN-(acyl)PI; und
(e) Auswählen einer Testverbindung, die den Spiegel an GlcN-(acyl)PI herabsetzt.

Revendications

1. Un ADN codant pour une protéine qui a pour activité de complémenter le phénotype d'une levure déficiente pour le gène de la GPI synthase, qui est un mutant dégénéré d'un ADN selon l'un quelconque de (a) à (c), et qui a une teneur en AT de 70% ou moins de l'ADN original selon l'un quelconque de (a) à (c) :

(a) un ADN codant pour une protéine qui comprend la séquence d'acides aminés de SEQ ID NO :2 ;
(b) un ADN qui s'hybride dans des conditions stringentes à l'ADN qui comprend la séquence nucléotidique de SEQ ID NO :1, dans lequel l'ADN code pour une protéine impliquée dans la biosynthèse de GPI chez les parasites du paludisme et a au moins 80% d'identité avec la séquence d'acides aminés de SEQ ID NO :2 ;
(c) un ADN codant pour une protéine qui comprend la séquence d'acides aminés de SEQ ID NO :2, dans laquelle un ou plusieurs acides aminés ont été ajoutés, supprimés, substitués et/ou insérés, dans lequel l'ADN code pour une protéine impliquée dans la biosynthèse de GPI chez les parasites du paludisme et a au moins 80% d'identité avec la séquence d'acides aminés de SEQ ID NO :2.

2. ADN selon la revendication 1, comprenant la séquence nucléotidique de SEQ ID NO :5.

3. Un vecteur dans lequel l'ADN selon la revendication 1 ou 2 est inséré.

4. Un transformant qui maintient, dans un état dans lequel il peut s'exprimer, l'ADN selon la revendication 1 ou 2, ou le vecteur selon la revendication 3.

5. Transformant selon la revendication 4, qui est

(a) un champignon déficient pour le gène de la GPI synthase ; ou
(b) une levure déficiente pour le gène de la GPI synthase.

6. Un procédé pour produire une protéine codée par l'ADN selon la revendication 1 ou 2, qui comprend les étapes consistant à cultiver le transformant selon la revendication 4 ou 5, et à récupérer la protéine exprimée à partir des transformants ou du surnageant de culture.

7. Un procédé de criblage pour un composé ayant une activité antipaludéenne, qui comprend les étapes consistant à :

(a) mettre en contact un échantillon test avec un champignon déficient pour le gène de la GPI synthase qui exprime l'ADN selon la revendication 1 ou 2 ;
(b) mesurer la croissance de ce champignon ; et
(c) sélectionner un composé test qui inhibe la croissance de ce champignon.

8. Un procédé de criblage pour un composé ayant une activité antipaludéenne, qui comprend les étapes consistant à :

(a) mettre en contact un échantillon test avec un champignon déficient pour le gène de la GPI synthase exprimant l'ADN selon la revendication 1 ou 2;
(b) déterminer la quantité d'une protéine à ancre GPI transportée par la paroi cellulaire fongique ; et
(c) sélectionner un échantillon test qui diminue la quantité de protéine à ancre GPI transportée par la paroi cellulaire, tel que déterminé dans l'étape (b).

9. Un procédé de criblage pour un composé ayant une activité antipaludéenne, qui comprend les étapes consistant à :

(a) introduire l'ADN selon la revendication 1 ou 2 dans un champignon déficient pour le gène de la GPI synthase et exprimant la protéine codée par l'ADN;
(b) préparer la protéine exprimée dans l'étape (a) ;
(c) mettre en contact la protéine préparée avec un échantillon test et un composé marqué qui a pour activité de se lier à la protéine ;
(d) détecter le composé marqué qui se lie à la protéine ; et
(e) sélectionner l'échantillon test qui diminue la quantité de composé marqué qui se lie à la protéine.

10. Un procédé de criblage pour un composé ayant une activité antipaludéenne, qui comprend les étapes consistant à :

(a) introduire l'ADN selon la revendication 1 ou 2 dans un champignon déficient pour GWT1, et exprimant la protéine codée par l'ADN mutant dégénéré ;
(b) préparer la protéine exprimée dans l'étape (a) ;
(c) mettre en contact la protéine préparée avec un échantillon test ;
(d) détecter le GlcN-(acyl)PI ; et
(e) sélectionner un composé test qui diminue le niveau de GlcN-(acyl)PI.

FIG. 1

YEp352GAPII-pfGWT1



YEp352GAPII-opfGWT1



FIG. 2


0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
OD660nm
0
6.25
12.5
25
50
CONC. (μg/ml)
pGAP-ScGWT1
pGAP-opfGWT1

FIG. 3


GROWTH INHIBITION (%)
120
100
80
60
40
20
0
0
20
40
60
80
100
COMPOUND (μg/ml)
COMPOUND 1
COMPOUND 2
COMPOUND 3
COMPOUND 4
COMPOUND 5

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 0204626 A **[0008] [0009] [0032] [0059] [0072] [0092]**
- US 60428589 B **[0132]**

Non-patent literature cited in the description

- **Gardner et al.** *Nature,* 2003, vol. 419, 498-511 **[0002] [0008]**
- **Schofield L et al.** *Nature,* 2002, vol. 418, 785-789 **[0004]**
- **Gerold, P. et al.** *Biochem. J.,* 1999, vol. 344, 731-738 **[0005]**
- **Naik, R. S. et al.** *J. Biol. Chem.,* 2003, vol. 278, 2036-2042 **[0005]**
- **Brophy et al.** *Antimicrobial Agents and Chemotherapy,* 2000, vol. 44, 1019-1028 **[0006]**
- **Carlton et al.** *Nature,* 2003, vol. 419, 512-519 **[0008]**
- **Pan et al.** *Nucleic acid res,* 1999, vol. 27, 1094-1103 **[0010]**
- **Costello ; Orlean.** *J. Biol. Chem.,* 1992, vol. 267, 8599-8603 **[0015]**
- **Franzot ; Doering.** *Biochem. J.,* 1999, vol. 340, 25-32 **[0015]**
- **Southern E.M.** *J. Mol. Biol.,* 1975, vol. 98, 503-517 **[0017]**
- **Saiki R.K. et al.** *Science,* 1985, vol. 230, 1350-1354 **[0017]**
- **Saiki R.K. et al.** *Science,* 1988, vol. 239, 487-491 **[0017]**
- **Karlin S. ; Altschul S. F.** *Proc. Natl. Acad. Sci. USA.,* 1990, vol. 87, 2264-2268 **[0019]**
- **Karlin S. ; Altschul S.F.** *Proc. Natl. Acad. Sci. USA.,* 1993, vol. 90, 5873-5877 **[0019]**
- **Altschul S.F. et al.** *J. Mol. Biol.,* 1990, vol. 215, 403 **[0019]**
- **Mark, D. F. et al.** *Proc. Natl. Acad. Sci. USA,* 1984, vol. 81, 5562-5666 **[0021]**
- **Zoll er, M. J. ; Smith, M.** *Nucleic Acids Research,* 1982, vol. 10, 6487-6500 **[0021]**
- **Wang, A. et al.** *Science,* vol. 224, 1431-1433 **[0021]**
- **Dalbadie-McFarland, G. et al.** *Proc. Natl. Acad. Sci. USA,* 1982, vol. 79, 6409-6413 **[0021]**
- **Hopp, T. P. et al.** *Biotechnology,* 1988, vol. 6, 1204-1210 **[0023]**
- **Kramer W. ; Fritz H-J.** *Methods Enzymol.,* 1987, vol. 154, 350 **[0024]**
- *Mol. Cell Biol.,* 1988, vol. 8, 466-472 **[0026]**
- Current Protocols in Molecular Biology. John Wiley & Sons, Inc, 1987, 11.4-11.11 **[0026]**
- Current protocols in Molecular Biology. John Wiley & Sons, Inc, 1987, 9.1-9.9 **[0027]**
- **Tanaka et al.** *Mol. Cell Biol.,* 1990, vol. 10, 4303-4313 **[0050]**
- **Igarashi et al.** *Nature,* 1991, vol. 353, 80-83 **[0051]**
- **Pla J. et al.** *Yeast,* 1996, vol. 12, 1677-1702 **[0051]**
- **Punt P.J. et al.** *GENE,* 1987, vol. 56, 117-124 **[0051]**
- **Monden P. et al.** *FEMS Microbiol. Lett.,* 2000, vol. 187, 41-45 **[0051]**
- **Yoko-o et al.** *Eur. J. Biochem.,* 1998, vol. 257, 630-637 **[0054]**
- **Sentandreu M et al.** *J. Bacteriol.,* 1998, vol. 180, 282-289 **[0054]**
- **Mouyna I et al.** *J. Biol. Chem.,* 2000, vol. 275, 14882-14889 **[0054]**
- **Thompson JR et al.** *J. Bacteriol.,* 1999, vol. 181, 444-453 **[0054]**
- **Petaja-Repo et al.** *J. Biol. Chem.,* 2001, vol. 276, 4416-23 **[0056]**
- **Okamoto et al.** *J. Biol. Chem.,* 2001, vol. 276, 742-751 **[0057]**
- **Costello L.C ; Orlean P.** *J. Biol. Chem.,* 1992, vol. 267, 8599-8603 **[0066]**
- **Franzot S.P ; Doering T.L.** *Biochem. J.,* 1999, vol. 340, 25-32 **[0066]**
- **Van Berkel MAA et al.** *FEBS Letters,* 1994, vol. 349, 135-138 **[0074]**
- **Gietz D et al.** *Nucl. Acids Res.,* 1992, vol. 20, 1425 **[0076]**
- **Chen MH et al.** *J. Biol. Chem.,* 1995, vol. 270, 26168-26177 **[0081]**
- **Van Der Vaat JM et al.** *J. Bacteriol.,* 1995, vol. 177, 3104-3110 **[0081]**
- **Hoyer LL et al.** *Mol. Microbiol.,* 1995, vol. 15, 39-54 **[0081]**
- **Delorenzi et al.** *Infect. Immun.,* 2002, vol. 70, 4510-4522 **[0099]**
- **Longtine et al.** *Yeast,* 1998, vol. 14, 953-961 **[0104]**
- **Sato ; Horii.** *Protein, Nucleic acid, and Enzyme,* 2003, vol. 48, 149-155 **[0121]**